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ABSTRACT 
 
IDENTIFICATION OF ATP8A2 GENE MUTATION IN A 
CONSANGUINEOUS FAMILY SEGREGATING 
CEREBELLAR ATROPHY AND QUADRUPEDAL GAIT 
 
Onur Emre Onat 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Tayfun Özçelik 
December, 2012 
 
 
Cerebellar ataxia, mental retardation, and dysequilibrium syndrome is a rare and 
heterogeneous neurodevelopmental disorder characterized by cerebellar atrophy, 
dysarthric speech, and quadrupedal locomotion. Here, a consanguineous family with 
four affected individuals which suggest an autosomal recessive inheritance was 
investigated. Homozygosity mapping analysis using high-resolution genotyping arrays 
in two affected individuals revealed four shared homozygous regions on 13q12, 
19p13.3, 19q13.2, and 20q12. Target enrichment and next-generation sequencing of 
these regions in an affected individual was uncovered 11 novel protein altering variants 
which were filtered against dbSNP132 and 1000 genomes databases.  Further 
population filtering using personal genome databases and previous exome sequencing 
datasets, segregation analysis, geographically-matched population screening, and 
prediction approaches revealed a novel missense mutation, p.I376M, in ATP8A2 
segregated with the phenotype in the family. The mutation resides in a highly 
conserved C-terminal transmembrane region of E1-E2 ATPase domain. ATP8A2 is 
mainly expressed in brain, in particular with the highest levels at cerebellum which is 
a crucial organ for motor coordination. Mice deficient with Atp8a2 revealed impaired 
axonal transport in the motor neurons associated with severe cerebellar ataxia and body 
tremors. Recently, an unrelated individual with a de novo t(10;13) balanced 
translocation whose one of the ATP8A2 allele was disrupted has been identified. This 
patient shares similar neurological phenotypes including severe mental retardation and 
hypotonia. These findings suggest a role for ATP8A2 in the neurodevelopment, 
especially in the development of cerebro-cerebellar structures required for posture and 
gait in humans. 
 
Keywords: Quadrupedal locomotion, CAMRQ, cerebellar atrophy, next-generation 
sequencing, ATP8A2. 
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ÖZET 
 
EL AYAK ÜZERİNDE YÜRÜYÜŞ VE SEREBELLAR ATROFİ  
AKTARILAN AKRABA EVLİLİĞİ YAPMIŞ BİR AİLEDE 
ATP8A2 GEN MUTASYONU SAPTANMASI 
 
Onur Emre Onat 
Moleküler Biyoloji ve Genetik, Doktora 
Tez Yöneticisi: Prof. Dr. Tayfun Özçelik 
Aralık, 2012 
 
 
Serebellar ataksi, mental retardasyon ve dengesizlik sendromu, serebellar atrofi, 
dizartirik konuşma ve el ayak üzerinde yürüme ile tanımlanan nadir heterojen bir sinir-
gelişimsel hastalıktır. Burada, hastalığın otozomal resesif olarak aktarıldığı bir ailede, 
ebeveynleri arasında akraba evliliği bulunan etkilenmiş dört bireyin durumu 
tanımlanmıştır. Etkilenmiş iki bireyde yüksek çözünürlüklü genotipleme yöntemi ile 
yapılan homozigotluk haritalaması sonucu 13q12, 19p13.3, 19q13.2 ve 20q12 
üzerinde dört adet ortak homozigot bölge tespit edilmiştir. Bu bölgelerin etkilenmiş 
bir bireyde hedefe yönelik yeni nesil dizilemesi sonucu bulunan varyantlar, 
“dbSNP132” ve “1000 genomes” veri tabanlarında filtrelenmiş ve 11 adet yeni protein 
yapısını değiştiren varyant belirlenmiştir. Bu varyantların, kişisel genom veri 
tabanlarında ve eksom dizileme veri setlerinde filtrelenmesi, segregasyon analizi, aynı 
bölgeden bireylerde toplum taraması ve öngörü yaklaşımları ile elenmesi sonucu 
olarak, ailede hastalığın kalıtımı ile uygun ATP8A2 üzerinde yeni bir yanlış anlam 
mutasyonu, p.I376M, ortaya çıkmıştır. Mutasyon E1-E2 ATPaz etki alanında evrimsel 
olarak son derece korunmuş C-terminal transmembran bölgesinde yer almaktadır. 
ATP8A2 en çok beyinde ifade edilir, özellikle motor koordinasyondan sorumlu 
serebellumda en yüksek seviyededir. Atp8a2 geni eksik farelerde motor nöronlarda 
bozuk aksonal transporttan kaynaklı ciddi serebellar ataksi ve vücut titremesi 
görülmüştür. Yakın zamanlarda, t(10;13) dengeli translokasyon taşıyan alakasız bir 
bireyin ATP8A2 bozulması sonucu ciddi mental retardasyon ve hipotoni gibi benzer 
nörolojik fenotipleri taşıdığı gösterilmiştir. Bu bulgular, insanlarda duruş ve yürüyüş 
için gereken serebro-serebellar yapıların gelişmesinde ATP8A2’nin bir rolü olduğunu 
düşündürmektedir.  
 
Ahahtar Sözcükler: ATP8A2, serebellar hipoplazi, hedefe yönelik yeni nesil dizileme, 
el ayak üzerinde yürüme, CAMRQ 
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Chapter 1 
Introduction 
1.1 Quadrupedal Locomotion in Humans 
Quadrupedalism is the form of locomotion of the majority of vertebrates and 
mammals. It uses limbs and legs. Bipedalism is the fundamental adaptation of 
hominids which separate them from other primates. However, bipedal gait including 
long-distance walking and running is one of the key characteristics of humans.[1-3] 
Actually, humans begin life with crawling on all fours but do not retain quadrupedal 
gait and continue life with up-right posture.[2, 4] The origin of human bipedalism is 
still on debate since its genetic background is poorly understood, but a century of 
research of fossil and comparative anatomy studies give valuable information about 
the development of the bipedal locomotion.[1-6]    
 
Bipedal walking in humans is controlled by central nervous system which 
transmits the signals to peripheral nervous system.[7] Detailed functional analysis of 
the brain regions revealed that cerebellum, cerebral cortex, occipital cortex, and basal 
ganglia are the crucial parts in controlling locomotion.[8] Especially, recent studies on 
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cerebellar disorders revealed that cerebellum has a particular role in controlling motor 
movements and balance in humans.[9, 10]  
1.2 Cerebellum and Motor Coordinates 
1.2.1 Function of the cerebellum 
The cerebellum is a brain region involved in motor control. Lesions in cerebellum are 
associated with loss of coordination (asynergia), drunk-like movement (ataxia), 
inability to perform rapid movements (adiadochokinesia), poor articulation 
(dysarthria), movement tremors (intention tremor), inability to decide when to stop 
(dysmetria), weak muscle tone (hypotonia), and abnormal eye movement 
(nystagmus).[11]   
 
 The role of cerebellum in cognitive functions such as articulation, emotion, and 
mental behavior has not been elucidated yet. The evidence underlying the causes of 
the cognitive function of the cerebellum comes from the anatomical investigations, 
clinical manifestation of the cerebellar disorders, and functional neuroimaging 
approaches, but genetic evidence is still missing.[12] Recent improvements in brain 
imaging techniques, genetics, and mouse genomics have provided identification of 
many genes involved in cerebellar malformations which in turn provided information 
about the function of the cerebellum.[13]  
 
 The strongest clues about the function of the cerebellum have come from 
animals and humans with cerebellar dysfunction. The essential role of the cerebellum 
is the coordinating motor movements such as typing, running, and talking. Patients 
with completely damaged or loss of the cerebellum continue to generate motor 
movements but they loses precision, coordination, and accurate timing.[14]  
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 The cerebellum functionally locates between the central nervous system (CNS) 
and peripheral nervous system (PNS). The PNS connects the CNS with the rest of the 
body by network of nerves. The input signals from the sensory organs unite with the 
input signals from the motor pathways.[15] These inputs transmitted to the CNS via 
sensory pathways and to muscles and glands via motor pathways. The signals from 
various parts of the spinal cord and brain integrated to the cerebellum via spinal and 
cranial nerves, respectively. Cerebellum analyzes these inputs, corrects mismatches 
between predicted and actual movements, calculates timing, and decides the action 
quickly.[16] These predictions are learnt according to past experiences which is called 
motor learning.[17] There are some evidence that the cerebellum participates in some 
types of motor learning with basal ganglia and cerebral cortex.[18] Cerebellum also 
helps to motor cortex in planning the next movement while controlling a motor 
movement.[19] 
1.2.2 Anatomy of the cerebellum and pathology characteristics  
The cerebellum constitutes 10% of the total volume of the brain locating at the bottom 
between the cerebral cortex and pons which is the part of brainstem.[20] It is separated 
from the cerebrum by a layer called dura mater. More than half of all neurons reside 
at the cerebellum with a regular repeating manner because of the presence of the 
granule cells. Cerebellum is divided into several distinct regions (Figure 1.1). First, it 
is divided into two hemispheres each of which divided into intermediate and lateral 
regions where vermis located at the middle line. According to its standing position, 
cerebellum classified in three regions: the anterior (front), posterior (behind) , and 
flocculonoduler lobes.[21]  
 
 The volume of the cerebellum is occupied by gray matter, also called the 
cerebral cortex at the outside, the internal white matter, and the deep nuclei. The gray 
and white matters are made up myelinated nerve fibers and the deep nucleus is 
composed of branched nerve bodies. The cerebellar output originates from the deep 
nuclei and is transmitted to white and gray matter.[22]  
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 The cerebellum coordinates motor functions at three levels: 
vestibulocerebellum, spinocerebellum, and cerebrocerebellum (Figure 1.1). 
Vestibulocerebellum consist of flocculonoduler lobes and a small portion of the 
vermis. Evolutionary it is the oldest part of the cerebellum. This region plays a role in 
the coordination of the balance of the movements with the help of vestibular system 
and also in the eye movements.[22] The spinocerebellum composed of most portions 
of the vermis and medial zone of the anterior and posterior lobes. This region involves 
in the coordination of the movements at the distal part of the body, especially hands 
and fingers. It receives input signals from the spinal cord, visual and auditory systems 
and transmits these signals to the cerebral cortex and brainstem. The 
cerebrocerebellum is the largest functional part including the both hemispheres and it 
provides connection with the cerebral motor cortex and cerebrum. The input signals 
from the motor and sensory pathways are received by cerebrocerebellum and the 
output signals are transmitted back to the ventrolateral thalamus and red nuclei where 
the cerebellum functions in the planning and coordination of the sequential voluntary 
movements.[19, 20]   
1.2.3 Cellular components of the cerebellum and neuronal circuits 
At cellular level cerebellum composed of three types of neuronal cells which are 
Purkinje, granule and deep nuclei cells and three types of axon fibers which are mossy, 
climbing and parallel fibers.  
1.2.3.1 Purkinje cells 
Purkinje cells are evolutionary the earliest cell types and are packed in the cerebral 
cortex, called Purkinje layer. These cells are one of the largest neurons in the human 
brain composed of dendritic bodies which are branched perpendicular to the cerebellar 
folds. These dendrites receive signals from the fibers which then travel into the deep 
cerebellar nuclei via axons.[23]  
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Figure 1.1: Schematic representation of the major functional and anatomical divisions 
of the cerebellum 
 
 
Purkinje cells are at the heart of cerebellar circuits connected with two layers. 
The dendrites of the Purkinje cells reach to the cerebellar nuclei through parallel fibers 
and to the inferior olivary nucleus through climbing fibers. They send inhibitory 
(GABAergic) signals to the deep nuclei to provide motor coordination in the cerebral 
cortex.[23] 
1.2.3.2 Granule cells 
Granule cells are the smallest but the most numerous neurons in the brain. They 
account for the half of the neurons in the CNS. These cells are packed at the bottom of 
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the cerebral cortex forming the dendritic claw. These dendritic claws receive excitatory 
signals from the mossy fibers originating at the pontei nuclei and inhibitory signals 
from the Golgi cells. The axons of the granule cells reach to the upper layer of the 
cerebral cortex and split into parallel fibers through dendritic bodies of the Purkinje 
cells. At this level, granule cells and the Purkinje cells contact each other at every 3-5 
parallel fibers forming synapses using glutamate as a neurotransmitter so it is 
excitatory.[22] These parallel fibers of the granule cells fire synchronization which 
results in the only excitatory signals present in the cortex. The synapse between 
Purkinje cells and granule cells has a role in motor learning.[24] 
1.2.3.3 Deep nuclei 
The deep nucleus is the center of the output signals from the cerebellum that resides at 
the core region within the gray matter. It consists of three nuclei: dentate nucleus 
communicates with the lateral parts of the cerebellar cortex; interpositus and fastigial 
nuclei communicate with the spinocerebellum. The neurons at the deep nuclei have 
large cell bodies and dendrites. Most of them use glutamate neurotransmitter which 
target several regions outside the cerebellum. A little portion of the neurons use GABA 
neurotransmitter and target the olivary nucleus which is the source of climbing 
fibers.[21] 
 
 The deep nuclei always receive excitatory signals from mossy and climbing 
fiber pathways and inhibitory signals from Purkinje cells in the cerebellar cortex. The 
deep nuclei inhibited by the Purkinje cells when the motor cortex is activated after a 
short delay with a negative feedback signal which prevent the overreaction and 
oscillation of the muscles.[23]  
1.2.3.4 Mossy fibers 
Mossy fibers are the major inputs to the cerebellum. They originate from many 
regions: most of them from pontei nuclei of the cerebral cortex and remaining fibers 
from vestibular nuclei, spinal cord, reticular formation, and the deep nuclei. These 
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fibers make synapses with the dendritic claws of the granule cells at the deep nuclei 
forming fiber rosettes within the structures called glomeruli. Mossy fibers function in 
the sensory pathway by transmitting the information from pontine nuclei to the granule 
cells, which is then transmitted to the Purkinje cells through the parallel fibers.[23]  
1.2.3.5 Climbing fibers 
Climbing fibers are the neuronal projections that transmit signals from inferior olivary 
nucleus to the brainstem. A climbing fiber emerging from the olivary nucleus passes 
through pons and enters the cerebellum. Then it forms synapses with the deep 
cerebellar nuclei and Purkinje cells. During the development of the cerebellum the 
Purkinje cells are surrounded by several climbing fibers which are then eliminated as 
the cerebellum matures resulting in a single powerful climbing fiber. In this way they 
function in the motor coordination, especially in timing.[23]  
1.2.3.6 Neuronal circuits of the cerebellum 
In summary, Purkinje cells and the deep nuclei are the major functional units of the 
cerebellum. They receive input signals from motor and sensory pathways. Motor 
signals activate deep nuclei which adjust the movement by increasing and decreasing 
the signal. The sensory signals activated with the movement and the resulting output 
signals reach the Purkinje cells and are corrected if wrong by negative feedback 
(Figure 1.2).  
 
 The cerebellum receives input motor signals from several parts of the brain 
using four tracts: the corticopontocerebella, olivocerebellar, vestibulocerebellar, and 
reticulocerebellar tracts. The sensory signals from the peripheral body regions enter to 
the cerebellum by using dorsal and ventral spinocerebellar tracts. These 
spinocerebellar tracts are the ones where the most rapid signal conduction since rapid 
cerebellar response to rapid muscle movements occurs via these tracts. 
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Figure 1.2: Neuronal circuits and cellular components of the cerebellum. 
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1.3 Cerebellar Dysfunction and Ataxia 
There are several diseases involving dysfunction of the cerebellum and producing 
ataxia. The clinical symptoms of the ataxic motor syndromes involve body 
disequilibrium, uncoordinated movement, tremor, dysarthria, extremity and eye 
movements. A small proportion of the diseases with cerebellar lesion do not result in 
ataxia. Patients with the cerebellar cognitive affective syndrome (CCAS) have defects 
in executive, visual, and linguistic abilities.[25]  
 
 The lesions on the different regions of the cerebellum have distinct 
consequences. Patients with cerebellar lesions without any damage to the central core 
of the cerebellum, which is called deep nuclei, can still perform motor functions but in 
slow rate. [21] The dysfunction of the vestibulocerebellum results in impairment in the 
balance and the eye control. The dysfunction of the spinocerebellum including vermis 
results in truncal ataxia which is drunk-like movement. The dysfunction of the 
cerebrocerebellum results in appendicular ataxia which is the inability to achieve 
voluntary and planned movements. These patients represent intention tremor, 
dysarthria, dysdiadochokinesia, and dysmetria.[25]   
 
 The cerebellar ataxias are a very diverse group of disorders according to the 
clinical representation and causes. The ataxic disorders caused by cerebellar 
dysfunction divided into three groups. First group involves acquired ataxias which are 
mostly caused by stroke, trauma, and intoxication such as alcohol induced 
degeneration, radiation poisoning, and vitamin B12 deficiency.[26] The second group 
is degenerative ataxias, which are caused by de novo mutations, including idiopathic 
late onset cerebellar ataxia (ILOCA) and multiple system atrophy (MSA).[27] The last 
group consists of the hereditary ataxias caused by genetic mutations segregated in the 
family with Mendelian inheritance. Hereditary ataxias include autosomal dominant 
cerebellar ataxias such as episodic ataxias and spinocerebellar ataxias; autosomal 
recessive cerebellar ataxias such as Friedreich’s ataxia, ataxia telangiectasia, and 
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Niemann Pick disease; and X-linked cerebellar ataxias such as fragile X-associated 
tremor/ataxia syndrome.[26]   
 
 The genetic ataxias are both genetically and phenotypically heterogeneous 
where they can be caused by mutations in several different genes or different mutations 
in the same gene can cause different phenotypes.[26]  
1.4 Autosomal Recessive Cerebellar Ataxias 
Autosomal recessive cerebellar ataxias are neurodegenerative diseases. Most of them 
are heterogeneous with respect to age of onset, severity, and the frequency of the 
disease. They are associated with both CNS and PNS. Several autosomal recessive 
cerebellar ataxia disorders may have the same phenotype, whereas mutations in the 
same genes may lead to distinct phenotype such as frataxin (FXN), polymerase gamma 
(POLG), aprataxin (APTX), ataxia telangiectasia (ATM) or senataxin (SETX).[10] 
Therefore, the clinical classification is still remains controversial. 
 
 Palau and Espinos classified autosomal recessive cerebellar ataxias in four 
groups depending on the molecular mechanism as congenital and developmental 
ataxias, metabolic ataxias, , degenerative and progressive ataxias, ataxias due to DNA 
repair defects.[9] The examples of these subgroups are described in Table 1.1 
1.5 Cerebellar Ataxia, Mental Retardation, and Disequilibrium 
Syndrome 
Cerebellar ataxia, mental retardation, and disequilibrium syndrome (CAMRQ) is a 
genetically heterogeneous disorder characterized by cerebellar atrophy, mental 
retardation, dysarthric speech, and hypotonia with or without quadrupedal gait.  
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Table 1.1: Classification of the most common autosomal recessive ataxia syndromes. 
Adopted from Palau and Espinós (2006).[9] 
 
Classification Gene Locus 
Congenital ataxias   
Joubert syndrome JBTS4 NPHP1 2q13 
Cayman ataxia ATCAY 19p13.3 
Metabolic ataxias   
Ataxia with isolated vitamin E deficiency α-TTP 8q13 
Refsum disease PhyH 10pter-p11.2 
DNA repair defects   
Spinocerebellar ataxia with axonal neuropathy TDP1 14q31 
Ataxia with oculomotor apraxia 1 APTX 9p13 
Ataxia telangiectasia ATM 11q22.3 
Xeroderma Pigmentosum A XPA 9q22.3 
Degenerative ataxias   
Infantile onset spinocerebellar ataxia C10orf2 10q22.3-q24.1 
Charlevoix-Saguenay spastic ataxia SACS 13q12 
Friedreich’s ataxia  FXN 9q13 
Marinesco-Sjögren syndrome SIL1 5q32 
 
 
 
1.5.1 Genetic heterogeneity 
This form of ataxia is first described by Tan in a large consanguineous family in 
Turkey.[28] Since then multiple consanguineous families with CAMRQ syndrome 
with autosomal recessive inheritance have been reported. Genetic analysis revealed a 
genetically heterogeneous condition (Figure 1.3).  
 
 The first locus of CAMRQ was mapped on the locus 17p13 and a missense 
mutation was reported on WDR81 (WD repeat domain 81) [CAMRQ2; MIM: 610185; 
also referred to as Uner Tan syndrome].[29-31] VLDLR (very low-density lipoprotein 
receptor) is the first gene identified as a cause of CAMRQ syndrome [CAMRQ1; 
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MIM: 224050] by using linkage mapping followed by candidate gene sequencing.[31-
34] Furthermore, CA8 (Carbonic anhydrase VIII) gene [CAMRQ3; MIM: 613227] 
identified in another consanguineous family using the same methodology.[35]   
1.5.1.1 Very low-density lipoprotein receptor 
VLDLR has a role in the neural positioning in the cortical brain and neuronal migration 
by forming complex with reelin (RELN), apolipoprotein E receptor 2 (APOER2), and 
the adaptor protein, disabled, drosophila, homolog of 1 (DAB1) [36], which regulates 
Purkinje cell alignment in the cerebellum.[37] RELN is responsible for Lissencephaly 
2 which is associated with cerebellum, hippocampus, and brainstem abnormalities 
[LIS2; MIM: 257320].[38] Mice knock-outs of reelin represent ataxic gait and 
trembling [38], whereas mice knock-outs of VLDLR appear normal with small 
cerebellum.[36] 
 
In humans VLDR is first identified in the North American Hutterite population 
as a cause of Disequilibrium syndrome [DES-H, MIM: 224050] with truncal ataxia, 
mental retardation, delayed ambulation, and cerebral gyral simplification (Table 
1.2).[39] However, none of the disequilibrium syndromes including DES-H have been 
characterized with quadrupedal gait in the literature.[32] VLDLR is the first gene 
reported by our group as responsible for CAMRQ1 with quadrupedal locomotion in 
two unrelated consanguineous Turkish families. During the course, two additional 
families with CAMRQ1 with VLDLR mutation identified (Figure 1.3). 
 
 Family A is a consanguineous family from southeastern Turkey with seven 
affected individuals (Figure 1.4) and Family D is another consanguineous family from 
western Turkey with three affected individuals (Figure 1.5).[32, 40] Family A and D 
have distinct clinical characteristics (Table 1.2). Genome wide linkage analysis in the 
family linked the disease locus at chromosomal locus 9p24.2. Following candidate 
gene sequencing identified a nonsense mutation (p.R257X) and a single nucleotide 
deletion (c.2339delT) in VLDLR gene in Family A and D, respectively.[32]  
13 
 
 
 
Figure 1.3: Genetic heterogeneity in CAMRQ. Four different loci identified in seven 
families with CAMRQ, so far. The candidate gene research furthers for two more 
families (represented on top). The genes carrying the causal mutations were shown at 
the bottom.  
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Table 1.2: Clinical characteristics of the families with VLDLR deficiency 
 
 Family A Family D DES-H 
Locus 9p24 9p24 9p24 
Gene VLDLR VLDLR VLDLR 
Gait Quadrupedal Quadrupedal Bipedal 
Mental retardation Profound Profound Moderate to profound 
Inferior cerebellum Hypoplasia Hypoplasia Hypoplasia 
Hypotonia Absent Absent Present 
Speech Dysarthric Dysarthric Dysarthric 
Corpus callosum Normal Normal Normal 
Barany caloric nystagmus Normal Not done Not done 
Tremor Very Present Absent 
Cortical gyri Mild simplification Mild simplification Mild simplification 
Ambulation Delayed Delayed Delayed 
Inferior vermis Absent Absent Absent 
Seizures Very rare Absent Various degree 
Strabismus Present Present Present 
Truncal ataxia Severe Severe Severe 
Upper extremity reflexes Vivid Vivid Vivid 
Lower leg reflexes Hyperactive Hyperactive Hyperactive 
Pes-planus Present Present Present 
 
 
Furthermore, in recent studies, VLDLR was found to be associated with very 
similar phenotypes. Another consanguineous family from Iran with eight affected 
individuals with a homozygous truncating mutation in the VLDLR gene (p.R448X) 
represents a phenotype with cerebellar ataxia, disturbed equilibrium, strabismus, and 
short stature.[33] In addition, a 21-kb long homozygous deletion in the VLDR gene is 
reported in unrelated consanguineous Turkish family with two affected sibs who had 
delayed psychomotor development, cerebellar atrophy, speech delay, severely ataxic 
bipedal gait, dysarthria, dysmetria, dysdiadochokinesis, and hyperreflexia.[34] 
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Figure 1.4: Pedigree of the Family A. Seven individuals in the consanguineous Turkish 
family are affected by CAMRQ1. 
 
 
 
 
 
 
 
Figure 1.5: Pedigree of the Family D. Three individuals in the consanguineous Turkish 
family are affected by CAMRQ1. 
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1.5.1.2 Carbonic anhydrase VIII 
CA8 gene encodes carbonic anhydrase VIII which binds to inositol 1,4,5-triphosphate 
(IP3) receptor, type 1 (ITPR1). Mutations in the ITPR1 is responsible for autosomal 
dominant spinocerebellar ataxia 15 [SCA15; MIM 606658] in humans.[41] CA8 
inhibits binding of IP3 to ITPR1 which inhibits calcium release from the endoplasmic 
reticulum.[42] Mice deficient with both Ip3r1 and Ca8 represents ataxia but not 
cerebellar atrophy.[43]  
 
 In humans, homozygous mutation (S100P) in CA8 gene detected by genome-
wide linkage analysis and following candidate gene sequencing reported as the cause 
of CAMRQ3 in a consanguineous Iraqi family with four affected sibs. All of the 
patients represent quadrupedal gait, ataxia and mild mental retardation.[35] Another 
missense mutation in CA8 was detected by using homozygosity mapping followed by 
exon sequencing in an unrelated consanguineous family with CAMRQ3 in four 
affected individuals.[44]  
1.5.1.3 WD repeat domain 81 
Family B is the first consanguineous family in the literature with quadrupedal gait 
(Figure 1.6). The family lives in the southeastern Turkey and consists of six affected 
sibs with cerebellar hypoplasia, dysarthric speech, mental retardation, truncal ataxia 
and quadrupedal locomotion (Table 1.3).[28]  
 
 The disease locus was mapped to chromosomal region 17p13 by linkage 
analysis [32]. Homozygosity mapping of the affected individuals broaden the region 
and following targeted next generation sequencing revealed a homozygous missense 
mutation (p.P856L) at WDR81 gene segregated with the autosomal recessive 
inheritance of the family.[29] The analysis of multiple brain regions of the affected 
individuals using Magnetic Resonance Imaging (MRI) revealed cerebellar atrophy and 
abnormalities in corpus callosum, precentral gyrus, and Brodmann areas.[29] 
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Figure 1.6: Pedigree of the Family B. Six of the 19 sibs of a first cousin marriage are 
affected by CAMRQ2. 
 
 
 
 WDR81 was a predicted uncharacterized gene with unknown function. In a 
very recent study, Gulsuner et al. (2011) stated that the WDR81 encodes a 
uncharacterized protein which is predicted to be a membrane-spaning transmembrane 
protein with six domains.[29] WDR81 expression is analyzed in different parts of the 
brain regions and the highest level of expression is detected in the cerebellum and 
corpus callosum. Analysis of the expression profiles of the mouse embryos using 
published expression datasets revealed that mouse Wdr81 is detected at the Purkinje 
cells in the cerebellum. Functional clustering analysis of the genes which are 
coexpressed with the Wdr81 revealed that these genes are especieally enriched in 
neurodevelopmental processes including neuronal differentiation, axonogenesis, and 
cell morphogenesis.[29] This suggested a role of WDR81 in nervous system 
development. 
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Table 1.3: Clinical characteristics of the family with WDR81 deficiency. 
 Family B 
Locus 17p13 
Gene WDR81 
Gait Quadrupedal 
Mental retardation Severe to profound 
Inferior cerebellum Hypoplasia 
Hypotonia Absent 
Speech Dysarthric 
Corpus callosum Reduced 
Ambulation Delayed 
Truncal ataxia Severe 
Upper extremity reflexes Vivid 
Tremor rare 
Pes-planus Present 
Strabismus Present 
Seizures Rare 
Barany caloric nystagmus Cvs defect 
Lower leg reflexes Hyperactive 
Inferior vermis Absent 
Cortical gyri Mild simplification 
 
 
 
1.6 Gene Identification in Mendelian Disorders 
The human genome consists of thousands of genes and finding a particular gene 
responsible for a given phenotype is literally defined as “needles in stacks of 
needles”.[45] Traditionally, disease gene identification begins with family-based 
linkage analysis. However, this analysis has difficulties in identifying disease causing 
de novo mutations. This problem was overcome with the development of high-
resolution microarrays for Genome-Wide Association (GWAS) and Next Generation 
Sequencing (NGS) technologies and as a consequence, family-based linkage studies 
in Mendelian disorders have become the focus of genetic studies.[46] 
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 Over the past decade, association studies in large cohorts with cases and 
controls using genome-wide single nucleotide polymorphism (SNP) microarrays were 
used to identify common risk factors in common diseases. However, association 
studies had weaknesses in identifying rare disease causing mutations through linkage 
disequilibrium (LD) with common SNPs.[47] Family-based linkage analysis using 
genome-wide SNP microarrays made it possible to identify genetic loci that 
encompass the rare variants. This approach using genome-wide SNP microarrays also 
contributed to overcome population stratification and heterogeneity problems.[48] 
Thus, combination of next generation sequencing technology with family-based 
linkage analysis become the most powerful and robust approach to identify disease 
causing rare variants (Figure 1.7).[49] 
1.6.1 Genetic mapping in autosomal recessive disorders 
Identification of familial disorder with autosomal recessive inheritance pattern is the 
first step in understanding the pathobiological events and certain pathways underlying 
the disease. The most commonly used method to map the disease causing loci in 
autosomal recessive case is the linkage analysis. Linkage analysis is suitable when a 
family with multiple generations including multiple affected and unaffected 
individuals is found. Under these circumstances, the disease loci can be detected by 
genotyping certain markers, which are genetically variable, in the family.[50] 
 
 However, the disease locus identification is not this simple in every case. The 
most important limitation is the number of the genetic markers surrounding the locus, 
which is recently overcome with the use of high-throughput genome-wide SNP 
genotyping arrays. With the use of this technology thousands to millions of SNPs can 
be genotyped in many individuals at one step. The disease causing locus can be 
identified by determining which alleles were present only in affected individuals in 
large families.[49] 
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Figure 1.7: Schematic representation of the gene identification in Mendelian diseases. 
The methods used to identify the causal genes responsible for autosomal recessive 
disorders are represented. In this study homozygosity mapping and next generation 
sequencing is used to identify disease causing genes. 
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 Most often families with multiple affected and unaffected individuals can not 
be obtained so mapping of gene locus involved in rare autosomal recessive disorders 
would be a difficult task. In such cases, homozygosity mapping analysis using 
genome-wide SNP arrays is the best way to identify disease locus. Homozygosity 
mapping is the detection of the regions which would probably be homozygous only in 
patients because of the presence of the homozygous mutation inherited from each 
parent (Figure 1.8). One of the overlapping homozygous blocks in the genomes of the 
each patient should contain the disease causing mutation. This procedure can give 
information in families with two or three affected individuals from the same 
kindred.[51] These homozygous intervals can be searched for disease causing gene by 
conventional Sanger sequencing.  
 
 The rate limiting step of the identification of the disease causing gene using 
homozygosity mapping is the total length of the intervals determined by the analysis. 
These regions can be several megabases long and can contain several genes. At these 
circumstances Sanger sequencing of the entire genes would be time consuming and 
expensive. Bioinformatics approaches try to prioritize the candidate genes at the 
intervals by their probability of involvement in a disease phenotype using functional 
predictions and online databases. However, this is not applicable when the functional 
information or characterization of a protein is absent or hypothetical genes present at 
the locus. With the advent of targeted capture of the determined homozygous regions 
and next generation sequencing technology, it is now possible to search the regions at 
single nucleotide resolution.[52-54] 
1.6.2 Consanguinity 
Homozygosity mapping is an efficient method when searching for a mutation 
segregating within a small and closed population with a small gene pool due to founder 
effect. In such a population the mutation would probably come from each carrier parent 
by segregating on the same haplotype. Co-efficiency of inbreeding increases with the  
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Figure 1.8: Homozygosity mapping of recessive disease genes. Rare mutations can be 
identified in autosomal recessive disorders in consanguineous families based on the 
fact that, the disease locus will not have tendency to recombine and will be identical 
by decent. So it is likely that these regions contain the disease gene.    
23 
 
level of consanguinity. Thus, homozygosity mapping is the most robust technique in 
consanguineous families with autosomal recessive disorders. 
 
Homozygosity mapping method depends on the fact that the regions adjacent 
to the disease causing mutation will be identical in affected individuals coming from 
a common ancestor in an inbred family. Percentage of homozygous regions, also called 
as inbreeding coefficient, of the siblings in consanguineous families, differs from 0.4 
to 12.5% depending on the degree of consanguinity.[55]  
 
 At the randomly mated populations the occurrence of a recessive disease is 
proportional to the square of disease allele frequency. The rate of consanguineous 
marriages increases in the southern and eastern rims of the Mediterranean basin 
(Figure 1.9). In some regions such as Saudi Arabia and Pakistan, the consanguinity 
rate reaches to 50% of the population. At such regions the occurrence of the recessive 
diseases is directly proportional to the disease allele frequency.[56]  
1.6.3 Genetic heterogeneity 
A Mendelian genetic disorder caused by more than a single gene or allele is defined as 
genetically heterogeneous. The increased usage of the next generation sequencing 
technologies revealed that Mendelian disorders with genetic heterogeneity is far 
greater than expected.[57] 
 
As a result of next generation sequencing experiments, millions of variants 
with no phenotypic effect were identified whereas individually rare mutations with 
deleterious effect were at very small proportional. These rare deleterious mutations 
were implicated in several genetically heterogeneous Mendelian disorders and also in 
common diseases such as breast cancer [58], inherited hearing loss [59], autism and 
schizophrenia.[60, 61] 
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Figure 1.9: Prevalence of the consanguineous marriages in the world. Consanguinity 
increases at the southern and eastern rims of the Mediterranean basin. (Copyright © 
2009, National Academy of Sciences. From Bittles et al., 2010 with permission] 
 
1.6.4 Targeted next generation sequencing 
Disease gene identification studies in consanguineous families with genetically 
heterogeneous autosomal recessive diseases were greatly improved with the combined 
use of homozygosity mapping, target-enrichment, and next generation sequencing. 
Such a sequencing reaction could generate thousands of genetic variations including 
structural variations, single nucleotide variants (SNVs), and small insertions or 
deletions (indels). More than 95% of these variants would be phenotypically neutral 
and identified in healthy populations.  The critical point here is the identification of 
the causal mutation among the remaining suspicious variants.[45, 62] 
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 The identification of the recessive causal mutation involves several steps 
depending on the exclusion of the irrelevant variants. As a first step, novel variants 
should be identified by discrete filtering of the variants against a set of polymorphisms 
with minor allele frequencies higher than 0.1% using databases or datasets such as 
NCBI dbSNP, 1000 Genomes Project, and NHLBI GO Exome Sequencing Project. 
The next step would be stratification of the candidate variants on the basis of their 
positional and functional impacts by coding (frameshift, stop codon, splice site, 
missense, silence) or noncoding (intronic, intergenic, UTR). Protein altering variants 
that reside at the exons, regulatory regions and canonical splice sites should be selected 
for further analysis. The most important step here is the filtering of the variants which 
are not segregated with the disease phenotype in the family. Population screening 
would be last filtering step of the novel homozygous protein altering variants. The 
remaining variants can be annotated using the computational approaches such as 
evolution-based conservation analysis as the measure of deleteriousness, constraint-
based prediction analysis concerning the effect of variation on the protein-coding 
sequence and analysis of the curated databases.[45, 62]  
 
 As a result of sequencing data annotation, the most likely culprit disease 
causing mutation is identified. Experimental analysis would provide a support of 
causality for the given phenotype. The most powerful approach is the identification of 
the same or different mutations in the same gene in different families or unrelated 
sporadic cases. However, the phenotype and/or the mutation would be extremely rare 
in some recessive cases. In such cases, molecular consequences of the causal mutation 
could be evaluated in vitro or the phenotypic consequences of the causal mutation 
could be evaluated in vivo in a model organism.  
1.6.5 Identification of the causal mutation in CAMRQ  
In this thesis, identification of a novel missense causal mutation in a consanguineous 
Turkish family with a genetically heterogeneous autosomal recessive disorder, 
Cerebellar Ataxia, Mental Retardation, and disequilibrium syndrome with or without 
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quadrupedal locomotion (CAMRQ), by using homozygosity mapping followed by 
target enrichment and next generation sequencing will be discussed. 
1.7 Subject and outline of the Thesis 
CAMRQ syndrome is observed in another consanguineous family (Family C) from 
southern Turkey with four affected individuals in three branches of the pedigree 
(Figure 1.3, Figure 3.1, and Table 3.1).[32, 63] 
 
 The involvement of previously identified CAMRQ genes VLDLR, WDR81 and 
CA8 genes were excluded by using Sanger sequencing and homozygosity analysis. 
Homozygosity mapping analysis revealed four shared homozygous regions on 
chromosomes 13, 19 and 20 (Table 3.2). In order to identify the culprit gene, all 
homozygous regions were sequenced using target enrichment followed by next-
generation sequencing and all segregated variants were evaluated using structural and 
functional predictions, and population screening (Table 3.19). In this thesis, the story 
behind the identification of a missense mutation in ATP8A2, encoding a P4-type 
transmembrane protein ATPase, aminophospholipid transporter, class I, type 8A, 
member 2, which is found to be associated with the phenotype in Family C is 
described.[64]  
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Chapter 2 
Materials and Methods 
2.1 Recruitment of Patients and Controls 
A consanguineous family from southern Turkey, Family C, in which four individuals 
had CAMRQ syndrome, was investigated (Figure 3.1). The only affected female in the 
family was withdrawn form the study since her parents did not give consent for 
publishing the DNA analysis results. The index patient of the study, coded as 05-993, 
recently died secondary to a respiratory infection. The study was approved by the 
institutional review boards (IRB) at the Cukurova and Baskent Universities (decision 
21/3, 08.11.2005 and KA07/47, 02.04.2007, respectively).  
 
A total of 605 healthy individuals with no family history of movement 
disorders were used as a control in the study. Two additional cohorts including patients 
with similar neurological phenotypes were used in the study to find another patient 
with the candidate mutation: A cohort of 58 patients with cerebellar phenotypes with 
or without quadrupedal locomotion and a cohort of 750 patients with degenerative 
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neurological disorders or structural cortical malformations. All the participants and/or 
their parents were asked to sign an informed consent form prior to the study.  
2.2 Clinical Investigations 
Clinical investigations were performed at Cukurova University while the patients were 
awake and the clinical description of the family was published elsewhere. [63] All 
clinical investigations performed were compatible with the Helsinki Declaration 
(http://www.wma.net). 
 
 The “Mini Mental State Examination” (MMSE) test is performed in order to 
measure mental statuses of the individuals. It measures ﬁve cognitive function: 
language, registration, orientation, recall, and attention/calculation. A score of 23 or 
lower out of 30 reveals a cognitive problem with varying degrees.[65] Standardized 
Turkish version of the MMSE test was used for the three of the four patients.[66]  
 
 Cranial MRI and full-body computed tomography (CT) screening studies were 
performed at Cukurova University, Medical Faculty, Adana, Turkey.  
2.3 DNA Isolation from the Family Members 
Peripheral blood samples obtained from the patients and their parents by a specialist 
using venipuncture technique. 10 ml venous blood samples were collected in K3-
EDTA containing BD Vacutainer® Blood Collection tubes (Becton Drive, NJ, USA). 
The tubes were transferred to the laboratory at cold chains, quickly divided into 1 ml 
aliquots in 1.5 ml eppendorf tubes, and stored at -80oC refrigerators. 
 
 DNA isolation was performed with 200 µl peripheral blood samples using 
Nucleospin® Blood kit (Macherey-Nagel Inc., PA, USA) according to protocols 
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manufacturers supplied. A second DNA isolation from patients (05-993, 05-994, and 
05-996) were carried out using Phenol-Chloroform DNA extraction method [67] to 
obtain genomic DNA with high quality and high quantity which is necessary for high-
throughput genotyping and sequencing reactions.  
 
 The quantities and qualities of the samples were measured by densitometry 
analysis using horizontal 1% gel electrophoresis, by spectrophotometric reading using 
NanoDropTM ND-1000 Spectrophotometer (NanoDrop Technologies, Inc., DE, USA), 
and by fluorometric quantification using PicoGreen® assay.[68] 
2.4 Genetic Mapping Techniques 
2.4.1 Genome-wide SNP Genotyping  
DNA from peripheral blood samples of four patients and their three obligate carrier 
parents and two siblings were genotyped using the GeneChip® Human Mapping 
Affymetrix 10K Xba arrays (Affymetrix, Inc., CA, USA) for haplotype construction. 
SNP genotyping experiments were performed according to the manufacturer's protocol 
(Affymetrix, Inc., CA, USA). Briefly, 250 nanogram of DNA was digested with XbaI 
and the fragmented DNA was ligated to the XbaI adaptor. PCR amplification of the 
fragments carried out using AmpliTaq Gold (Applied Biosystems, CA, USA) enzyme 
following by array hybridization. Affymetrix GTYPE v4.1 software (Affymetrix, Inc., 
CA, USA) was used to generate CEL files. Exploration, normalization, and retrieval 
of genotype calls were achieved using Affymetrix Genotype Console Software v2.1 
(Affymetrix, Inc., CA, USA) with the default parameters. 
 
 For homozygosity mapping analysis, three patients’ (05-993, 05-994, and 05-
996) DNA were genotyped by using GeneChip® Human Mapping Affymetrix 250K 
NspI arrays as in the protocol that the manufacturer supplied (Affymetrix, Inc., CA, 
USA). Briefly, 250 nanograms of DNA was digested using NspI restriction enzyme 
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followed by linker ligation, PCR amplification, fragmentation, labeling, and array 
hybridization. Affymetrix GTYPE v4.1 software (Affymetrix, Inc., CA, USA) was 
used to generate CEL files. Image data were normalized and genotypes were called 
using Affymetrix Genotype Console Software v2.1 (Affymetrix, Inc., CA, USA) with 
the default parameters using the BRLMM algorithm. 
 
 In addition, a higher resolution Illumina Human610-Quad BeadChip arrays 
(Illumina, Inc., CA, USA) were used to genotype two affected individuals (05-994 and 
05-996) in order to confirm homozygous regions detected by Affymetrix SNP array. 
The experiments were performed according to manufacturer's instructions. Briefly, 
200 nanogram of genomic DNA was whole-genome amplified, fragmented with FMS 
reagent (Illumina, Inc., CA, USA), precipitated with 2-propanol and resuspended in 
RA1 hybridization buffer supplied by the manufacturer (Illumina, Inc., CA, USA). 
After overnight hybridization, the arrays were subjected to single-base extension, 
labeling, and coating with XC4 (Illumina, Inc., CA, USA). The image data were 
obtained by Illumina Bead Array Reader (Illumina, Inc., CA, USA). Normalization of 
the image data and genotype calling were achieved using Bead Studio software 
(Illumina, Inc., CA, USA) with the default parameters. 
2.4.2 Homozygosity mapping analysis and haplotype construction 
Homozygosity mapping is used to identify the locus containing the gene underlying 
recessive diseases. It is based on enrichment of homozygosity in the region harboring 
the disease causing gene in the affected individuals in a family.[51] Advances in high 
throughput SNP genotyping made this technique crucial in the identification of the 
disease causing recessive locus.  
 
 Processing and analysis of the Affymetrix and Illimuna SNP genotyping data 
was carried out using web-based HomozygosityMapper software [69] to identify 
homozygous regions. Homozygosity mapping using the Affymetrix 250K SNP arrays 
was performed in the three affected patients. According to array data sheet supplied 
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by the manufacturer, these arrays capable of genotyping a total of 262,264 SNPs with 
a median physical distance of 5.0 Kb and an average distance of 11.0 Kb between 
SNPs. The average heterozygosity of these SNPs is 0.30. 
 
 Homozygosity mapping analysis was repeated using Illimuna SNP array which 
has the genomic coverage of 620,901 SNPs. This provide marker spacing down to 1.5 
Kb (median physical distance: 2.7 Kb, average distance: 4.7 Kb according to data sheet 
provided by the manufacturer) with a mean heterozygosity rate of 0.22. This analysis 
with relatively low average heterozygosity and high density of SNP chips excluded the 
previously detected homozygous blocks with a length of 0.01 and 1.4 cM. The 
contiguous homozygous blocks detected by Affymetrix SNP array on chromosomes 
13 and 19 were evaluated as a single block in Illimuna array most probably due to high 
false positive rate of Affymetrix SNP data. 
 
  Haplotype blocks were analyzed by hand for each homozygous blocks 
including flanking regions detected by Illimuna SNP array data, separately using 
Affymetrix 10K SNP data. One affected individual (05-999), her sibling (05-1000), 
and her obligate carrier parents (05-997 and 05-998) leaved from the study by request. 
Linkage analysis is a powerful technique to identify critical region segregating with 
the disease. However, a meaningful LOD scores can be obtained in a large informative 
families. Therefore, haplotypes constructed were used for segregation of variants 
detected. 
 
 In order to saturate the homozygosity of the most likely candidate locus, 13q12, 
polymorphic microsatellite markers, also known as short tandem repeats (STRs), were 
genotyped by appropriate primers (see Appendix A). The selected STR markers 
D13S787, D13S1243, D13S742, D13S283, D13S1294, and D13S221 were 
determined using “Simple Repeats” tract of UCSC Genome Browser database (human 
reference genome NCBI36/hg18). 
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2.5 The Candidate Gene Approach 
2.5.1 Selecting a candidate gene 
Homozygosity mapping is a powerful technique to identify disease locus without any 
information about the disease causing genes. Candidate gene approach allows 
investigating genetic basis of the disorder. Selecting the appropriate candidate gene 
focus on the etiological role of the genes in disease, by understanding of the underlying 
biological pathway.[70] 
 
 The candidate disease loci identified by homozygosity mapping could contain 
several genes. In such a situation, the candidate genes can be identified by several 
methods, including database search, prediction analysis using bioinformatics tools, or 
expression analysis.  
 
 After detecting the shared regions, the genes involved in the homozygous 
blocks were extracted using web based Ensembl BioMart data mining tool. By using 
BioMart several information from several databases about the corresponding genes 
can be obtained such as chromosome names, gene loci, chromosomal bands, transcript 
counts, gene biotypes, gene statuses, gene ontology (GO) functions, Mendelian 
Inheritance of Man (MIM) associations, associated diseases, protein family domains, 
expression profiles,  and gene functions. 
 
 As a next step, corresponding genes on the homozygous blocks were prioritized 
using computational prediction tools. The GeneWanderer is a web-based tool which 
measures the probability by comparing the relative positions of each candidate genes 
to genes known to be involved in the disease pathogenesis by using protein-protein 
interactions.[71]  
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2.5.2 Testing the Candidate Gene 
2.5.2.1 Determination of the coding regions of the candidate genes 
Coding regions of the selected candidate genes were determined using Ensembl 
database (according to the human reference assembly GRCh37) and the corresponding 
sequences with the flanking regions were extracted by using the BioMart data mining 
tool of the Ensembl database.  
2.5.2.2 Primer design and quality 
Appropriate primers (Appendix A) were designed for sequencing coding exons, exon-
intron boundaries, untranslated regions (UTRs) using web-based Primer3 (v. 0.4.0) 
software.[72] In order to verify 3’ and 5’ self-complementarity, internal hairpin 
structures, and Tm differences, In-Slico PCR tool of the UCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgPcr) was used. Also, primers were analyzed using 
BLAT tool of UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgBlat) to 
check assembly to the entire genome. The primers were purchased from IONTEK, Inc. 
(Istanbul, Turkey). 
2.5.2.3 Amplification of the coding regions 
The coding regions were amplified by conventional PCR technique in TechneTM TC-
512 thermal cycler (Bibby Scientific, Inc., UK) with the following template conditions: 
initial denaturation step at 95oC for five minutes, followed by 35 cycles of denaturation 
(95oC for 30 seconds), annealing (60oC for 30 seconds) and elongation (72oC for 30 
seconds), and final elongation for five minutes at 72 oC. The template PCR conditions 
were optimized according to the GC-content of the amplified region and/or low-or-
high melting temperatures (Tm) of the primers by increasing or decreasing the 
annealing temperatures.  
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 PCR reactions were carried out in a total volume of 25 μL with the following 
ingredients: 75-150 ng of template DNA samples, 1X Taq polymerase buffer, 10 pmol 
of each primer, 0.2 mM dNTP, 1.0 mM MgCl2, and 1.25 unit Taq polymerase enzyme 
(MBI Fermentas, NY, USA). The template PCR cocktail were optimized when the 
GC-content of the targeted region is higher than 55% by addition of the BSA or 
DMSO, which help to dissolve secondary structure of DNA. Additional optimization 
is achieved by increasing or decreasing the amount of MgCl2 and/or primers when 
unwanted fragments obtained. 
2.5.2.3 Visualization of the PCR products 
It is necessary to check suitable PCR amplification which should contain a single PCR 
fragment prior to sequencing. PCR products were run in the 1% agarose gel (Basica 
LE, EU) which was completely dissolved in 1X TAE buffer. As a fluorescence tag, 30 
ng/ml ethidium bromide (EtBr) was added to the agarose gel. PCR products were 
mixed with 6X loading dye (MBI Fermentas, NY, USA) and loaded onto agarose gel.  
 
 The PCR products were run horizontally at the magnetic field (90-120 Volts) 
for 25-40 minutes according to the size of the products at room temperature. pUC Mix 
Marker 8 and Mass Ruler DNA Ladder (MBI Fermentas, NY, USA) were used as 
DNA markers (Figure 2.1). PCR products were visualized using GelDoc imaging 
system (Bio-Rad, CA, USA) and the images were captured by MultiAnalyst software 
version 1.1 (Bio-Rad, CA, USA). 
2.5.2.4 Sequencing of the candidate genes 
The PCR products were sequenced using conventional automated Sanger method. The 
sequencing reactions were carried out by Refgen, Inc., (Ankara, Turkey) using ABI 
3130 XL capillary sequencing instrument (Applied Biosystems, Inc., CA, USA). The 
purification of the PCR products was also carried out by the company using 
MinEluteTM 96 UF PCR Purification Kit (Qiagen, MD, USA). 
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2.5.2.5 Visualization and analysis of the sequencing data 
As a result of Sanger sequencing, raw sequence data files were obtained in the AB1 
sequence trace format. Each sequence trace file was aligned to the corresponding 
reference sequence extracted from NCBI database and analyzed by using CLCBio 
Main Workbench 6 software (CLC bio, Denmark) with the default parameters. The 
possible variations found were searched in the NCBI SNP database. 
 
 
 
 
 
 
 
Figure 2.1: DNA Markers used in the study. MassRuler DNA Ladder: 10 µL per lane, 
1% agarose gel, 1X TAE 7 V/cm, 45 minutes. pUC Mix Marker 8: 0.5 µg per lane, 
1.7% agarose gel, 1X TBE, 5 V/cm, 1.5 hours (http://www.fermentas.com/en/support/ 
printed-media). 
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2.6 Targeted next generation sequencing analysis  
Since 2007, several next generation sequencing technologies such as Roche 454, 
Illumina Genome Analyzer (GA), and ABI SOLiD have emerged and improved. Since 
the disease loci identified contains many genes, targeted next generation sequencing 
of these candidate intervals determined by homozygosity mapping would be the best 
option because of its advantages on focus time, expenses, and data storage. In order 
the identify disease causing mutation, Illimuna GA platform was used to sequence the 
targeted region in an affected individual (05-996). The sequencing procedure involves 
several steps which were summarized in Figure 2.2. 
2.6.1 Probe and Chip design 
Target enrichment method allows that selected regions were enriched in the genomic 
DNA library. The homozygous regions were analyzed using UCSC Genome Browser 
and as a result, 45,181 unique probes on chromosomes 13, 19, and 20 with a total 
length of 16,711,445 base pairs were designed. The designed probes were reanalyzed 
by using Sequence Search and Alignment Hashing Algorithm (SSAHA) software [73] 
with the less stringent parameters to determine uniqueness of the probes and efficiency 
of mapping. SSAHA maps sequence reads to a reference genome using pair-wise 
alignment.  
 
 Next, the probes then printed on a custom designed sequence capture 
microarrays, Roche NimbleGen Human Sequence Capture HD2 2.1M (Roche, 
Madison, USA), which is an ideal solution for targeted enrichment of the human 
disease associated regions. These high density microarrays constitudes 2.1 million 
long oligonucleotide probes with more than 60-bp single-probes. The manufactured 
arrays targeted an extended region of 16,756,626 base pairs.  
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Figure 2.2: Schematic representation of the next generation sequencing and analysis 
algorithm. Software packages and databases used were given at the bottom of boxes.  
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2.6.2 Single-end library construction and sequence capture  
DNA sample from an affected individual (05-996) was captured using the custom 
designed Nimblegen Human Sequence Capture HD2 2.1 M microarrays (Roche 
NimbleGen, WI, USA) according to the protocol supplied by the manufacturer (Roche 
NimbleGen, WI, USA) with modifications at the W. M. Keck Facility at Yale 
University. This process includes fragmentation of the DNA sample, ligation of the 
adapter sequences, and amplification of the produced DNA templates (Figure 2.3).  
 
Briefly, genomic DNA was sheared randomly into fragments by sonication and 
the GS FLX Titanium adaptors were ligated to these fragments. The verification of the 
sizes of the adaptor-ligated templates was carried out by agarose gel electrophoresis. 
The DNA sample was extracted from the gel and amplified by ligation-mediated PCR 
with the universal primers supplied. The PCR products were purified to avoid primer 
dimers and then hybridized in the appropriate buffer supplied to the capture array at 
42.0°C. Washing steps repeated two times at 47.5 °C and three more times at room 
temperature. The fragments which are bound to designed probes on the chip were 
eluted using 125 mM NaOH solution. These fragments amplified again by ligation-
mediated PCR. The amplified fragments are purified one more time and ready for 
sequencing. Captured DNA samples were sequenced by Illumina Genome Analyser 
IIx platform (Illimuna, CA, USA) as single-end 74- and 75-base pair reads. For 
additional information, see manufacturer's manual (http://www. nimblegen.com/ 
products/seqcap/arrays/2.1m/). 
2.6.3 Analysis of the targeted NGS data 
Next generation sequencing results in huge data which requires several steps for 
annotation. These steps include quality control filtering, alignment to reference 
sequences, variant calling and annotation. In order to achieve these steps several 
commercial and non-commercial pipelines generated.  
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Figure 2.3: Representation of the library construction and sequence capture 
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2.6.3.1 Alignment and read mapping 
Illumina sequence data were mapped to reference genome (human reference genome 
NCBI36 / hg18) using Mapping and assembly with qualities (Maq) [74] and Burrows-
Wheeler Aligner (BWA) [75] software packages. 
 
 Maq is suitable for alignment of the single-end short reads (<200 bp) to a 
reference genome in order to detect SNVs. The software is able to index all the reads 
with up to 2 or 3 mismatches by using ungapped alignment. While assembling the 
reads on the reference, Maq calls the heterozygote and homozygote bases by 
maximizing the posterior and phred qualities at each position. The manufacturer’s 
protocol involving detailed description, Maq codes and commands, and examples can 
be downloaded from http://maq.sourceforge.net/maq-manpage.shtml. 
 
 BWA is suitable for relatively short sequences to a reference genome by using 
a gapped Burrows-Wheeler Transform (BWT) algorithm in order to detect short indels. 
This algorithm can be used to map short queries up to 200bp with error rate lower than 
3%. The manufacturer’s protocol involving detailed description, BWA codes and 
commands, and examples can be downloaded from http://bio-bwa.Sourceforge.net/ 
bwa.shtml. 
2.6.3.2 Genotype and variant calling 
Alignment data obtained by using BWA and Maq was used for SNV and short indel 
calling, respectively. Variant detection and analysis were carried out using Sequence 
Alignment/Map Tools (SAMtools)  software package.[76]  SAMtools has ability to 
sort, merge, and index reads retrieved from Maq and BWA tools and generate a pile 
up of read bases. The detected homozygous and heterozygous variants were generated 
as variant calling output format which can be annotated using other resources.   
 
 Genotype calling is performed by using default cut-off rules such as an average 
Phred-type quality score of 20, a minimum read number of 2, a minimum coverage of 
41 
 
8, a minimum variation frequency of 0.01, and a minimum error rate of 0.01. All cut-
off values were set to zero while doing analysis, in order to obtain all possible SNVs 
and indels.  Phred quality scores can be obtained from the image data with the formula 
“QPhred = -10log10P (error rate)”. [77] Note that, 1% error rate is equal to a Phred score 
of 20. 
  
 Variant coordinates were converted to the updated human genome assembly 
GRCh37/hg19 by using Batch Coordinate Conversion tool (liftOver) of UCSC 
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgLiftOver). Read mapping and 
genotype calling analysis were repeated with the converted coordinates. 
2.6.3.3 Fold enrichment and coverage analysis 
The fold enrichment factor explains the total count of reads on each individual base 
pair. The analysis carried out using pileup module of SAMtools. The fold enrichment 
was calculated by dividing the mean number of covered bases to mean number of 
excluded bases.[78] Base coverage is the mean number of how many times of each 
base at the targeted region was read. Coverage calculations were evaluated using the 
mpileup module of SAMtools and coverage calculation of the coding regions were 
evaluated with intersectBED command of the BEDtools software packages.[79]  
 
 Samtools mpileup module provides information of alignment coverage across 
the targeted region by calculating mean of the read depths of each base in the multiple 
alignments. The called bases were classified as zero-covered bases for the ones with 
<1X mean read depth, low-coverage bases for the ones with 1-3X mean read depth, 
and high-covered bases for the ones with ≥4X mean read depth. The average coverage 
percentage values were calculated for each.  
 
 BEDtools utilities have ability to evaluate overlapping features and coverage 
calculations. In order to determine zero-covered, low-covered, and high-covered bases 
which were located in the coding regions, sequencing data files were intersected with 
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the exome data (genome assembly NCBI36/hg18, exome_B_NCBI36.bed, created 
from HAVANA & ENSEMBL data on 2008, downloaded from ftp://ftp.sanger.ac.uk/ 
pub/fsk/exome/)  and the evolutionary conserved protein-coding exons (genome 
assembly GRCh17/hg19, Exoniphy, downloaded from UCSC Genome Browser Genes 
and Gene Prediction tracts). A total statistics indicating the coverage percentages of 
each region was calculated. Using the start-end coordinates of the coding regions and 
the constitutive exons, zero- and low-covered regions were annotated. 
 
 The exoniphy program determines the constitutive exons which are 
evolutionarily conserved across species by multiple alignments of the coding regions 
using a phylogenetic hidden Markov model.[80] Constitutive exon coverage was 
calculated using BEDtools and non-covered (low- and zero-covered) constitutive 
exons were determined. The genes corresponding to the non-covered constitutive 
exons were extracted from Ensembl BioMart database and evaluated by the same tool 
according to expression profiles, mice knock-out studies, or involvement in a 
phenotype.  
 
 Zero- and low-coverage regions were further analyzed visually by using 
Integrative Genomics Viewer (IGV) platform.[81] IGV allows interactive exploration 
of the genomic datasets. 
2.6.3.4 Genotype calling error analysis 
A Mendelian error describes a wrong allele inherited from none of the parents. 
Mendelian errors were calculated and evaluated using PLINK Whole Genome 
Association Analysis Toolset.[82] 
 
 PLINK has ability to analyze, visualize and annotate genotype/phenotype data. 
The annotation includes management of the data (merge, intersect, flip files, and 
extract subsets), summary statics (allele and genotype frequencies, missing genotype 
rates), and population stratification (linkage, significance, association, CNV, and 
haplotype analyses).  
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 Mendelian error rates calculated by comparing SNP genotypes obtained from 
Illumina Human610-Quad BeadChip array and targeted next generation sequencing 
data obtained from NimbleGen Human Sequence Capture HD2 2.1 M microarrays 
using “Mendel” module of the PLINK software package.  
2.6.3.5 Positional and functional annotation of the variants  
The next step of the analysis of variants determined at the targeted region is the 
positional and functional annotation of the variants and determination of the novel 
variants by filtering of the SNPs.  
 
 Annotation and filtering of the variants carried out using ANNOVAR software 
package [83]. ANNOVAR software package has an ability to annotate genetic variants 
detected from high-throughput sequencing data by performing gene-based, region-
based, and filter-based annotations. Functional annotations such as protein coding 
alterations at the amino acid level can be detected using gene-based annotations.  By 
using region-based annotation positional specification, conservation across species, 
segmental duplications, GWAS hits, OMIM hits and genomic variants can be 
determined. Filter based-annotation is used to identify SNPs that are reported in NCBI 
dbSNP database, 1000 genomes datasets, and NHBLI-EVS exome sequencing projects 
datasets. 
  
 Conversion of the SAMtools variant calling output file into ANNOVAR 
annotation input file can be achieved by using “convert2annovar” script. Annotation 
of the variants using ANNOVAR can be achieved by either manually (for detailed 
manual visit http://www.openbioinformatics.org/annovar/annovar_startup.html) or 
automatically by using “summarize_annovar” script. This developed pipeline allows 
annotation of the sequence data with steps on a cluster. The automated annotation 
generates an excel file with gene annotation, exonic function, amino acid change and 
its effect, conservation analysis and predictions, population screening, and SNP 
identifiers (Figure 2.4).  
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Figure 2.4: Algorithm of the ANNOVAR annotation pipeline. Functional annotation 
of the variants carried out using summarize_annovar script of the ANNOVAR 
software package. 
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 As a result, novel variants were determined by exclusion of the SNPs with 
heterozygosity rates higher than 0.01 using dbSNP132 database. Novel homozygous 
and heterozygous variants were classified according to their genomic location as 
intronic, protein coding, intergenic, non-coding RNA, upstream, downstream, exonic 
splicing, intronic splicing, 3’UTR, and 5’UTR. The protein coding variants then 
classified according to their functional effects as frameshift insertion, frameshift 
deletion, frameshift block substitution, stop-gain, stop-loss, nonframeshift insertion, 
nonframeshift deletion, nonframeshift block substitution, nonsynonymous SNV, 
synonymous SNV. Novel homozygous protein altering variants were considered as a 
potential disease causing mutation. 
2.6.3.6 File formats 
Targeted next generation sequencing generates a huge data which should be annotated. 
For functional annotation of the targeted next generation sequencing data several files 
were generated in order to make them usable for the next annotation in the pipeline.  
 
The raw data in the form of “.bcl” files were generated by sequencing of the 
targeted region using Illumina Hiseq 2000 platform and converted to “.qseq” files 
through the use of Illumina’s BCL converter tool to obtain “.fastq” files for further 
analysis. The FASTQ format is a text-based file with the sequencing read data. FASTQ 
files validated, indexed and aligned to the human reference genome in order to obtain 
output files in the SAM format using the BWA tool which uses Burrows-Wheeler 
Transform algorithm and Maq which uses ungapped algorithm. The “.sam” file is 
designed to store nucleotide alignments. After the alignment is performed, “.sam” files 
converted to the “.bam” files by SAMtools which are binary representations of the 
reads. The “.bam” files than indexed and used to generate “.pileup” files which 
includes additional tracks such as diversity and SNP by mpileup module of the 
SAMtools. PILEUP file than converted to several formats such as VCF, IGV, and BED 
for annotations and coverage analysis.  
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2.7 Identification of the disease causing mutation 
Novel homozygous protein altering variants at the homozygous blocks determined by 
combining Illimuna SNP array and targeted next generation sequencing data were 
considered as potential disease causing mutation candidates. In order to find the 
disease causing gene, the remaining candidate variants were subjected to exclusion 
and the remaining variant was defined as the culprit mutation. 
2.7.1 Population screening 
2.7.1.1 Population datasets 
Functional novel variants were further analyzed in two population datasets: 1000 
genome datasets (http://www.1000genomes.org, data release, phase I) and NHLBI 
Exome Sequencing Project (EVS) (http://evs.gs.washington.edu/EVS/, data release 
ESP6500).  Common variants were excluded if minor allele frequency (MAF) was 
higher than 0.01.  
 
 1000 genomes, a deep catalog of the human genetic variation, project aimed to 
determine SNPs in different populations by using next generation sequencing. The 
pilot project composed of sequencing data of 2,500 healthy individuals in the “.vcf” 
format which are available for researchers. The sequencing data was annotated with 
1000 genome database by using tabix module of the SAMtools. 
 
 EVS database is a collaborating group project aims to discover novel genes in 
non-neurological phenotypes such as lung, blood, and heart disorders by using next-
generation sequencing. The data release ESP6500 composed of 6503 samples. The 
sequencing data can be analyzed individually for each variant on the project site or can 
be annotated by ANNOVAR. 
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2.7.1.2 Alleles specific PCR analysis 
Functional variants which had not been recognized by a restriction enzyme were 
genotyped by allele specific PCR (AS-PCR) method in Turkish population in order to 
exclude rare variants as disease causing mutation. The cohort consists of 305 random 
healthy individuals and 300 region-match healthy controls which constitute a total of 
1210 control chromosomes. The mutant and wild type primers, and also the reference 
primer which is used as internal control designed by using web-based Primer3 software 
and analyzed using In-Slico PCR and BLAT tools of UCSC Genome Browser 
(Appendix A). The primers were purchased from IONTEK, Inc. (Istanbul, Turkey). 
PCR products were visualized on 1.5% agarose gel electrophoresis. 
2.7.1.3 Restriction fragment length polymorphism analysis 
Functional variants which are recognized by restriction enzymes were analyzed by 
using restriction fragment length polymorphism (RFLP). Restriction enzymes were 
determined by using web-based NEBcutter tool.[84] The related fragments were 
amplified by the appropriate primers (Appendix A). Restriction enzyme digestion was 
carried out with at 37oC, overnight. The cocktail composed of 5 µL of PCR products, 
2 µL of appropriate reaction buffer (10x), and 2 units restriction enzyme (MBI 
Fermentas, NY, USA) in 20 µL completed with double-distilled H20.The digested 
samples were visualized on 2.0% agarose gel electrophoresis. 
2.7.2 Confirmation of the candidate variants 
Novel functional homozygous variants were analyzed by conventional Sanger 
sequencing explained in section 2.5.2.4, AS-PCR, and RFLP methods in order to 
confirm targeted next generation sequencing results. The related regions were 
amplified by the appropriate primers (Appendix A). The sequencing results were 
evaluated using CLC Main Workbench 6. 
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2.7.3 Segregation analysis of the candidate variants 
Segregation analysis of the novel homozygous candidate variants were facilitated 
using haplotyping analysis explained in section 2.4.2 in order to determine if the 
candidate genes were co-segregated with the autosomal recessive disease.   
 
 The candidate genes that were not co-segregated with the disease in 
homozygous state were confirmed by conventional Sanger sequencing in three 
affected individuals (05-993, 05-994, and 05-996). The related regions were amplified 
by the appropriate primers (Appendix A). The sequencing results were evaluated using 
CLC Main Workbench 6. 
2.8 Screening the candidate genes in neurological disease cohorts 
The most important step in candidate gene approach is the identification of other 
mutations in randomly chosen subjects with the disease. For this purpose the candidate 
genes were further screened in two cohorts of patients with neuro-developmental 
phenotypes with unknown causal mutation.  
 
 The first cohort consisted of 58 patients with ataxia. Among these, twelve 
patients have cerebellar ataxia with or without quadrupedal locomotion. The screening 
of the mutations carried out using AS-PCR.  
 
 The second cohort consisted of 750 patients with neuro-degenerative diseases 
or structural cortical malformations for whom the underlying genetic cause is missing. 
Analysis of the region was carried out by evaluation of the homozygous regions 
spanning the linkage interval. The genotyping of the patients were carried out using 
Illumina Human 370 Duo or 610 Quad BeadChip microarrays at Yale University, CT, 
USA.  
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2.9 Functional Characterization of ATP8A2 
2.9.1 Prediction tools and databases 
Predictive analytics compose of several statistical techniques and is used to provide 
predictive models concerning biological, biochemical, and evolutionary functions of 
the candidate genes. Also, several databases used in the study (see section 2.12 and 
Table 2.1) in order to collect information about candidate genes and data to use in 
analysis.  
 
 Evolutionary conservation analysis is carried out by multiple sequence 
alignment of the protein sequences of the orthologs of the candidate genes. The protein 
sequences in the fasta format were extracted from Ensembl database (see section 2.11 
for reference sequence IDs and chromosomal locations). The homologous protein 
sequences were aligned using the appropriate modules of CLCMain Workbench 6 
(CLC Bio, Aarhus, Denmark). This software also generates phylogenetic tree using 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) algorithm that is 
evaluated by bootstrap analysis. UPGMA algorithm creates a root tree by assuming a 
constant rate of evolution by calculating a bootstrap value using pairwise similarity 
matrix. 
 
 Conservation analysis using multiple alignments is validated using prediction 
tools. First, Phylogenetic p-Value (phyloP) and Genomic Evolutionary Rate Profiling 
(GERP) scores of the each candidate variant were extracted using the approapriate 
tracts of the UCSC Genome Browser: phyloP46wayall track21 and allHg19RS_BW 
track20, respectively. GERP score can be defined as neutral if the substitution occurs 
in multiple alignments, and as under functional constraints if not.[85] The phyloP score 
identifies acceleration (for negative scores) or conservation (for positive scores) in a 
subtree using likelihood ratio test.[86] Next, web-based prediction tools were used 
which depend on the effect of the mutated amino acid on the protein structure and 
function. So, disease causing probabilities of the candidate variants were evaluated 
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using SIFT [87], Polyphen2 [88], and MutationTaster [89] tools. By using “liftOver” 
tool of the UCSC Genome Browser, the variant coordinates were converted into the 
human genome assembly GRCh37/hg19.  
  
 Functional domains and predicted membrane-spanning domains of the 
ATP8A2 protein were determined using Protein Family (Pfam) database [90] and 
Transmembrane Prediction (TmPred) tool (http://www.ch.embnet.org/software/ 
TMPRED_form), respectively. Pfam is a database including collection of protein 
families predicted by multiple sequence alignments and hidden Markov models 
(HMMs). TMpred predicts the possible membrane spanning regions of the 
transmembrane domains. The possible effects of the each candidate variant on the two- 
and three-dimensional protein structure were predicted using web-based Protein 
Structure Prediction PSIPRED server [91] and Have yOur Protein Explained (HOPE) 
project tools [92], respectively.  
 
 The protein altering candidate variants were further evaluated in several 
databases. The description and websites of the databases were given in Table 2.1 
2.9.2 Expression analysis 
2.9.2.1 cDNA libraries construction 
cDNA synthesis was carried out with random hexamer primers using RevertAidTM 
First Strand cDNA Synthesis kit (Fermentas, NY, USA) after DNaseI (Fermentas, NY, 
USA) digestion. First-strand cDNAs were obtained from multiple commercially 
available human RNA samples [Clontech: 636567 (Corpus Callosum), 636643 
(Human Total RNA Master Panel); Agilent: 540005 (Total Brain), 540007 
(Cerebellum), 540053 (Brain Stem), 540117 (Frontal Cortex), 540135 (Striatum), 
540137 (Occipital Cortex), 540143 (Parietal Cortex), 540157 (Fetal Brain)]. The 
quantities and the qualities of the samples were measured by NanoDrop 
spectrophotometry.  
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Table 2.1: Databases used to evaluate novel homozygous protein altering candidate 
variants 
 
Databases Description Website 
HapMap International HapMap Project hapmap.ncbi.nlm.nih.gov 
DGV Database of Genomic Variants projects.tcag.ca/variation 
DDBJ DNA Data Bank of Japan www.ddbj.nig.ac.jp 
ALFRED Human ALlele FREquency 
Database 
alfred.med.yale.edu/alfred 
CGAP SNP 
 
CGAP Genetic Annotation 
Initiative 
lpgws.nci.nih.gov/perl/snpbr 
FESD II Functional Element SNPs 
Database 
sysbio.kribb.re.kr:8080/fesd 
F-SNP Functional SNPs compbio.cs.queensu.ca/F-SNP 
Gene Viewer Displays SNPs in mRNA 
sequences 
lpgws.nci.nih.gov/GeneViewer 
GWAS A genotype-phenotype 
association database 
www.gwascentral.org/index 
JSNP Japanese SNP Database snp.ims.u-tokyo.ac.jp 
PhenCode Paving the Path between 
Phenotype and Genome 
globin.bx.psu.edu/phencode 
SNAP SNP Annotation Platform snap.humgen.au.dk/views 
SNPper Look for known SNPs in public 
databases 
snpper.chip.org/bio/snpper 
Tagger Selection and evaluation of tag 
SNPs from genotype data 
www.broadinstitute.org/tagger 
HGMD The Human Gene Mutation 
Database 
www.hgmd.cf.ac.uk/ac 
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2.9.2.2 Semi-quantitative RT-PCR analysis 
Semi-quantitative RT-PCR assay was performed using conventional PCR of the 
cDNAs obtained. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as 
reference since it is highly expressed in the leukocytes as a housekeeping gene. The 
reaction was performed using the following protocol: Initial denaturation step at 95oC 
for five minutes, followed by 25 cycles of denaturation (95oC for 30 seconds), 
annealing (60oC for 30 seconds) and elongation (72oC for 30 seconds), and final 
extension for five minutes at 72 oC. 25µL reaction mixture composed of 100 ng of 
template DNA samples, 1X Taq polymerase buffer, 10 pmol of each primer, 0.2 mM 
dNTP, 1.0 mM MgCl2, and 1.25 unit Taq polymerase enzyme (MBI Fermentas, NY, 
USA). 
2.9.2.3 Real time Quantitative RT-PCR analysis 
Real-time Quantitative Reverse Transcription PCR (QRT-PCR) assay was performed 
using iQTM SYBR® Green Supermix according to standard protocols (BioRad, CA, 
USA) with ABI 7500 Fast Real-Time PCR System (Applied Biosystems, CA, USA). 
The relative quantifications were calculated by normalizing Ct values to reference 
genes beta-actin (ACTB) and GAPDH. The expression data were analyzed using the 
Pfaffl method [93]. 
 
 Real-time QRT-PCR primers were designed at the exon-intron boundaries in 
order to prevent amplification of the DNA contaminations by Primer3 software 
(Appendix A) and verified by In-silico PCR and BLAT tools of the UCSC Genome 
Browser. Each primer was normalized by diluting cDNAs from 1-5-6 fold to verify 
efficiency. Primers were purchased from Iontek, Inc., Istanbul, Turkey. 
 
 The reaction was carried out in 25µL cocktail including 12.5 µL SYBR Green 
Supermix, 5 pmol from each primer, 100 ng of cDNA, and double-distilled H2O by 
using the following conditions: Initial denaturation step at 95oC for ten minutes, 
followed by 45 cycles of denaturation (95oC for 30 seconds), annealing (60oC for 30 
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seconds) and elongation (72oC for 30 seconds), and final extension for five minutes at 
72 oC. Melting curve analysis were carried out in order to detect contaminations and/or 
improper binding of the primers, if any, by using dissociation-chracteristics of double-
stranded DNA, just after the final elongations step by raising the temperature 0.5oC 
per 15 seconds from 55oC to 94oC.  
2.9.2.4 Data mining from published expression datasets 
NCBI Gene Expression Ombibus (GEO) is a database of curated gene expression 
experiments (http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi). Microarray 
expression data of the mouse brain tissues at the embryonic days E9.5, E11.5 and 
E13.5 were extracted from the database.[94] The data was evaluated with GeneSpring 
GX V11.1 software (Agilent Technologies, Inc.). Quality control and filtering analysis 
was carried out using the appropriate modules of the software as in the manufacturer’s 
protocol (A detailed protocol can be obtained from the http://www.chem.agilent.com/ 
cag/bsp/products/gsgx/manuals/GeneSpring-manual.pdf). Differentially expressed 
genes within day groups were annotated and filtered using One-way ANOVA Test 
(Bonferroni corrected p < 0.001). By using “Find Similar Entity Lists” module of the 
GeneSpring software genes that are predicted to be correlated with the candidate gene 
(R≥0.95) were detected. The human disease associations of the related genes were 
evaluated by Mouse Genome Informatics (MGI) database.[95] 
 
 Functional annotation clustering of the correlated genes was evaluated by the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) tool.[96, 
97] 
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2.10 Enzymes, Chemicals, and Reagents 
2.10.1 Enzymes 
 
Table 2.2: Enzymes used in the experiments 
Enzyme Company 
Proteinase K Appligene, CA, USA 
Taq DNA Polymerase Fermentas, NY, USA 
DNase I Fermentas, NY, USA 
Bpil Fermentas, NY, USA 
Phusion® Hot Start Flex New England Biolabs, UK 
OneTaq® Hot Start New England Biolabs, UK 
OneTaq® DNA Polymerase New England Biolabs, UK 
iQ SYBR Green Bio-Rad, CA, USA 
Phusion Hot Start II High-Fidelity Finnzymes, Finland 
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2.10.2 Solutions and buffers 
 
Table 2.3: Solutions and buffers used in the experiment 
 
Solutions and Buffer Content 
Ethidium bromide: 10 mg/ml in water (stock solution) 
 30 ng/ml (working solution) 
  
Acrylamide:bisacrylamide (30%): 29.5 gr acrylamide 
 0.44 gr bisacrylamide 
 ddH2O to 100 ml 
  
Agarose gel loading buffer (6X): 15% coll 
 0.05% bromophenol 
 0.05% xylene cyanol 
  
1X TAE (Tris-acetic acid-EDTA): 40mM Tris-acetate, 
 2 nM EDTA 
 pH 8.0 
  
1X TBE (Tris-Boric Acid-EDTA) 89 mM Tris-base 
 89 mM boric acid 
 2 mM EDTA 
 pH 8.3 
  
SSC (20X): 175.32 gr Sodium Chloride 
 88.23 gr Sodium Citrate 
 ddH20 to 1 lt 
 pH 7.0 
  
10% APS 1 g Ammonium persulfate 
 ddH2O to 10 ml 
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2.10.3 Chemicals and reagents 
 
Table 2.4: Reagents and chemicals used in the experiment 
 
Reagent/Chemical Company 
Acetic acid Sigma, MO, USA 
Acrylamide Sigma, MO, USA 
Agarose Basica LE, EU 
Ammonium per sulfate Carlo Elba, Italy 
Anti-Digoxigenin-AP, Fab fragments Roche, Germany 
Bakers yeast RNA Sigma, MO, USA 
BCIP Roche, Germany 
Bisacrylamide Sigma, MO, USA 
Bromophenol blue Sigma, MO, USA 
BSA Promega, CA, USA 
CHAPS Sigma, MO, USA 
Denhardt's reagent Invitrogen, CA, USA 
dNTPs Fermentas, NY, USA 
EDTA Fermentas, NY, USA 
Ethanol Merck, Germany 
Ethidium bromide Sigma, MO, USA 
Ficoll Type 400 Sigma, MO, USA 
Formamide (Deionized) Ambion, TX, USA 
Heparin Sigma, MO, USA 
Herring sperm DNA Invitrogen, CA, USA 
MgCl2 Fermentas, NY, USA 
NBT Roche, Germany 
NH4OAc Ambion, TX, USA 
TEMED Sigma, MO, USA 
Tris-Base Bio-Rad, CA, USA 
Tris-HCl Sigma, MO, USA 
Trizol reagent Invitrogen, CA, USA 
Tween-20 Sigma, MO, USA 
Xylene Cyanol Sigma, MO, USA 
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2.11 Reference sequences used in this study 
 
Table 2.5: Accession codes and locations of the ortholog sequences of the candidate 
genes 
 
 Species Ensemble Gene ID Location 
APBA3 orthologes   
Bos taurus ENSBTAG00000008395 7:21440493-21447907 
Canis familiaris ENSCAFG00000019193 20:55713773-55721057 
Cavia porcellus ENSCPOG00000026376 687:63474-66471 
Dipodomys ordii ENSDORG00000005324 5484:7506-12773 
Felis catus ENSFCAG00000019172 4155:157830-165598 
Gorilla gorilla ENSGGOG00000004637 19:3832569-3843515 
Homo sapiens ENSG00000011132 19:3750771-3761673 
S.tridecemlineatus ENSSTOG00000000352 1:2124399-2130070 
Macaca mulatta ENSMMUG00000009672 19:3590577-3601845 
Macropus eugenii ENSMEUG00000013011 8213:22976-31616 
Microcebus murinus ENSMICG00000014756 3672:14526-20558 
Mus musculus ENSMUSG00000004931 10:81268172-81273247 
Myotis lucifugus ENSMLUG00000010776 504:187520-193685 
Otolemur garnettii ENSOGAG00000017147 1:16443947-16451566 
Pan troglodytes ENSPTRG00000010275 19:3753399-3763164 
Procavia capensis ENSPCAG00000000644 6138:24641-33058 
Rattus norvegicus ENSRNOG00000020466 7:9930015-9934987 
Sarcophilus harrisii ENSSHAG00000002223 G410.1:26352-32251 
Sorex araneus ENSSARG00000004110 129:653-6870 
Sus scrofa ENSSSCG00000013492 2:75521565-75529547 
ATP8A2 Orthologs   
Bos taurus ENSBTAG00000019529 12:33754809-34054513 
Danio rerio ENSDARG00000077492 24:21980347-22077198 
Dipodomys ordii ENSDORG00000000239 2794:7266-241256 
Felis catus ENSFCAG00000001581 1872:202599-915634 
Gallus gallus ENSGALG00000017106 1:181054445-181328604 
Gorilla gorilla ENSGGOG00000003045 13:7288395-7801797 
Homo sapiens ENSG00000132932 13:25946209-26599989 
Macaca mulatta ENSMMUG00000008520 17:5281514-5918044 
Monodelphis domestica ENSMODG00000008674 4:295073504-295928157 
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Mus musculus ENSMUSG00000021983 14:59647531-60197179 
Ochotona princeps ENSOPRG00000003638 2068:4320-730369 
Otolemur garnettii ENSOGAG00000003827 1:5252098-5877244 
Pan troglodytes ENSPTRG00000005721 13:24918459-25571779 
Pteropus vampyrus ENSPVAG00000000898 3706:27656-465399 
Tarsius syrichta ENSTSYG00000002400 3466:9606-14765 
Tetraodon nigroviridis ENSTNIG00000012718 6:3751410-3769309 
Tursiops truncatus ENSTTRG00000012736 1304:21683-467711 
Xenopus tropicalis ENSXETG00000010674 272.1:102868-323788 
PCP2 Orthologs   
Bos taurus ENSBTAG00000008906 7:17700404-17701870 
Canis familiaris ENSCAFG00000018302 20:52407779-52409628 
Cavia porcellus ENSCPOG00000020356 42:14877819-14878832 
Equus caballus ENSECAG00000006836 7:4617290-4618648 
Erinaceus telfairi ENSETEG00000018017 259696:1910-2915 
Felis catus ENSFCAG00000001595 445:41838-44033 
Gorilla gorilla ENSGGOG00000002452 19:7845053-7847186 
Homo sapiens ENSG00000174788 19:7696509-7698570 
Loxodonta africana ENSLAFG00000007547 114:1659014-1660387 
Macaca mulatta ENSMMUG00000028904 19:7582857-7585049 
Macropus eugenii ENSMEUG00000001483 980:33754-36479 
Microcebus murinus ENSMICG00000010552 430:12274-14003 
Monodelphis domestica ENSMODG00000015012 3:463179948-463181640 
Mus musculus ENSMUSG00000004630 8:3623371-3625545 
Otolemur garnettii ENSOGAG00000001240 821.1:493965-495066 
Pan troglodytes ENSPTRG00000010396 19:7732220-7734353 
Procavia capensis ENSPCAG00000010909 728:34704-36528 
Rattus norvegicus ENSRNOG00000000993 12:2529466-2531706 
Sorex araneus ENSSARG00000010822 733:287-1115 
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2.12 Web Sources 
Table 2.6: Web-tools used in analysis and design 
 
Web-Tool Web address Reference 
HomozygosityMapper www.homozygositymapper.org [69] 
BioMart www.ensembl.org/biomart/martview - 
GeneWanderer compbio.charite.de/genewanderer/ [71] 
Ensembl www.ensembl.org - 
Primer3 frodo.wi.mit.edu [72] 
BLAT genome.ucsc.edu/cgi-bin/hgBlat - 
In-Slico PCR genome.ucsc.edu/cgi-bin/hgPcr - 
SSAHA www.sanger.ac.uk/resources/ssaha [73] 
Maq maq.sourceforge.net [74] 
BWA bio-bwa.sourceforge.net [75] 
SAMtools samtools.sourceforge.net [76] 
liftOver genome.ucsc.edu/cgi-bin/hgLiftOver - 
BEDtools code.google.com/p/bedtools [79] 
IGV www.broadinstitute.org/igv [81] 
PLINK pngu.mgh.harvard.edu/~purcell/plink [82] 
ANNOVAR www.openbioinformatics.org/annovar [83] 
dbSNP www.ncbi.nlm.nih.gov/projects/SNP - 
1000 Genomes www.1000genomes.org - 
EVS evs.gs.washington.edu/EVS - 
NEBcutter tools.neb.com/NEBcutter2 [84] 
Genome Bioinformatics genome.ucsc.edu - 
GERP mendel.stanford.edu/SidowLab [85] 
phyloP compgen.bscb.cornell.edu/phast [86] 
SIFT sift.jcvi.org/ [87] 
PolyPhen2 genetics.bwh.harvard.edu/pph2 [88] 
MutationTaster www.mutationtaster.org/ [89] 
Pfam pfam.sanger.ac.uk/ [90] 
TMpred www.ch.embnet.org/TMPRED - 
HOPE www.cmbi.ru.nl/hope/home [92] 
PSIpred bioinf.cs.ucl.ac.uk/psipred [91] 
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Chapter 3 
Results 
3.1. Clinical Assessment of the Family 
The consanguineous family from Adana-Turkey has four affected individuals with 
mental retardation, dysarthric speech, and truncal ataxia (See the pedigree in Figure 
3.1). All the patients in the family had significant developmental delay noted in 
childhood (Table 3.1). Two of the patients (05-994 and 05-999) exhibited quadrupedal 
locomotion (Figure 3.2). These patients did not show any ataxic movements during 
quadrupedal walking. The woman (05-999) had ability to stand upright and maintain 
the position with bent knees and hips. She preferentially got back to quadrupedal 
position while walking. The man (05-994) could only stand by support (Figure 3.3, 
left). One of the male patients (05-996) walked quadrupedally during infancy, acquired 
occasional drunk-like ataxic bipedal gait later in his adulthood with 
dysdiadochokinesia and dysmetria (Figure 3.3, right). The last patient (05-993) also 
walked quadrupedally during childhood, but exhibiting total inability to walk during 
his adulthood. 
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Table 3.1: Physical, radiological, and genetic characteristics of the patients. Adopted 
from Ozcelik et al., 2008 [32] with permission 
 
 05-993 05-994 05-996 
Gait (childhood) Quadrupedal Quadrupedal Quadrupedal 
Gait (adulthood) None Quadrupedal Bipedal 
Truncal ataxia Severe Severe Severe 
Corpus callosum Normal ? Normal 
Inferior cerebellum Mild hypoplasia ? Mild hypoplasia 
Cortical gyri Mild 
simplification 
? Mild 
simplification 
Mental retardation Profound Profound Profound 
Hypotonia Absent Absent Absent 
Speech Dysarthric Dysarthric Dysarthric 
Tremor Present Present Present 
Seizures Rare Rare Rare 
Barany caloric nystagmus Pvs defect Pvs defect Pvs defect 
Ambulation Delayed Delayed Delayed 
Lower leg reflexes Hyperactive Hyperactive Hyperactive 
Upper extremity reflexes Vivid Vivid Vivid 
Pes-planus Present Present Present 
Strabismus Present Present Present 
Inferior vermis Normal ? Normal 
 
Abbreviations used in this table: PVS, pulmonary valve stenosis 
 
 
 All affected individuals of the family had severe dysarthric speech with great 
difficulty in articulation using a limited vocabulary. All three affected individuals 
examined had severe mental retardation determined by MMSE test. Two of the 
patients (05-994 and 05-996) had zero and the other (05-993) had 3 points in the test. 
The test revealed that they followed very simple questions and commands, but they 
disoriented in time and place. They were not aware of the time or the place. They also 
did not exhibit consciousness in arithmetic calculations and memory. However, none 
of the patients showed autistic features. 
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Figure 3.1: Family pedigree of the affected individuals. (Copyright © 2013, Copyright 
Clearance Center, Inc. Adopted from Tan et al., 2006 [63] with permission). 
 
  
Neurological examinations of the affected individuals were carried out at the 
Cukurova University University Hospital by specialists which revealed that they had 
bilateral dysmetria and dysdiadochokinesia with severe truncal ataxia. Motor 
examinations revealed normal muscle tone and power and no sensory loss. Patients’ 
lower extremities were hyperactive and upper extremities were vivid. Cranial MRI and 
whole-body CT examinations of the patients revealed normal corpus callosum and 
inferior vermis whereas mild cerebral and cerebellar atrophy, mild cerebral cortical 
simplification. 
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Figure 3.2: Quadrupedal walking of patients 05-994 (left) and 05-999 (right). 
(Copyright © 2013, Copyright Clearance Center, Inc. From Tan et al., 2006 [63] 
with permission).  
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Figure 3.3: Standing postures of the quadrupedal man (05-994) and bipedal ataxic man 
(05-996). (Copyright © 2013, Copyright Clearance Center, Inc. From Tan et al., 2006 
[63] with permission). 
 
3.2. Genetic Mapping 
Close examination of the pedigree revealed that CAMRQ inherited in the family with 
autosomal recessive transmission. Homozygosity mapping analysis is a useful method 
to map recessive traits in consanguineous families. 
3.2.1. Homozygosity mapping using Affymetrix arrays 
Homozygosity mapping analysis was facilitated with Affymetrix 250K NspI 
genotyping data which was generated using DNA of three affected individuals (05-
993, 05-994 and 05-996) (Figure 3.4). As a result 23 shared homozygous regions 
detected for a mutation segregating within the three affected individuals (Table 3.2). 
Since nine of the homozygous blocks were located in centromeric or telomeric regions, 
they were excluded from the study. The two consecutive blocks on chromosome 13 
were supposed as a single block and selected as the first candidate locus. 
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Figure 3.4: Homozygosity mapping analysis using Affymetrix arrays. Shared 
homozygosity regions of the three affected individuals (05-993, 05-994 and 05-996) 
were determined using web-based online HomozygosityMapper software. Y-axis of 
the graph indicates genome-wide homozygosity scores (max=1000). Red bars refer to 
the common homozygous intervals. 
 
 
3.2.2. Candidate gene sequencing 
The shared homozygous blocks contain 563 genes including 286 protein coding (see 
Appendix B), 149 pseudogenes, 15 processed transcripts, and 113 RNA genes. 
Because of the huge number of genes, a candidate gene approach determined. The 
shared homozygote interval on 13q region evaluated as the primary candidate. 
 
 The 1.3 Mb long candidate region on chromosome 13q contains 10 protein 
coding genes (Table 3.3). Among these ATP12A (ATPase, Na+/K+ transporting, alpha 
polypeptide-like 1), ATP8A2 (ATPase, class I, type 8a, member 2), MTMR6 
(Myotubularin-related protein 6), NUPL1 (Nucleoporin-like 1), CENPJ (Centromeric 
protein j), and SACS (Sacsin) genes expressed at the cerebellum. Especially CENPJ 
gene causes primary microcephaly [MIM: 609279] with mental retardation and SACS 
gene causes spastic ataxia [MIM: 270550].  
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Table 3.2: Shared homozygous regions of Affymetrix 250K data 
Chr:Start-End SNP Start-SNP End Number 
of SNPs 
Size (bp) 
1:1,156,131-2,283,313 rs2887286-rs2843130 10 1,127,182 
2:193,892,056-195,377,437 rs6746137-rs16831761 110 1,485,381 
3:48,531,740-49,696,633 rs9851771-rs2131104 18 1,164,893 
3:50,539,219-52,446,788 rs1107312-rs6766038 62 1,907,569 
3:155,104,305-156,147,664 rs4131239-rs1450107 70 1,043,359 
5:68,638,941-70,701,990 rs6879078-rs5005863 3 2,063,049 
9:38,708,759-41,227,099 rs16935357-rs3012258 12 2,518,340 
9:43,553,500-44,768,659 rs11261805-rs11263386 3 1,215,159 
12:123,153,825-124,181,820 rs6489190-rs7979528 27 1,027,995 
13:24,982,832-26,080,014 rs4769349-rs17082385 126 1,097,182 
13:26,080,617-26,474,189 rs41516145-rs11149407 52 393,572 
19:40,264,738-41,416,143 rs2190846-rs3852872 34 1,151,405 
19:41,502,602-43,044,329 rs6508964-rs6509018 38 1,541,727 
20:44,460,376-46,115,853 rs12480250-rs6066353 106 1,655,477 
Centromeric and telomeric regions 
1:121,213,673-142,821,805 rs6600668-rs6668639 4 21,608,132 
2:90,242,076-91,965,175 rs842160-rs55651153 4 1,723,099 
8:43,156,798-46,924,211 rs7007551-rs2353200 14 3,767,413 
9:45,088,879-68,781,772 rs2217821-rs41349147 5 23,692,893 
11:51,563,636-55,050,890 rs7484073-rs10792084 7 3,487,254 
19:2,909,033-4,822,855 rs10853963-rs4807651 33 1,913,822 
19:5,458,230-6,977,118 rs674316-rs4807918 50 1,518,888 
19:6,977,924-8,103,881 rs7256969-rs10411185 50 1,125,957 
19:24,240,785-28,319,922 rs17272051-rs7258458 23 4,079,137 
 
Abbreviations used in this table: Chr, chromosome; bp, base pair; SNP, single nucleotide polymorphism 
 
 
 The genes reside at the 13q region were prioritized to select candidate genes 
using web-based GeneWanderer tool.[71] This approach prioritizes genes reside in a 
genomic interval found by comparing protein-protein interactions and being involved 
in a disease or phenotype. As a result CDK8, GTF3A, POLR1D, MTMR6, CENPJ are 
the first five candidates (Table 3.4) which were prioritized by association with 
spinocerebellar ataxia and protein-protein interactions with previously identified 
CAMRQ genes (VLDLR and CA8).  
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 Table 3.3: Genes located on the 13q candidate homozygous region 
 
Chr:Start-End (bp) Gene Biotype Status 
13:24982295-25171798 RP11-556N21.4 pseudogene known 
13:24993688-24995180 RP11-169O17.5 processed transcript putative 
13:24995064-25086948 PARP4 protein coding known 
13:25129366-25129451 AL359538.2 miRNA novel 
13:25140981-25144866 PSPC1P2 pseudogene known 
13:25141011-25171814 TPTE2P6 processed transcript novel 
13:25183217-25183313 AL359538.1 miRNA novel 
13:25254549-25285921 ATP12A protein coding known 
13:25277694-25277803 RNY1P7 misc RNA known 
13:25278540-25278926 RPL26P34 pseudogene known 
13:25316815-25320322 IRX1P1 pseudogene known 
13:25324795-25326309 ANKRD20A10P pseudogene known 
13:25338290-25454059 RNF17 protein coding known 
13:25457171-25497018 CENPJ protein coding known 
13:25498815-25542625 TPTE2P1 pseudogene known 
13:25511014-25512491 LINC00357 processed transcript putative 
13:25517713-25518636 SLC25A15P3 pseudogene known 
13:25562715-25563063 RPL34P27 pseudogene known 
13:25670006-25673392 PABPC3 protein coding known 
13:25715794-25716046 AL359757.1 pseudogene novel 
13:25735822-25746426 FAM123A protein coding known 
13:25746966-25754217 RP11-165I9.4 lincRNA novel 
13:25755579-25763898 RP11-165I9.8 antisense novel 
13:25767245-25784433 RP11-165I9.6 processed transcript putative 
13:25780187-25780640 RPL23AP69 pseudogene known 
13:25802307-25862147 MTMR6 protein coding known 
13:25820669-25820753 AL590787.1 miRNA novel 
13:25874262-25875576 RP11-271M24.2 antisense novel 
13:25875662-25923938 NUPL1 protein coding known 
13:25939937-25940293 TCEB2P1 pseudogene known 
13:25946209-26599989 ATP8A2 protein coding known 
13:26027137-26027428 Metazoa_SRP misc RNA novel 
13:26091257-26091363 RNU6-78 snRNA known 
13:26437388-26437805 RP11-467D10.2 pseudogene known 
13:26442061-26455095 AL138815.1 protein coding known 
 
Abbreviations used in this table: Chr, chromosome; bp, base pair; misc RNA, miscellaneous RNA, miRNA, microRNA 
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Table 3.4: Gene prioritization using GeneWanderer 
 
Rank Gene Symbol Score Start (bp) End (bp) 
1 CDK8 0.06336 25,726,755 25,876,568 
2 GTF3A 0.06135 26,895,848 26,907,957 
3 POLR1D 0.01466 27,094,002 27,139,547 
4 MTMR6 0.01304 24,718,338 24,759,703 
5 CENPJ 0.01227 24,354,411 24,395,084 
6 CDX2 0.00785 27,434,277 27,441,316 
7 PDX1 0.00775 27,392,156 27,397,393 
8 WASF3 0.00213 26,029,839 26,161,081 
9 LNX2 0.00208 27,018,049 27,092,719 
10 SHISA2 0.00167 25,516,734 25,523,197 
11 RPL21 0.00149 26,723,691 26,728,704 
12 NUPL1 0.00093 24,773,665 24,814,560 
13 ATP8A2 0.00087 24,844,208 25,493,419 
14 GSX1 0.00057 27,264,779 27,266,088 
15 ATP12A 0.00040 24,152,694 24,183,917 
16 GPR12 0.00032 26,230,959 26,231,963 
17 RNF6 0.00029 25,684,904 25,694,507 
18 PABPC3 0.00029 24,568,275 24,570,704 
19 USP12 0.00010 26,540,432 26,644,027 
20 RNF17 0.00005 24,236,300 24,352,058 
21 RASL11A 0.00000 26,742,463 26,745,826 
 
Abbreviations used in this table: bp, base pair 
 
 
 
 All in all, taking expression and prioritization analysis and database searches 
into account MTMR6, NUPL, CENPJ and SACS genes were selected as the first 
candidates for sequencing. The 96.8% of the 57 exons, the exon-intron boundaries and 
untranslated regions of these four genes were sequenced with 93 primers (see 
Appendix A for the full list of primers) but no mutations associated with the disease 
were detected (Table 3.5). Further sequencing using candidate gene priorization 
approach would be time and expense consuming so the Affymetrix array genotyping 
results were evaluated. 
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Table 3.5: Statistics of the sequencing results of the 13q region 
 
Genes Exon 
Number 
Total 
Reactions 
Exons not  
Sequenced 
Completed 
(%) 
MTMR6 15 19 1 100 
CENPJ 17 18 1 94.4 
NUPL1 16 22 0 100 
SACS 9 36 1 97.2 
 
 
3.2.3. Homozygosity mapping using high-resolution Illimuna arrays 
Homozygosity mapping analysis using Affymetrix 250K NspI array results with 23 
shared homozygous loci. 9 of them were excluded since they were at the centromeric 
or telomeric regions. Remaining 14 loci on chromosomes 1, 2, 3, 5, 9, 12, 13, 19, 20 
could not be excluded from the study. Affymetrix 250K SNP Array contains of 
approximately 262,264 SNPs and do not represent all regions of the genomes. Also 
the experiment resulted with low confidence (79.5%) since 53.787 SNPs were not 
informative for haplotyping.  
 
Therefore, the homozygosity mapping analysis were repeated with a more 
comprehensive SNP array, Illumina Human610-Quad BeadChip with 599,012 SNP 
and 21889 CNV probes, using DNA’s of the two patients (05-994 and 05-996). 
Homozygosity mapping analysis were carried out using web-based 
HomozygosityMapper software using 589,904 informative SNPs (98.5% coverage) 
for both patients (Figure 3.5). As a result four shared homozygous blocks were 
identified in two affected individuals (Table 3.6). All other previously reported regions 
including the telomeric and centromeric ones and also previously identified locus for 
CAMRQ syndrome were excluded by this analysis (Figure 3.6).   
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Table 3.6: Shared homozygous regions of Illimuna arrays 
 
Chr Start End SNP start SNP end Size (in bp) 
13 23,644,401 26,534,333 rs4769238 rs11618503 2,889,932 
19 3,136,845 14,337,400 rs1465245 rs4926182 11,200,555 
19 39,666,967 45,543,787 rs1529712 rs1560725 5,876,820 
20 41,015,889 45,954,292 rs2425479 rs6094661 4,938,403 
 
Abbreviations used in this table: Chr, chromosome; bp, base pair; SNP, single nucleotide polymorphism 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Homozygosity mapping analysis using high-resolution Illimuna arrays. 
Shared homozygosity regions of the two affected individuals (05-994 and 05-996) 
were determined using web-based online HomozygosityMapper software. Y-axis of 
the graph indicates genome- wide homozygosity scores (max=1000). Red bars refer to 
the common homozygous intervals. (Copyright © 2012, Rights Managed by Nature 
Publishing Group. From Onat et al., 2012 [64] with permission). 
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Figure 3.6: Comparison of the Affymetrix and Illimuna arrays. Homozygosity 
mapping analysis using Affymetrix 250K NspI array results with 23 shared 
homozygous loci. 9 of them were located at the centromeric or telomeric regions. 
Affymetrix array experiment resulted with 208.477 informative SNPs (79.5% 
coverage). Homozygosity mapping analysis was repeated with a Illumina Human610-
Quad BeadChip with 589,904 informative SNPs (98.5% coverage). Four shared 
homozygous blocks were identified which excluded many of the regions identified by 
Affymetrix arrays including the telomeric and centromeric ones. 
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3.3 Targeted next generation sequencing of the homozygous regions 
Four common homozygous intervals determined by high-resolution Illimuna 
genotyping contain 882 genes with 2,263 transcripts and 16,935 exons which 
constitute a total of 4,068,182 base pairs. The shared regions constitute a total of 
24,905,710 base pairs with intergenic and intragenic regions which may be involved 
in regulation of the transcription. The region also contains 594 known protein coding 
genes so candidate gene prioritization would not be work. Because of the huge number 
of genes it is not possible to sequence all exons with exon-intron boundaries and 
untranslated regions; therefore a genome-wide approach was aimed.  
 
As a next step, targeted enrichment followed by next generation sequencing 
technology is the most promising step towards maximizing the efficiency and cost. 
Sample preparation, capture and sequence enrichment, and data analysis are the major 
steps that encompass workflow.  
3.3.1 Sample Preparation 
The quality of the next generation sequencing data depends on the optimal sample 
preparation. Genomic DNA with high quality and high quantity is necessary for 
targeted next generation sequencing experiments as in all high-throughput sequencing 
or genotyping experiments.  
 
Genomic DNA isolations of the selected individuals were carried out using 
phenol-chloroform extraction method. The quantities and qualities of the samples were 
measured by gel electrophoresis using densitometry analysis (Figure 3.7 and Table 
3.7), spectrophotometry measurements (Table 3.8), and PicoGreen method (Table 3.9, 
Table 3.10, and Figure 3.8). 
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Table 3.7: DNA concentrations as a result of densitometric measurements 
 
Sample Concentration (ng/µl) Dilution Total (ng/µl) 
05-992 70.23 1/5 351.15 
05-994 67.57 1/5 337.85 
05-996 94.37 1/5 471.85 
Affy DNA 25ng 22.76 1/2 45.52 
Affy DNA 50ng 50 1 reference 
MassRuler 10k 25 1 reference 
MassRuler 8k 20 1 reference 
 
Abbreviations used in this table: ng, nano gram; µl, microliters; Affy, Affymetrix 
 
 
 
 
 
 
 
Figure 3.7: Density measurements using agarose gel electrophoresis. DNA samples 
were run on 1% agarose gel at 70V for 50 minutes.  Lane 1: MassRuler DNA Ladder 
Mix (1 µl); Lanes 2-4: DNA samples diluted 1:5 in TE (1 µl); Lanes 5-6: Affymetrix 
Reference gDNA (25 ng, 50 ng); Lane 7: pUC mix Marker 8 (1 µl). Gel image was 
captured with BioRad Gel Doc 2000 system, DNA quantitation was performed using 
BioRad Multi Analyst 1.1 software. Affymetrix gDNA (50 ng) and MassRuler (10k: 
25 ng, 8k: 20 ng) used as reference. Affymetrix gDNA (25 ng) used as control. 
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Table 3.8: DNA concentrations as a result of spectrophotometric measurements 
 
Sample 260/280 260/230 Conc. 
(ng/µl) 
Dilution Total 
(ng/µl) 
Total DNA 
(95 µl) 
Affy DNA  
(50 ng) 
1.79 1.78 49.82 1 49.82 - 
Affy DNA  
(25 ng) 
1.87 1.22 22.76 1/2 45.52 - 
05-992 1:5 1.77 2.10 63.88 1/5 319.40 30.34 
05-994 1:5 1.84 2.28 123.48 1/5 617.40 58.65 
05-996 1:5 1.82 2.21 95.99 1/5 479.95 45.60 
 
Abbreviations used in this table: Conc., concentration; ng, nano gram; µl, microliters; Affy, Affymetrix 
 
 
 
 
Table 3.9: DNA concentrations as a result of PicoGreen analysis 
 
Well Fluorescein  Dilution 
Factor 
Counts Concentration 
(ng/ml) 
Total 
DNA 
Reference 1246 0 0 -2,62 - 
Reference 5125 1 3879 6,81 - 
Reference 5156 1/10 3910 6,89 - 
Reference 43385 1/100 42139 99,88 - 
Reference 413440 1/1000 412194 1000,04 - 
05-992 123510 1/5 122264 294,79 147,39 
05-992 200728 1/5 199482 482,62 241,31 
05-994 303311 1/5 302065 732,15 366,08 
05-994 343331 1/5 342085 829,50 414,75 
05-996 235531 1/5 234285 567,28 283,64 
05-996 252286 1/5 251040 608,03 304,02 
Affy DNA 66914 1/2 65668 157,12 31,42 
Affy DNA 58375 1/2 57129 136,34 27,27 
05-992 67102 1/10 65856 157,57 157,57 
05-994 174756 1/10 173510 419,44 419,44 
05-994 59471 1/20 58225 139,01 278,02 
05-992 374703 1/2 373457 905,81 181,16 
05-996 130496 1/10 129250 311,78 155,89 
 
Abbreviations used in this table: ng, nano gram; µl, microliters; Affy, Affymetrix 
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Table 3.10: Average concentrations of samples of PicoGreen measurements 
 
Samples 1:2 1:5 1:5 1:10 1:20 Average 
(ng/µl) 
Total DNA 
(95 µl) 
05-992 181 147 241 157  - 182 17.2 
05-994  - 366 414 419 278 369 35.1 
05-996  - 283 304 155  - 247 23.5 
Affy DNA  
(50ng) 
 - 31 27  -  - 58  - 
 
Abbreviations used in this table: ng, nano gram; µl, microliters; Affy, Affymetrix 
 
 
 
 
 
 
 
 
Figure 3.8: Linear regression graph of PicoGreen assay 
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3.3.2 Capture and sequence enrichment 
The next step to be considered for targeted next generation sequencing experiment is 
the make-up of the library to be sequenced. So the capturing reaction should recover 
the fragments with low bias and high complexity to obtain a high percentage of 
coverage of the targeted region. The minimal critical regions at the shared homozygous 
regions determined by homozygosity mapping using Illimuna genotyping data 
(chr13:23,644,401-26,534,333, chr19:3,136,845-14,337,400, chr19:39,666,967-
45,543,787, chr20:41,015,889-45,954,292, according to hg19 reference genome) was 
captured using 3 µg input DNA of one affected individual, 05-996 by custom-designed 
Nimblegen Human Sequence Capture HD2 microarray. A total of 16,756,626 base 
long unique probes were designed to target homozygous regions and as a result 
captured with 629-fold enrichment (Table 3.11). Captured DNA sample of the affected 
individual was sequenced by Illimuna Genome Analyzer IIx using Titanium series 
reagents. 29.2% of the reads mapped to the targeted homozygosity intervals. Average 
read length was 74.32 base-pairs with 4,764,521 single-end 75 base-pair reads 
contributing 20.42 fold coverage and 10,059,448 single-end 74 base-pair reads 
contributing 42.55 fold coverage. A total of 48.62 million reads were sequenced with 
62.96 fold mean coverage depth. As a result, 97.41% of the targeted bases being 
covered by at least four reads (Table 3.11). 
3.3.3 Data Analysis 
3.3.3.1 Variant calling and error rates 
Since next generation sequencing is a valuable technique for understanding disease 
and health, management and analysis of the huge data obtained requires several steps. 
At first, error sources and rates in the original raw data should be determined. Data 
should be analyzed by computational methods including assembly, alignment, and 
variation detection. Variant annotation requires a broad range of genetic analysis 
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including comparative genomics, polymorphism detection, analysis of coding and 
non-coding regions, and identifying mutant genes in disease pathways. 
 
 
 
Table 3.11: Statistics of targeted next generation sequence data. (Copyright © 2012, 
Rights Managed by Nature Publishing Group. From Onat et al., 2012 [64] with 
permission). 
 
Patient ID 05-996 
Number of lanes 3 
Read Type (SR/PE) SR 
Read length 75 bp 
Total number of reads  48,627,393 
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 Interval size (bp) 16,756,626 
Fold enrichment 629 
% mapped to the interval 29.20 
Mean coverage (fold) 62.96 
% of bases covered at least 4X  97.41 
Mean error rate (%) 0.61 
2nd base error rate (%) 0.25 
Last base error rate (%) 2.36 
 
Abbreviations used in this table: SR, single repeat; PE, paired end; bp, base pair 
 
 
 
 It is critical to assess the quality of the sequencing reactions by evaluating the 
sequencing errors and artifacts. Variant calling accuracy is affected by several factors 
such as library generation, read mapping, variation in unique and repetitive elements, 
detecting indels with short reads, difficulties in mapping homopolymer regions and 
GCC motifs, and artificial amplification.[98]  Next generation sequencing platforms 
had an average of 0.1-1% error rate which reaches to 3-4.5% at homopolymer 
regions.[99] Comparison analysis between the Illimuna SNP genotyping data and 
Illimuna targeted sequencing data revealed a mean error rate of 0.61% (0.24%-2.36%) 
determined on overall sequencing data. 
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3.3.3.2 Analysis of the low-coverage regions 
As mentioned, as a result of targeted next generation sequencing, 97.41% of the 
targeted bases being covered by at least four reads. Therefore, 2.59% of the targeted 
bases which constitutes 434,494 bases were whether covered less than four reads 
(239,122 bp) or did not covered at all (195,372 bp) (Table 3.12, see also Figure 3.9). 
So in principle, mutations in these low and zero coverage regions could also be disease 
causing and should be analyzed. 
 
 The non-covered bases would reside at the coding exons, exon-intron 
boundaries, untranslated regions, introns, and intragenic regions. Classification of 
these non-covered bases according to their physical location would provide 
information about the functional consequences of the possible variations since the non-
covered bases at the non-coding regions would not be important in coverage 
calculations.  
 
 The targeted regions contain 5,235 exons that compose a total of 1,067,180 
bases (genome assembly NCBI36/hg18, exome_B_NCBI36.bed,  created from 
HAVANA & ENSEMBL data on 2008, downloaded from ftp://ftp.sanger.ac.uk/ 
pub/fsk/exome/) of which 919,453 bases are on the evolutionary conserved protein-
coding exons (genome assembly GRCh17/hg19, Exoniphy, downloaded from UCSC 
Genome Browser Genes and Gene Prediction tracts).  
 
Evaluation of the low and zero coverage regions using mpileup module of 
Samtools and intersectBED command of BEDtools revealed that 14,027 bases reside 
at the exonic regions which increase the coverage to 98.69%. A more detailed analysis 
of the exonic region revealed that only 4,505 bases place on the constitutive parts 
which comprise 99.51% coverage with at least four times readings (Table 3.12, see 
also Figure 3.9). These 4,505 bases correspond to 77 exons in 9 genes (Table 3.13) 
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Table 3.12: Coverage analysis of the next generation sequencing data 
 
 Base pairs Percentage 
Interval size  16,756,626 100 
Bases  covered (>3X) 16,322,132 97.41 
Low covered bases (1-3X) 239,122 1.42 
Zero covered bases 195,372 1.17 
Bases non-covered 434,494 2.59 
Bases non-covered at the noncoding regions 420,467 2.51 
Bases non-covered at the exonic regions 14,027 0.08 
Bases non-covered at the UTRs and boundaries 9,522 0.05 
Bases non-covered at the constitutive exons 4,505 0.03 
Total number of exons 1,067,180 5.49 
Exonic coverage (>3X) 14,027 98.69 
Total number of constitutive exons 919,454 6.37 
Constitutive exonic coverage (>3X) 4,505 99.51 
 
 The genes located at the low or zero coverage regions with the constitutive 
exons were evaluated in detail. It is revealed that they neither have cerebellar 
expression nor display a phenotype compatible with cerebellar involvement in mouse 
knockouts (Table 3.13). Based on these results, we concluded that it is highly unlikely 
that a causative mutation is missed at the low or zero coverage regions. 
3.4 Identification of the Disease-Causing Determinants 
With the advent of next generation sequencing technology, identifying novel disease 
genes has become facilitated. Figure 3.10 summarizes the procedure followed in this 
study to identify disease-causing genes. The common step in disease-causing gene 
identification is mutation testing in a candidate gene, but the other steps are unique to 
the case. In general the method we used can be divided into those that determination 
of the chromosomal location of the disease locus, next generation sequencing, 
genotype calling and functional annotation of the variants, evaluation and exclusion of 
the variants, identification and confirmation of the disease-causing variant. 
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Figure 3.9: Graphical representation of the coverage analysis of the next generation 
sequencing data. 97.41% of the targeted bases covered by at least four reads. Among 
these, 99.51% of the constitutive exons in protein coding regions were found to be 
covered by at least four reads. The numbers corresponds to base pairs. Coverage 
analysis carried out using intersectBED command of BEDtools and mpileup module 
of Samtools.
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Table 3.13: List of genes corresponding to low and zero coverage regions. (Copyright © 2012, Rights Managed by Nature Publishing 
Group. From Onat et al., 2012 [64] with permission). 
Gene Name Gene Biotype MIM 
accession 
Exp. in 
cerebellum 
Exp. in 
brain 
Exp. in 
nerve 
MGI Phenotype of the homozygous mice 
GNA15 Protein coding - no no no Normal hematopoiesis and normal response to 
inflammatory challenges 
CLASRP Protein coding - no yes yes - 
DOHH Protein coding - yes yes no Embryonic lethal 
SAFB2 Protein coding - yes yes yes Born at the expected Mendelian ratio and did 
not show any obvious defects in growth or 
fertility 
PAK4 Protein coding - yes yes yes Die at midgestation exhibiting heart defects as 
well as impaired neuronal development and 
yolk sac vasculature 
CHAF1A Protein coding - yes yes yes Lethality before implantation, embryonic 
growth arrest, and abnormal heterochromatin 
morphology 
AC006271.1 Pseudogene - no no no - 
C1QTNF9 Protein coding - no no no - 
C1QTNF9-AS1 Processed 
transcript 
- no no no - 
 
Abbreviations used in this table: MIM, Mendelian Inheritance in Man; Exp., expression 
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Figure 3.10: Schematic representation of the disease-causing gene identification 
method. 
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3.4.1 Genotype calling and analysis 
After the sequencing reaction was completed, image analysis and base calling was 
performed using Illumina Pipeline version 1.5 with default parameters to generate 
primary sequencing data. Genotype calling is the process done to determine positions 
in which a SNP or variant has been called. Obtained 75 base pair single-end reads were 
then aligned against the reference human genome (NCBI36/hg18) using Maq and 
BWA software packages to determine single nucleotide variants and insertion/ 
deletions, respectively. SNVs and indels were extracted and analyzed using SAMtools 
software package. Positional annotations of the genetic variants carried out using the 
ANNOVAR software package. 
 
 As a result, a total of 35,325 variants (18,292 heterozygous + 17,033 
homozygous) were detected within the targeted homozygous regions (Table 3.14). 
Among these, heterozygous variants composed of 3,866 SNVs, 7,948 insertions, and 
6,478 deletions; and homozygous variants composed of 15,311 SNVs, 687 insertions 
and 1,035 deletions. As a result, a total of 489 protein coding heterozygous variations 
(457 exonic, 23 exonic splicing and 24 intronic splicing variants) and 596 protein 
coding homozygous variations (581 exonic, 10 exonic splicing and 5 intronic splicing 
variant were detected (See Table 3.14 for detailed analysis). 
3.4.2 SNP calling and filtering 
Exclusion of the variants that matching with previously reported SNPs is the first 
filtering step, since the NCBI dbSNP database assumed not to contain pathogenic 
variations. Non-pathogenic SNP calling and filtering carried out using the ANNOVAR 
software package by utilizing dbSNP132 in hg18 coordinates.  
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Table 3.14: Statistics of the genetic variants after base calling and positional annotations 
 
                                       Functional Annotation 
  Protein Coding Noncoding Regions 
 Total Exonic Exonic; 
splicing 
Splicing Intergenic Intronic ncRNA Upstream; 
downstream 
UTR 
Total number of 
variations 
35325 1038 23 24 13447 16819 1562 1493 919 
Heterozygous variations 18292 457 13 19 6997 8789 789 760 468 
SNVs 3866 106 3 5 1533 1798 190 133 98 
Insertions 7948 311 10 8 2859 3820 321 369 250 
Deletions 6478 40 0 6 2605 3171 278 258 120 
Homozygous variations 17033 581 10 5 6450 8030 773 733 451 
SNVs 15311 569 8 4 5773 7189 682 678 408 
Insertions 687 6 1 1 264 333 34 27 21 
Deletions 1035 6 1 0 413 508 57 28 22 
 
Abbreviations used in this table: SNV, single nucleotide variation; ncRNA, noncoding RNA; UTR, untranslated region
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 As a result, 43.8% of the total variants (15,470 variants) called as SNP and 
excluded from the study. Remaining 18,726 novel variants (15,946 heterozygous + 
2,780 homozygous) were analyzed (See Table 3.15 for detailed statistics). Novel 
heterozygous variants composed of 3,188 SNVs, 7,948 insertions, and 5,662 deletions; 
and novel homozygous variants composed of 1,736 SNVs, 687 insertions and 634 
deletions.  As a result of positional annotations, a total of 467 novel protein coding 
heterozygous variations (437 exonic, 12 exonic splicing variant and 18 intronic 
splicing variant) and 126 novel protein coding homozygous variations (121 exonic, 3 
exonic splicing variant and 2 intronic splicing variant) were detected (Table 3.15).  
3.4.3 Functional annotation of the novel homozygous variants 
 Since the family pedigree revealed an autosomal recessive inheritance, the 
patients would carry a homozygous mutation. After the exclusion of the previously 
reported dbSNP32 variants, the variants were evaluated according to their positions. 
126 novel protein coding homozygous variations (See Appendix C for the full list of 
the variants) were selected for further functional annotation according to their exonic 
function. As a result, novel protein coding homozygous variants classified as 
frameshift deletion, frameshift insertion, nonframeshift deletion, nonframeshift 
insertion, synonymous SNV, and nonsynonymous SNV (Figure 3.11). The 92 protein 
altering variations were selected for further analysis. 
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Table 3.15: Statistics of the novel genetic variants filtered by using dbSNP32 database 
 
                                      Functional Annotation 
  Protein Coding Noncoding Regions 
 Total Exonic Exonic; 
splicing 
Splicing Intergenic Intronic ncRNA Upstream; 
downstream 
UTR 
SNPs filtered by dbSN132 15470 480 8 4 5981 7407 674 570 346 
Novel variants 19855 558 15 20 7466 9412 888 923 573 
Novel Heterozygous variants 16798 437 12 18 6410 8056 717 710 438 
SNVs 3188 87 2 5 1263 1482 151 115 83 
Insertions 7948 311 10 8 2859 3820 321 369 250 
Deletions 5662 39 0 5 2288 2754 245 226 105 
Novel Homozygous variants 3057 121 3 2 1056 1356 171 213 135 
SNVs 1736 111 2 1 544 705 102 170 101 
Insertions 687 6 1 1 264 333 34 27 21 
Deletions 634 4 0 0 248 318 35 16 13 
 
Abbreviations used in this table: SNV, single nucleotide variation; ncRNA, noncoding RNA; UTR, untranslated region
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Figure 3.11: Functional annotation of the novel homozygous coding variants 
 
3.4.4 Population Screening 
According to the NCBI database dbSNP build 132 (2010) contains 19,727,605 
validated SNPs which were used to filter non-pathogenic variants. Meanwhile, with 
the development of the next generation sequencing technology, sequencing of 
individual genomes has become possible. As a consequence, open source public 
databases that contain catalogue of common and rare variations generated.  These 
databases can be ordered as 1000 genomes, NHLBI Exome Sequencing Project, 
Database of Structural Variants and International HapMap Project.  
 
 The 92 protein altering variations (exonic splicing, intronic splicing, 
nonsynonymous SNVs, frameshift indels) were further filtered using these databases 
with the criteria that if the MAF of the common variant was lower than 0.1%.  Actually, 
allele frequency of 1% or higher is the classic definition of the polymorphism, but at 
coding regions the allele frequencies have reduced down towards 0.1% [100]. As a 
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result, 10 homozygous novel coding missense SNVs and one homozygous novel 
coding nonframeshift deletion (Table 3.16). 
 
 Four of the 11 coding variants (ZNF234 p.G602E, MEGF8 p.V2502I, 
CYP2A6 p.V80M, MBD3L3 p.G124S) were excluded by screening the unpublished 
exome sequencing data of Yale University of 2400 individuals with non-neurological 
disorders. Seven missense variants (ATP8A2 p.I376M, APBA3 p.A97T, MUC16 
p.A6352V, MUC16 T6290I, ZNF823 p.C250R, SERINC3 p.M116T, PCP2 p.E6) with 
minor allele frequency of 0.1% or higher were selected for further analysis (Table 
3.16). 
3.4.5 Exclusion of the variants 
Figure 3.12 summarizes the analysis, annotation and exclusion of the genetic variants 
determined used targeted next generation sequencing of the homozygous regions of 
the affected individual (05-996).  
3.4.5.1 Database Search 
As a first step in determination of the disease causing variant, remaining 7 variant were 
evaluated in the several databases in order to understand their biological functions (see 
Table 3.17). Online Mendelian Inheritance in Man (OMIM) database focuses on the 
relationships between genotype and phenotype. We did not find any reported 
phenotype related with candidate genes. The Universal Protein Resource (UniProt) 
database is a catalog of information on proteins. According to this database none of 
candidate genes reported to be involved directly in a neurological function. Kyoto 
Encyclopedia of Genes and Genome (KEGG) database shows the molecular functions 
of the genes in diverse biological pathways. None of the genes reported to be involved 
in a neurological pathway.  
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Table 3.16: Novel homozygous protein altering variants at the targeted region (Copyright © 2012, Rights Managed by Nature 
Publishing Group. Adopted from Onat et al., 2012 [64] with permission). 
 
Chr Position Base 
change 
Het/Hom Gene Segdup Simple 
Repeats 
dbSNP pgVariation 1000 
Genomes 
Yale 
Data 
Candidate SNVs 
chr13 25026001 C>G Hom ATP8A2 None None Novel Novel Novel Novel 
chr19 3710974 C>T Hom APBA3 None None Novel Novel Novel Novel 
chr19 8929391 G>A Hom MUC16 None None Novel Novel Novel Novel 
chr19 8929577 G>A Hom MUC16 None None Novel Novel Novel Novel 
chr19 11694601 A>G Hom ZNF823 None 1 Novel Novel Novel Novel 
chr20 42574904 A>G Hom SERINC3 None None Novel Novel Novel 1 
Candidate deletion 
chr19 7604325 CTC>- Hom PCP2 None None Novel Novel Novel Novel 
Excluded by Yale exome sequencing data 
chr19 49353814 G>A Hom ZNF234 None None Novel Novel 1:11,2:0 9 
chr19 47571934 G>A Hom MEGF8 None None Novel Novel Novel 11 
chr19 46047668 C>T Hom CYP2A6 1 None Novel Novel Novel 13 
chr19 7007590 C>T Hom MBD3L3 1 None Novel Novel 1:285,2:11 461 
 
Abbreviations used in this table: Chr, chromosome; SNV, single nucleotide variation; Het, heterozygous, Hom, homozygous; Segdup, segmental duplication 
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Figure 3.12: Schematical representation of the analysis, annotation, and exclusion of 
the genetic variants 
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Table 3.17: Database annotation of the novel homozygous protein altering variants 
GENE ATP8A2 APBA3 MUC16 MUC16 ZNF823 SERINC3 PCP2 
CHR chr13 chr19 chr19 chr19 chr19 chr20 chr19 
POSITION (HG_19) 26128001 3759974 9068391 9068577 11833601 43141490 7698326-7698328 
TYPE Sub Sub Sub Sub Sub Sub Del 
BASE CHANGE C>G C>T G>A G>A A>G A>G CTC>- 
CCDS POSITION C1128G C289T G19055A C18869T A748G A347G - 
STATUS Coding-missense Coding-missense Coding-missense Coding-missense Coding-missense Coding-missense Coding 
AA CHANGE I376M A97T A6352V T6290I C250R M116T E6 
UNIPROT  
Function: Catalytic activity: May modulate processing of the 
beta-APP 
-      May be involved in 
transcriptional 
regulation. 
May be involved in 
cellular transformation. 
- 
Subcellular Location: Multi-pass membrane 
protein. 
- Single-pass type I membrane protein. 
Secreted, extracellular space. 
Nucleus (Probable) Multi-pass membrane 
protein 
- 
Tissue Specificity: - Expressed in all the tissues with 
lower levels in brain and testis. 
Overexpressed in ovarian carcinomas and 
ovarian low malignant (LMP) tumors 
- Increased expression in 
lung tumor tissues  
- 
Similarity: Cation transport 
ATPase-P family. 
Contains 2 PDZ (DHR), 1 PID 
domains 
Contains 2 ANK repeats, 56 SEA domains Krueppel C2H2-type 
zinc-finger family. 
Belongs to the TDE1 
family 
- 
Induction: - - Up-regulated in ovarian cancer cells - - - 
Polymorphism:  - - The number of repeats is highly 
polymorphic. 
- - - 
OMİM: - - - - - - - 
KEGG PATHWAY - - - - - - - 
JAX KO&MGI - Deletion in mutants causes 
abnormalities in colon 
morphology Surviving 
homozygotes display postnatal 
viability and decreased life span. 
Homozygous null mice are viable and fertile 
with no gross histological abnormalities. 
Homozygous male mice father larger litters 
when crossed to wild-type females. 
. 
- TDE1 overexpression 
reduces apoptosis caused 
by serum starvation. Did 
not alter cell growth rate, 
immortalization, or 
motility 
Mice homozygous for 
a null mutation do not 
exhibit any detectable 
abnormalities. 
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EXPRESSION        
Fetal brain 143,9 4,8 4,55 4,55 NA 147,85 NA 
Whole brain 41,95 4,15 3,85 3,85 - 564,1 - 
Temporal Lobe 74,65 4,2 4 4 - 335,85 - 
Parietal Lobe 58,8 4,45 4,25 4,25 - 386,5 - 
Occipital Lobe 46,5 4,1 3,9 3,9 - 393,8 - 
Prefrontal Cortex 135,45 5,85 5,5 5,5 - 522,75 - 
Cingulate Cortex 102,25 4,3 4,1 4,1 - 157 - 
Cerebellum 28,75 3,5 3,35 3,35 - 188,3 - 
Cerebellum Peduncles 97,05 4,85 4,6 4,6 - 180,25 - 
Amygdala 104,3 4,75 4,4 4,4 - 321,95 - 
Hypothalamus 138,75 5,35 5 5 - 290,7 - 
Thalamus 93,7 4,45 4,2 4,2 - 209,15 - 
Subthalamic Nucleus 102,45 4,3 4,2 4,2 - 298,15 - 
Caudate nucleus 24,8 3,9 3,7 3,7 - 136,8 - 
Globus Pallidus 45,35 3,6 3,55 3,55 - 242,25 - 
Olfactory Bulb 8 3,9 3,7 3,7 - 176,8 - 
Pons 39,45 4,25 4 4 - 192,65 - 
Medulla Oblongata 70,35 4,4 4,2 4,2 - 296,95 - 
Spinal cord 15,65 4,75 4,5 4,5 - 146,95 - 
Ciliary Ganglion 11,5 3,3 3,15 3,15 - 60,75 - 
Trigeminal Ganglion 7,4 3,45 3,4 3,4 - 29,3 - 
Thymus 8,4 4,4 4,05 4,05 - 453,85 - 
Tonsil 9,05 4,8 4,45 4,45 - 94,1 - 
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Lymph node 8,85 5,1 4,1 4,1 - 88,9 - 
Bone marrow 8,95 4,15 3,95 3,95 - 191,8 - 
Whole Blood 9 9,15 4,85 4,85 - 399,1 - 
Appendix 9,75 4,25 4,2 4,2 - 51 - 
Skin 7,2 3,45 3,3 3,3 - 26,85 - 
Adipocyte 9,4 4,55 4,35 4,35 - 276,6 - 
Thyroid 10,35 10,3 5,35 5,35 - 197,45 - 
Adrenal gland 7,7 3,7 3,55 3,55 - 290,4 - 
Adrenal Cortex 9,2 4,3 4,25 4,25 - 117,95 - 
Prostate 9,85 7,5 5,15 5,15 - 318,9 - 
Salivary gland 8,25 4 3,9 3,9 - 28,65 - 
Pancreas 7,75 3,55 3,35 3,35 - 62,5 - 
Heart 8,95 4,5 4,05 4,05 - 40,65 - 
Skeletal Muscle 8,35 3,95 3,9 3,9 - 7,85 - 
Smooth Muscle 9,9 5,55 5,15 5,15 - 338,95 - 
Uterus 7,55 4,15 4,25 4,25 - 248,95 - 
Trachea 8,25 3,9 61,7 61,7 - 201,8 - 
Lung 9,2 4,9 4,6 4,6 - 381,25 - 
Kidney 7,35 3,4 3,2 3,2 - 127,8 - 
Liver 9,65 4,55 4,25 4,25 - 105,45 - 
Placenta 9,35 5 4,85 4,85 - 762,4 - 
Ovary 6 3 2,85 2,85 - 59,65 - 
Testis 9,2 4,25 4 4 - 393,35 - 
 
Abbreviations used in this table: Chr, chromosome; sub, substitution; del, deletion; aa, amino acid; ccds, consensus coding sequence  
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 Next, the candidate genes were searched in The Jackson Laboratory Knock-
Out (JAX KO) Mice and Mouse Genome Informatics (MGI) databases (Table 3.17). 
As a result, mice knock-out models of APBA3, MUC16, SERINC3, and PCP2 have 
been identified.  
 
Deletion of APBA3 in mice causes morphological and physiological 
abnormities in colon. Blood urea nitrogen levels increase while serum chloride, 
sodium and potassium levels decrease in these mice. Surviving APBA3 homozygote 
knockouts display diarrhea, postnatal viability and decreased life span. MUC16 
homozygous null mice are viable and fertile with no histological abnormalities.  
 
SERINC3 is a member of TDE1 (Tumor Differentially Expressed) family. 
TDE1 overexpression reduces apoptosis but did not alter cell growth rate, 
immortalization, or motility.  
 
Next, mice homozygous for a null mutation in PCP2 do not exhibit any 
detectable abnormalities. To conclude, none of the candidate genes is reported to be 
involved in neurological processes.  
 
 Lastly the candidate genes corresponding to 7 candidate variants were 
evaluated in several open source databases including Database of Genomic Variants 
(DGV) [101], The Allele FREquency Database (ALFRED) [102], SNPper [103], 
Cancer Genome Anatomy Project – Genetic Annotation Initiative (CGAP-GAI, 
http://gai.nci.nih.gov/cgap-gai/) , Japanese SNP (JSNP) [104], Functional SNPs (F-
SNP) [105], SPSmart [106], National Human Genome Research Institute Genome 
Wide Association Studies  (NHGRI GWAS) [107] for genomic variants. As a result, 
five functional SNVs for MUC16, one functional SNV for ZNF823 and on functional 
SNV for PCP2 were detected. However, no reported functional indels, genomic and 
structural SNVs/indels, CNVs, or associated SNPs were detected (Table 3.18).
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Table 3.18: Evaluation of the candidate genes in several databases 
 Database ATP8A2 APBA3 MUC16 ZNF823 SERINC3 PCP2 
International HapMap Project HapMap - - - - - - 
Genomic Variants DGV - - - - - - 
Genome-Wide Association studies NHGRI - - - - - - 
OMIM disease associations NCBI - - - - - - 
ALFRED USNatSciFnd - - - - - - 
SNPper CHIP - - - - - - 
CGAP SNP index NCI - - - - - - 
SPSmart Meta Search USC - - - - - - 
F-SNP (functional SNPs) Queen's Uni - - - - - - 
CGAP-GAI  NCI - - - - - - 
JSNP Database Uni of Japan - - - - - - 
NHLBI ESP Uni of Wash 1 splice-3 1 splice-5 5 nonsense 
2 splice-5 
1 nonsense 1/4873 1 nonsense 
1 splice-5 
 
Abbreviations used in this table: DGV, Database of Genomic Variants; NHGRI, National Human Genome Research Institute; NCBI, National Center for Biotechnology Information; USNatSciFnd, U.S. 
National Science Foundation; NCI, National Cancer Institute;  USC, University of South California; Uni, university; CGAP-GAI, Cancer Genome Anatomy Project-Genetic Annotation Initiative; ESP, 
Exome Sequencing Project
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3.4.5.2 Segregation Analysis by haplotype construction 
Segregation analysis is achieved in order to determine if the selected candidate genes, 
underling the distribution in CAMRQ family, were inherited in Mendelian autosomal 
recessive manner.  
 
Segregation analysis was facilitated by haplotype construction and confirmed 
by Sanger sequencing. Haplotype construction of the all homozygous regions was 
carried out using Affymetrix 10K genotyping data which was generated using DNA 
of the selected family members (05-992, 05-993, 05-994, 05-995 and 05-996). In 
addition, markers D13S221, D13S283, D13S742, D13S787, D13S1243, and 
D13S1294 were used to confirm the linkage disequilibrium among the affected 
individuals for the most likely candidate locus on chromosome 13q12 (Figure 3.13, 
Figure 3.14, and Figure 3.15). As a result, four of the 7 candidate variants were 
excluded by segregation analysis. Confirmation of the haplotyping analysis carried our 
using Sanger sequencing of the excluded variants in three affected individuals (05-
993, 05-994, and 05-996) (Figure 3.16). 
 
 All in all, a 3-bp in-frame deletion (PCP2 p.E6del) and two missense variants 
(ATP8A2 p.I376M and APBA3 p.A97T) were determined to be consistent with the 
recessive inheritance of the disease allele in the family (Table 3.19). 
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Figure 3.13: Pedigree of Family C with haplotype structure of the disease interval on 
chromosome 13q12. Haplotype segregating with the disease is boxed. ATP8A2 
p.I376M variant is bold. Positions are given as Mb. Please note that the DNA of one 
affected individual is not available for the study. (Copyright © 2012, Rights Managed 
by Nature Publishing Group. From Onat et al., 2012 [64] with permission). 
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Figure 3.14: Haplotype structure of homozygous region on chromosome 19. 
Haplotype segregating with the disease on chromosomal region 19:3,136,845-
14,337,400 is boxed. APBA3 p.A97T, PCP2 p.E6del, MUC16 p.T6290I, MUC16 
p.A6352V and ZNF823 p.C250R variants are bold. Positions are given as Mb. 
(Copyright © 2012, Rights Managed by Nature Publishing Group. From Onat et al., 
2012 [64] with permission). 
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Figure 3.15: Haplotype structure of homozygous region on chromosome 20. 
Haplotype segregating with the disease on chromosomal region 20:41,015,889-
45,954,292 is boxed. SERINC3 c.1128 C4G variant is bold Positions are given as Mb. 
(Copyright © 2012, Rights Managed by Nature Publishing Group. From Onat et al., 
2012 [64] with permission). 
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Figure 3.16: Segregation analysis of the variants in the affected individuals (05-993, 
05-994 and 05-996) by using Sanger sequencing. The variants (a) ZNF823 p.C250R 
(b) SERINC3 p.M116T (c) MUC16 p.A6352V and (d) MUC16 p.T6290I do not co-
segregate with the disease. 
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Table 3.19: Novel coding variants identified by targeted next-generation sequencing of 05-996. (Copyright © 2012, Rights Managed by 
Nature Publishing Group. From Onat et al., 2012 [64] with permission). 
 
Gene Position (hg19) 
Base 
Change 
Effect 
dbSNP 
132 
pgVar 1000g 2400e 
GERP 
(Score) 
PhyloP 
(Score) 
SIFT 
(Score) 
Polyphen2 
(Score) 
M.Taster 
(p-value) 
Candidate Variants 
ATP8A2 chr13:26.128.001 C>G I376M Novel Novel Novel 0 2,18 1,091 D. (0,02) P.D. (1,00) D.C. (0,995) 
APBA3 chr19:3.759.974 C>T A97T Novel Novel Novel 0 -4,11 -0,308 T. (0.16) B. (0,14) P. (0,999) 
PCP2 chr19:7.698.326 CTC>- E6del Novel Novel Novel 0 N.A. 0,168 N.A. N.A. P. (0,717) 
Variants not cosegregated with the disease phenotype in the family 
MUC16 chr19:9.068.391 G>A A6352V Novel Novel Novel 0 -1,45 -0,803 N.A. N.A. P. (0,999) 
MUC16 chr19:9.068.577 G>A T6290I Novel Novel Novel 0 2,35 2,273 N.A. N.A. P. (0,999) 
ZNF823 chr19:11.833.601 A>G C250R Novel Novel Novel 0 0,63 1,532 D. (0,00) P.D. (1,00) P. (0,994) 
SERINC3 chr20:43.141.490 A>G M116T Novel Novel Novel 1 3,98 2,524 T. (0,34) B. (0,13) D.C. (0,999) 
Variants excluded with population screening  
MBD3L3 chr19:7.056.590 C>T G124S Novel Novel 45:02,2 461 0,74 -0,345 T. (0,58) Ps.D (0,70) P. (0,999) 
CYP2A6 chr19:41.355.828 C>T V80M Novel Novel Novel 13 2,72 1,568 T. (0,10) P.D. (0,99) P. (0,996) 
MEGF8 chr19:42.880.094 G>A V2502I Novel Novel Novel 11 5,11 6,197 T. (0,06) P.D. (0,99) P. (0,996) 
ZNF234 chr19:44.661.974 G>A G602E Novel Novel 11:02,2 9 1,89 2,503 D. (0,04) P.D. (0,99) P. (0,970) 
 
Abbreviations used in this table: M.Taster, MutationTaster, D., Damaging; T., Tolerated; P.D., Probably Damaging; Ps.D, possibly damaging; B., Benign; N.A., Not Available; D.C., Disease Causing; P., 
Polymorphism, 1000g, 1000 genomes; 2400e, Yale exome sequencing project; pgVar, pgVariation database; chr, chromosome 
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3.4.5.2 Exclusion of the APBA3 as the disease causing gene 
Amyloid beta (A4) precursor protein-binding, family A, member 3 (APBA3), p.A97T 
variant was excluded from the study based on the conservation considerations and 
prediction analyses.  Protein sequences of the sequenced species are downloaded from 
Ensembl database and alignments done using CLC Workbench 6. Multiple sequence 
alignment and conservation analysis revealed that four of 20 species (O. garnetti, S. 
scrofa, C. porcellus, S. tridecemlineatus) sequenced have threonine (T) at the 
orthologous site (Figure 3.17). Pair-wise alignment of the APBA3 in 46 vertebrates 
carried out using USCS Genome Browser Multiz Alignments tract which revealed two 
more species (O. garnetti, I. tridecemlineatus, and T. nigroviridis) sequenced have 
threonine (T) at the site (Figure 3.18). These results suggest that this variant would be 
a polymorphism and not damaging to humans.  
 
 Next, the secondary structures of the both wild-type and mutant APBA3 
protein sequences were predicted using Protein Structure Prediction Server 
(PSIPRED) v.3.0. As a result, the p.A97T amino acid change had no effect on protein 
secondary structure (Figure 3.19). Additionally, the p.A97T alteration did not reside 
in any of the three protein family domains (one PID, phosphotyrosine interaction 
domain; two PDZ domains) found by Protein Families (Pfam) database (Figure 3.20).   
  
 Next, evolutionary conservation analysis by prediction tools used to improve 
multiple alignment results. GERP identifies the substituted elements in multiple 
alignments. The presence of the substitutions reveals a neutral element; the absence of 
the substitutions reveals a functional constraint. A negative GERP score (-4.11) for the 
mutated nucleotide suggests that this site is probably evolving neutrally. PhyloP 
algorithm computes conservation or acceleration p-values based on a model of neutral 
evolution. PhyloP score of the variant (-0.308) suggests a faster evolution than 
expected for this site. Furthermore, web-based SIFT, PolyPhen2 and MutationTaster 
tools predict whether an amino acid substitution affects protein function. The 
predictions based on conservation of the residues in sequence alignments. The variant 
was predicted as “tolerated” by SIFT (SIFT score, 0.16), “benign” by PolyPhen2 
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(PSIC score difference, 0.0) and “polymorphism” by MutationTaster (p-value, 0.999) 
(Table 3.19).  
 
 In conclusion, conservation analysis using multiple and pair-wised alignments 
together with the prediction of mutant secondary protein structure, protein family 
domains, and amino acid substitution effect on protein function strongly suggest that 
this variant is a neutral polymorphism. 
 
 
 
 
 
 
 
Figure 3.17: Amino acid sequence homology of the APBA3 protein. Conservation 
analysis of the APBA3 p.A97T variant among 20 species sequenced. Four of the 20 
species have threonine (T) at the mutation site. A97T residue is represented with a box. 
The bootstrap values on the tree represent the phylogenetic distances. (Copyright © 
2012, Rights Managed by Nature Publishing Group. From Onat et al., 2012 [64] with 
permission). 
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Figure 3.18: Conservation analysis of the APBA3 p.A97T variant among 46 species 
sequenced using pair-wise alignment. A97T residue was represented by red arrow. 
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Figure 3.19: The PSIPRED protein secondary structure prediction of the wild-type and 
mutant sequences of APBA3 
 
 
 
 
 
Figure 3.20: Pfam domain analysis of the APBA3. p.A97T variant do not reside in any 
of the three domains found. The numbers represent the amino acid positions of the 
protein. 
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3.4.5.3 Exclusion of the PCP2 as the disease causing gene 
Purkinje cell protein-2 (PCP2) is highly expressed in cerebellar Purkinje cells and 
retinal bipolar neurons. The expression pattern of Pcp2 reveals a role in the 
development of CNS.[108] However, its function remains unknown. Mice 
homozygous for null PCP2 mutation do not exhibit any detectable phenotypic change 
such as loss of balance, intention tremor, and ataxia which are associated with 
cerebellar defects in humans. Also, the structure and shape of Purkinje cells is not 
affected in these knock-out mice.[109-112] 
 
 PCP2 p.E6del variant was excluded from the study based on population 
screening. The 180 healthy control individuals which were from the geographically 
same region with the family were selected for genotyping using RFLP. In 360 healthy 
chromosomes, four heterozygous individuals were identified and verified by Sanger 
sequencing (Figure 3.21). This yields an expected homozygote frequency of 
approximately 1 in 8,000 which is much higher than expected.  
    
 Multiple and pair-wise sequence alignments of the region containing the 
mutation suggested that it was not conserved among species. PCP2 p.R6 is deleted in 
eight of the 20 species sequenced (Figure 3.22 and Figure 3.23), and the deletion was 
also predicted as “polymorphism” by MutationTaster (p-value, 0.717) (Table 3.19).   
 
 To conclude, population screening together with the literature searches 
involving gene knock-outs and the conservation considerations using multiple and 
pair-wise alignments and the prediction tools strongly revealed that this variant is a 
neutral polymorphism. 
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Figure 3.21: Confirmation of the PCP2 p.E2del variant by Sanger sequencing. 
Sequence data of family members (05-992 and 05-993) and unrelated healthy 
individuals (wild type: 10-120; carriers: 10-237, 10-245, 10-350, 10-373) are shown. 
(Copyright © 2012, Rights Managed by Nature Publishing Group. From Onat et al., 
2012 [64] with permission). 
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Figure 3.22: Amino acid sequence homology of the PCP2 protein. PCP2 p.E6del 
variant is represented with a box. The bootstrap values on the tree represent the 
phylogenetic distances. (Copyright © 2012, Rights Managed by Nature Publishing 
Group. From Onat et al., 2012 [64] with permission). 
 
 
Figure 3.23: Conservation analysis of the PCP2 p.E6 variant among 46 species 
sequenced using pair-wise alignment. p.E6 residue was represented by red arrow. 
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3.4.6 ATP8A2 p.I376M as the disease causing mutation 
The remaining variant at chr13:26,128,001 (hg19; c.1128 C>G) results in an isoleucine 
(I) to methionine (M) substitution at residue 376 and is located in exon 12 of ATPase, 
aminophospholipid transporter, class I, type 8A, member 2 (ATP8A2, 
ENSG00000132932, ENST00000381655) gene. The mutation co-segregated with the 
disease in the family (Figure 3.13). 
 
 The longest isoform of the ATP8A2 encodes 1,148 amino acids. According to 
the Pfam database, the protein has 2 protein family domains; E1 E2 ATPase domain 
at amino acids 123-396 and haloacid dehalogenase-like hydrolase (HAD) domain at 
amino acids 425-830. The mutation lies in the C terminal transmembrane site of E1 
E2 ATPase domain (Figure 3.24). 
 
 
 
 
Figure 3.24: Graphical representation of the predicted functional and structural 
elements of ATP8A2 protein. ATP8A2 is composed of an E1 E2 ATPase domain and 
a haloacid dehalogenase-like hydrolase (HAD) domain. Ten transmembrane domains 
were predicted by TMPRED. The mutation represented by red dot lies in the 
transmembrane region of C-terminal end of E1 E2 ATPase domain. (Copyright © 
2012, Rights Managed by Nature Publishing Group. From Onat et al., 2012 [64] with 
permission). 
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 ATP8A2 is a multi-pass transmembrane protein. Web-based TransMembrane 
Prediction (TMpred, http://www.ch.embnet.org/software/TMPRED_form.html) tool 
makes a prediction of regions spanning membrane and their orientation. According to 
TMpred predictions, ATP8A2 has 10 membrane spanning transmembrane helices 
(Table 3.20). The p.I376M mutation lies inside the fourth transmembrane spanning 
domain represented in Figure 3.24.  
 
 
Table 3.20: Locations and orientations of the predicted transmembrane helices of 
ATP8A2 
 
Transmembrane 
Helices 
Start End Length Score Orientation 
1 95 113 -19 1176 inside-out 
2 118 137 -20 1093 outside-in 
3 317 338 -22 2534 inside-out 
4 363 382 -20 1489 outside-in 
5 888 906 -19 1457 inside-out 
6 913 931 -19 1425 outside-in 
7 965 983 -19 1416 inside-out 
8 997 1018 -22 1114 outside-in 
9 1030 1049 -20 2317 inside-out 
10 1064 1084 -21 1415 outside-in 
 
 
 Since there is no structural model or information known for ATP8A2 protein, 
the consequences of the amino acid change were evaluated by comparing the predicted 
secondary and tertiary protein structures of the wild-type and mutant ATP8A2 protein 
sequences by using web-based PSIPred and HOPE tools. As a result, the wild type 
protein is predicted to contain 27 beta-strands and 32 alpha-helices. I376 residue is 
located at the N-terminus of the 11th alpha-helix. The mutation enlarges the 11th and 
12th alpha-helices and creates an additional alpha-helix at residue 401 (Figure 3.25) 
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 Multiple sequence alignment analysis using CLC Workbench 6.0 revealed that 
the isoleucine (I) allele conserved in all 19 species sequenced (Figure 3.26). Protein 
sequences of the sequenced species are downloaded from Ensembl database. 
Additionally, pair-wise alignment of the ATP8A2 in 46 vertebrates carried out using 
USCS Genome Browser Multiz Alignments tract which revealed p.I376 is highly 
conserved across species (Figure 3.27). In particular the isoleucine residue is 
completely conserved across all species sequenced including the most distantly related 
ortholog T. nigroviridis determined by bootstrap analysis of the phylogenetic trees. 
Human ATP8A2 and T. nigroviridis ATP8A2 have 49.09% similarity with a distance 
score of 0.76 (Figure 3.28). 
 
 
 
 
 
Figure 3.25: The secondary protein structures of the wild-type and mutant ATP8A2 
protein sequences predicted by using PSIPRED tool. The wild type protein is predicted 
to contain 27 beta-strands and 32 alpha-helices. I376 residue is located at the N-
terminus of the 11th alpha-helix. The mutation enlarges the 11th and 12th alpha-
helices and creates an additional alpha-helix at residue 401. (Copyright © 2012, Rights 
Managed by Nature Publishing Group. From Onat et al., 2012 [64] with permission). 
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 Next, evolutionary conservation analysis by using prediction tools revealed 
that the mutation is under evolutionary constraints. Positive GERP and PhyloP scores 
(2.18 and 1.091, respectively) revealed that the mutation evolved as a functional 
constraint. Furthermore, the mutation was predicted to be “damaging” (SIFT score, 
0.16), “probably damaging” (Polyphen2 PSIC score difference, 0.00) and “disease 
causing” (p-value, 0.995) (Table 3.19).  
 
 In conclusion, conservation analysis using multiple and pair-wised alignments 
together with the prediction of mutant secondary protein structure, protein family 
domains, and amino acid substitution effect on protein function strongly suggest that 
this variant is a causative mutation. 
 
 
 
Figure 3.26: Amino acid sequence homology of the ATP8A2 protein. Multiple amino 
acid sequence alignments show the sequence homology of ATP8A2 protein in 
vertebrates. I376 residue is indicated with a box. The bootstrap values on the tree 
represent the phylogenetic distances. (Copyright © 2012, Rights Managed by Nature 
Publishing Group. From Onat et al., 2012 [64] with permission). 
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Figure 3.27: Conservation analysis of the ATP8A2 p.I376M variant among 46 species 
sequenced using pair-wise alignment. p.I376 residue, represented by red arrow, 
conserved among all species sequenced 
   
 
  
Figure 3.28: Phylogenetic tree analysis of multiple sequence alignments of ATP8A2 
from 19 sequenced species. Human ATP8A2 is the most similar with P. troglodytes 
(98.23%) and less similar with T. nigroviridis (49.09%). 
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Mutation screening in unrelated families, isolated cases and healthy controls is 
one of the most popular methods for providing evidence that a candidate gene is 
responsible for the disease of interest. Identifying mutations in other families or in two 
or more unrelated individuals with the same phenotype and in none of the healthy 
individuals strongly suggests that the selected gene is responsible for the diseases. 
ATP8A2 c.1128 C>G mutation was evaluated in several healthy and affected 
individuals (Table 3.21). 
 
 Firstly, the mutation genotyped by allele specific PCR in 58 isolated ataxia 
patients of which 12 of them have cerebellar phenotype with or without quadrupedal 
locomotion. None of the patients have G allele neither in heterozygous nor in 
homozygous state (Table 3.21). 
 
Next, the status of ATP8A2 was evaluated in a cohort of 750 patients with 
structural cortical malformations or degenerative neurological disorders including 
cerebellar phenotypes in which the causative mutation is still unknown. According to 
the SNP genotyping data generated by Illumina Human 370 Duo or 610K Quad 
BeadChips none of the patients were found to harbor a homozygous interval (≥ 2.5 
cM) surrounding the ATP8A2 locus. Analysis of the exome sequencing data of the 
same group did not reveal any mutations, including compound heterozygous 
substitutions, in ATP8A2 (Table 3.21). 
 
 By allele specific PCR the c.1128 C>G mutation was screened in 1,210 healthy 
control chromosomes, including 305 individuals from the same geographic region as 
the family.  As a result, none of the individuals in this control population have G allele 
neither in heterozygous nor in homozygous state. Together with the 1,092 healthy 
controls from 1000 genomes database, 6500 healthy controls form Exome Variant 
Server database, and exome sequencing data of the 2400 patients with non-
neurological phenotypes, the mutation was screened in 22808 healthy and affected 
individuals with a MAF of 0.0 (Table 3.21). 
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Table 3.21: Mutation screening of ATP8A2 p.I376M in isolated cases, healthy 
controls, patients with non-neurological phenotypes and databases. 
Population A B MAF Ind (#) Method 
Turkish Control 610 0 0 305 Allele spesific PCR 
Region-matched controls 600 0 0 300 Allele spesific PCR 
Yale exomes* 4800 0 0 2400 Exome sequencing 
1000 genomes 2182 0 0 1092 WGS 
EVS 13000 0 0 6500 Exome sequencing 
Yale Patients** 1500 0 0 750 Illumina SNP array 
Hacettepe Patients*** 116 0 0 58 Allele spesific PCR 
Total 22808 0 0 11404  
 
* The cohort consist of 2400 patients with non-neurological phenotypes 
** The cohort consisted of 750 patients with structural cortical malformations or degenerative neurological disorders 
*** 58 ataxia patients, 12 had cerebellar phenotype with or without quadrupedal gait 
Abbreviations used in this table: EVS, Exome variant server; MAF, minor allele frequency; Ind(#), number of the individuals; 
WGS, whole genome sequencing 
3.5 Characterization of ATP8A2 
The transmembrane protein, ATP8A2, consists of three protein coding, one nonsense 
mediated RNA decay transcript and two processed transcript isoforms according to 
Ensembl database (Table 3.22). The longest isoform (ENST00000381655) contains a 
total of 9,575 base pairs long transcript with 37 exons (See Appendix D for the full list 
of exons). This transcript encodes a 1,188 amino acids long 112 kD protein 
(ENSP00000371070).  
 
Table 3.22: Transcripts of ATP8A2 according to Ensembl database 
Name Transcript ID Length 
(bp) 
Protein ID Length 
(aa) 
Biotype 
001 ENST00000381655 9575 ENSP00000371070 1188 p.c. 
003 ENST00000381648 476 ENSP00000371062 141 p.c. 
201 ENST00000255283 3674 ENSP00000255283 1123 p.c. 
004 ENST00000281620 3891 ENSP00000281620 643 n.m.d 
002 ENST00000466079 169 No protein product - p.t. 
006 ENST00000491840 2227 No protein product - p.t. 
 
Abbreviations used in this table: p.t., processed transcript; p.c., protein coding; n.m.d., nonsense mediated decay; aa, amino 
acid; bp, base pair 
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3.6 Expression of ATP8A2 
3.6.1 Real time RT-PCR analysis 
ATP8A2 expression studies revealed that the protein is highly expressed in newborn 
and embryonic tissues with the strongest expression in mouse heart, brain and 
testis.[113, 114] In order to confirm expression profiles of ATP8A2, we analyzed 
expression of the transcript ENST00000381655 by using quantitative real-time RT-
PCR and semi-quantitative RT-PCR in a cDNA panel of multiple human tissues (lung, 
thyroid, prostate, trachea, skeletal muscle, spleen, liver, adrenal gland, fetal liver, 
hearth, kidney, colon, thymus, salivary gland, placenta, big uterus, big testis, whole 
brain, and fetal brain). ATP8A2 was detected with the highest levels in testis, whole 
brain, trachea, thyroid, and fetal liver (Figure 3.29 and Figure 3.30) 
 
 Since the patients have cerebellar phenotype, we evaluated the possible 
involvement of ATP8A2 in motor functions by evaluating the expression profile in of 
ATP8A2 transcript in different human brain regions (strata parietal cortex, strata 
brainstem, strata occipital cortex, strata striatum, strata frontal cortex, corpus callosum, 
cerebellum)  by quantitative real-time RT-PCR and semi-quantitative RT-PCR. 
Human ATP8A2 is expressed in all regions of the brain with the highest level of 
expression in the cerebellum (Figure 3.31). ATP8A2 expression in the patients cannot 
be evaluated since the gene is not expressed in lymphocytes. 
3.6.2 Annotation clustering of early embryonic mouse brain genes 
In order to identify predicted biological function of ATP8A2 in brain development, a 
bioinformatics approach was performed upon updating related approaches.[115] In 
this approach, a large set of genes which are correlated with ATP8A2 were detected 
and then categorized by functional annotation clustering (Figure 3.32). 
 
 
117 
 
 
 
Figure 3.29: Expression profiles of ATP8A2 in multiple human tissues. The expression 
of the transcript ENST00000381655 was analyzed by using semi-quantitative RT-
PCR. The highest levels of expression was obseved in testis and brain regions. 
 
 
 
 
 
 
Figure 3.30: Real-time expression profiles of ATP8A2 in multiple human tissues. The 
expression of the transcript ENST00000381655 was analyzed by using quantitative 
real-time RT-PCR. The highest levels of expression were detected in testis, fetal liver, 
thyroid and trachea. 
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Figure 3.31: Real-time expression profiles of ATP8A2 in different human brain 
regions. The expression of the transcript ENST00000381655 was analyzed by using 
quantitative real-time RT-PCR. The highest levels of expression were detected in 
cerebellum. (Copyright © 2012, Rights Managed by Nature Publishing Group. 
Adopted from Onat et al., 2012 [64] with permission). 
 
 
 As a first step, expression data set of mouse brains at early embryonic days 9.5, 
11.5, and 13,5  (GSE8091) [94] was extracted from the Gene Expression Omnibus 
(GEO) database. Expression data were grouped into embryonic days and 3,611 
differentially expressed genes were filtered (One-way ANOVA test Bonferroni 
corrected p<0.001). By using GeneSpring GX expression data analysis software, 218 
genes found to be significantly correlated with ATP8A2 according to their expression 
profiles (R>0.95) (Figure 3.33). According to the MGI database, 24 of these genes 
were associated with human diseases including neurological phenotypes (Table 3.23). 
Especially, ATP8A2 is co-expressed with doublecortin (DCX) which is responsible for 
Lissencephaly, X-linked [LISX1; OMIM: 300067] [116], and WD repeat domain 81 
(WDR81) which is associated with Cerebellar Ataxia and Mental Retardation with or 
Without Quadrupedal Locomotion 2 [CAMRQ2; OMIM: 610185] [29] suggesting that 
these genes could represent similar developmental pathways. 
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Figure 3.32: Schematic representation of the functional annotation clustering of a set 
of genes which are correlated with ATP8A2.  
 
 
 
 Next, those 218 genes correlated with ATP8A2 expression profile were 
evaluated by the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) tool. Functional annotation clustering analysis revealed that positively 
correlated genes were enriched for those involved in neuron differentiation 
(Bonferroni corrected p-value: 2.1E-3), cell and neuron projection morphogenesis 
(Bonferroni corrected P values: 1.4E-3, and 1.5E-3, respectively) and axonogenesis 
(Bonferroni corrected p-value: 1.9E-3) (see Appendix E for the full list of functional 
annotation clusters). 
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Figure 3.33: Graphical representation of the expression profiles of the filtered 
differentially expressed genes within day groups. Expression data set of mouse brains 
at early embryonic days 9.5, 11.5, and 13.5 were grouped into embryonic days and 
3,611 differentially expressed genes were filtered. By using GeneSpring GX 
expression data analysis software, 218 genes found to be significantly correlated with 
ATP8A2 according to their expression profiles. 
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Table 3.23: Genes associated with human diseases which are co-expressed with 
Atp8a2   
MGI ID Symbol Gene Name MIM 
ID 
MIM Term 
102806 Acvr2a activin receptor IIA 261800 Pierre Robin Syndrome 
104311 Ptger4 prostaglandin E receptor 4  607411 Patent Ductus Arteriosus 
104741 Nfkbia nuclear factor of kappa light 
polypeptide gene enhancer 
in B-cells inhibitor, alpha 
270150 
603165 
Sjogren Syndrome 
Dermatitis, Atopic 
107164 Ppp3ca protein phosphatase 3,  
catalytic subunit, alpha 
104300 Alzheimer Disease; AD 
107978 Klc1 kinesin light chain 1 104300 Alzheimer Disease; AD 
108085 Hpgd hydroxyprostaglandin 
dehydrogenase 
607411 Patent Ductus Arteriosus 
1201673 Shox2 short stature homeobox 2 127300 Leri-Weill Dyschondrosteosis 
   249700 Langer Mesomelic Dysplasia 
1277124 Asah1 N-acylsphingosine 
amidohydrolase 1 
228000 Farber Lipogranulomatosis 
1277171 Dcx doublecortin 607432 Lissencephaly 1; LIS1 
1354956 Trfr2 transferrin receptor 2 604250 Hemochromatosis, Type 3; HFE3 
1858896 Spast spastin 182601 Spastic Paraplegia 4 
2135272 Vangl2 vang-like 2 182940 Neural Tube Defects 
2148705 Foxp2 forkhead box P2 602081 Speech-Language Disorder 1; 
SPCH1 
2389465 Tbx22 T-box 22 303400 Cleft Palate, X-Linked; CPX 
88059 App amyloid beta (A4)  
precursor protein 
104300 Alzheimer Disease; AD 
96015 Hba-a1 hemoglobin alpha,  
adult chain 1 
141800 
141900 
Hemoglobin--Alpha Locus 1 
Hemoglobin--Beta Locus 
96432 Igf1 insulin-like growth  
factor 1 
601489 Insulin-Like Growth Factor-
Binding Protein, Acid-Labile 
Subunit; IGFALS 
96909 Maf avian musculoaponeurotic 
fibrosarcoma  
610202 Cataract, Pulverulent, Juvenile-
Onset 
97530 Pdgfra platelet derived growth  
factor receptor, alpha 
142340 Diaphragmatic Hernia, Congenital 
98347 Snrpn small nuclear  
ribonucleoprotein N 
105830 
176270 
Angelman Syndrome; AS 
Prader-Willi Syndrome; PWS 
98371 Sox9 SRY-box containing gene 9 114290 Campomelic Dysplasia 
98737 Thbs1 thrombospondin 1 270150 Sjogren Syndrome 
99414 Id4 inhibitor of DNA binding 4 166710 Osteoporosis 
99846 Gdi1 guanosine diphosphate 
dissociation inhibitor 1 
300104 GDP Dissociation Inhibitor 1; 
GDI1 
2681828 Wdr81 WD repeat domain 81 610185 Cerebellar hypoplasia, mental 
retardation, and quadrupedal 
locomotion 2 
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Chapter 4 
Discussion 
CAMRQ is a rare genetically heterogeneous disorder characterized by cerebellar 
ataxia, mental retardation and dysarthric speech with or without quadrupedal gait.[28, 
31] The first locus was mapped to chromosomal region 17p13 in Family B [31] and 
the causative mutation identified in WDR81 using homozygosity mapping and targeted 
next generation sequencing.[29] Two additional loci have been mapped so far on 
chromosomes 9p24 and 8q12 in consanguineous families, and causative mutations 
have been identified in VLDLR and CA8, respectively, using genome-wide linkage 
analysis and candidate gene sequencing.[32, 35]  
 
 In this thesis, identification of the fourth gene locus in a consanguineous family 
of two affected siblings and an affected nephew with CAMRQ inherited with 
autosomal recessive transmission is described (Figure 1.3).  
4.1 Disease Gene Identification 
Disease gene identification amongst thousands of variants obtained via next generation 
sequencing is a major challenge, and requires prioritization of the novel variants 
123 
 
depending on the number of affected individuals which are clinically well-
characterized and availability of the family members, the inheritance pattern, the 
severity and frequency of the disease. Figure 3.10 summarizes the strategy followed 
in this study to identify disease-causing gene.  
 
 Whole genome homozygosity mapping analysis, which is a powerful technique 
to map recessive traits in consanguineous families, revealed 23 shared homozygous 
regions in the three affected individuals. Candidate gene prioritization among 563 
genes at the homozygous blocks and Sanger sequencing did not revealed a causative 
mutation segregated with the disease in the family.  
 
 The high number of shared homozygous regions detected by 250K SNP arrays 
gave rise to thought that SNPs were detected with less accuracy which would result in 
non-contiguous homozygous regions due to low number of informative SNPs. A 
recent study presented that 250K arrays is problematic in detection of homozygosity 
since they have high false-positive heterozygosity rate (>4%) and low SNP density 
with more non-informative alleles. These non-informative alleles generate additional 
homozygosity peaks appear as backgrounds.[117] These backgrounds can be 
eliminated either by linkage calculation with parental genotypes or by recently 
developed more comprehensive SNP arrays. These high-resolution arrays are more 
informative compared with 250K SNP arrays since they have high density of SNPs 
and also contain HapMap-derived-SNPs with high heterozygosity rate.[117]  
 
 The problem is achieved by repeating the homozygosity mapping with more 
comprehensive high-resolution genome-wide arrays in two affected individuals, which 
in turn revealed four contiguous common homozygous intervals. These regions 
contain a total of 882 genes with 2,263 transcripts and 16,935 exons, so a genome-
wide approach was determined. By using targeted enrichment of the homozygous 
regions and next generation sequencing several missense variants were identified. 
These variants were annotated and filtered using segregation analysis, population 
screening, protein conservation, and disease gene prediction approaches.  
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 Consequently, a novel missense variant in ATP8A2 (c.1128 C>G; p.I376M) is 
identified as the causal mutation that segregates with the phenotype in the family. 
4.2 Overview of Variant Filtration and Prioritization 
With the development of the high-resolution genotyping arrays and the next-
generation sequencing technologies, human disease gene identification is greatly 
facilitated.[29, 118, 119] However, in majority of the cases multiple candidate 
variations on many candidate genes detected. Among these, none of the variants could 
be on a gene with a protein product or cosegregate with the phenotype in the family. 
The mutation could be on an uncharacterized gene or present only in one isoform. The 
mutation could be a missense so did not cause a truncated protein.  In such situations, 
in order to demonstrate the causality of the identified gene, two or more independent 
cases with a mutation on the corresponding gene should be identified.   
 
 In the absence of independent cases, where the mutation is associated with an 
extremely rare and genetically heterogeneous autosomal recessive phenotype as in our 
unique consanguineous family, narrowing the list of potential genetic culprits by 
excluding the harmless ones could be applied (Figure 2.4 and Figure 3.12). 
Improvements in bioinformatics likely increased the success rate of identifying the 
disease causing gene. The first filtering step is the exclusion of the variants which are 
previously reported by NCBI dbSNP because these variants assumed to be non-
pathogenic. However, the criteria for SNP filtering should depend on the allele 
frequencies or genotyping rates since more than six million SNPs in this database 
identified by the SNP discovery projects and not curated to be involved in disease 
pathogenesis.[120] Thus, by definition of a polymorphism, SNPs with MAFs greater 
than 1% which fit the Hardy-Weinberg equilibrium should be selected as a filtering 
criterion.[121]  
 
 The second step involves screening of the variations for novelty with 
comparison to personal genome databases and previous exome sequencing databases. 
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The remaining variants that match with the previously detected variants by next 
generation sequencing projects could be further excluded using open source public 
databases that contain catalogue of common and rare variants such as 1000 genomes, 
NHLBI Exome Sequencing Project, Database of Structural Variants and International 
HapMap Project. The screening of the candidate variations in the geographically 
and/or ethnically matched unaffected individuals would distinguish the putative 
mutation from the unknown rare SNPs.   
 
 Disease phenotypes are due to mutations that cause amino acid changes which 
result in the loss of a critical protein function.[122] Thus, the variants annotated 
according to the positions and their effects on the protein function. The protein altering 
variants including nonsynonymous SNPs, frameshift coding insertions/deletions and 
splice site variants could be pathogenic and potential disease causing candidates. These 
candidates should be further evaluated in the family to determine whether the gene 
cosegregated with the phenotypic trait. 
 
 Another filtering option is the functional annotation of the variants in several 
databases. OMIM database contains several germ-line mutations associated with 
corresponding phenotypes.[123] Association of a gene with a phenotype allows 
comparison of the phenotypic similarities so the genes associated with the irrelevant 
phenotypes could be excluded from further analysis. Besides that, mice knock-out or 
knock-in studies provide useful information for understanding the role of the genes 
since they are the most closely related animals to humans.[124] The loss of gene 
expression in mice often causes phenotypic changes which could be compared with 
the human disease phenotypes. Databases such as JAX KO and MGI collect those 
information which can be used to evaluate candidate genes. Other databases including 
KEGG, UniProt, DGV, F-SNP, etc. were given in (Table 2.1) 
 
 Next, conservation analysis would provide evolutionary comparison between 
cross-species and give information about the predicted deleteriousness of the amino 
acid change. The region where the mutation resides in a gene would be evolutionary 
conserved across species. In addition, several tools can be used to predict the impact 
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of potential causal substitutions according to their effect on protein secondary 
structure.[62] As a result of multiple sequence alignments across species sequenced 
and consequences of the prediction tools, the variants with the mutant allele at many 
orthologous species at the same site and with no effect on protein structure could be 
considered as non-pathogenic, and could not be involved in the disease pathogenesis. 
 
 Lastly, the fold enrichment and coverage analysis reveal the total number of 
reads on each individual bases and how many times those bases are read within the 
targeted region. The targeted bases can be classified as zero-coverage bases which did 
not read at all, low-coverage bases with 1-3X mean read depth, and high-covered bases 
at least four read depths. The analysis revealed a mean coverage depth of 62.96-fold 
across the targeted homozygosity intervals with 97.41% of the targeted bases being 
covered by at least four reads. Thus, analysis of these non-covered regions including 
gaps would be one of the important challenges of the sequencing analysis, since 
disease causing mutations at these points could be missed. In sequencing reactions the 
non-covered regions are mostly associated with GC-low and GC-rich regions because 
they are difficult to amplify because of their secondary structures. These regions 
comprise about 1% of the human genome and they are epigenetically important so 
need to be evaluated.[125] Evaluation of these regions revealed that only 0.03% of the 
targeted bases that are non-covered are located on the constitutive coding exons and 
functionally important. This stated that 99.51% of the constitutive regions are covered 
by at least four reads (Table 3.12 and Figure 3.9). Evaluation of these genes encoding 
for the constitutive exons in the low- or zero-coverage regions were revealed that, they 
either do not have cerebellar expression or do not display a phenotype compatible with 
cerebellar involvement in mouse knockouts (Table 3.13). These results suggested that 
missing a causative mutation at the non-covered regions seems highly unlikely. 
 
 All of these strategies are enriched for discrete filtering, stratification, and 
functional annotation to explore which of the observed variants are more likely to 
affect phenotype. In conclusion, an evolutionary conserved novel missense mutation 
in ATP8A2 gene segregated with the CAMRQ in the family remained to be the only 
127 
 
causal mutation. However, biological evidence is still necessary in order to 
demonstrate the identified mutation is the causal of the phenotype. 
4.3 ATP8A2 is associated with CAMRQ 
ATP8A2 is one of the members of P4-ATPases subfamily of P-type ATPases, which 
are a large group of ion and lipid pumps involved in the transport across membranes.  
4.3.1 Biochemical properties of P-type ATPases 
The P-type ATPases are calcium pump (Ca+2-ATPase), proton-potassium pump 
(H+K+-ATPase), sodium-potassium pump (Na+K+-ATPase), and the plasma 
membrane proton pump (H+-ATPase). P-type ATPases include five subgroups: Type 
I involves in transition of K+ and heavy metals; type II involves in transition of Ca+2; 
type III involves in the transition of H+ and Mg+2; type IV involves in the transition of 
aminophospholipids; and type IV in the transition of cations.[126]  
 
 P4-type ATPases are key regulators of lipid asymmetry that catalyze transport 
by altering the curvature of the phospholipid bilayer by phosphorylation reactions in 
order to flip aminophospholipids from the endoplasmic reticulum to the cytoplasmic 
leaflet.[127] The best studied ones are the sarcoplasmic reticulum Ca+2-ATPase which 
functions in muscle contradiction and plasma membrane associated Na+K+-ATPase 
which functions in the stimulation and neuronal cells.[128] Functional analysis and 
homology searches revealed that the transport mechanism through P4-type ATPases 
conserved among all species.[127]  
 
ATP8A1, the closest homolog of ATP8A2, is the first ATPase identified in 
human red blood cells. Biochemical analysis revealed that this ATPase is activated by 
aminophospholipids and inhibited by phosphatases. [129] This ATPase was found to 
play role in transport across membrane by catalyzing rapid flipping of 
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phosphatidylserine. ATP8A2 was first purified from photoreceptor membranes and 
play role in transport across membranes by catalyzing active transport of 
phosphatidylserine. [130]  Mice deficient for either Atp8a1 or Atp8a2 cannot survive 
after birth. This reveals overlapping function of both genes. CDC50 protein family is 
reported to play role in export of some types of ATPases from the endoplasmic 
reticulum. Both ATP8A1 and ATP8A2 make complex with CDC50A to operate their 
function in photoreceptor outer segment membranes. [130] In a more recent study, 
downregulation of the CDC50A by using RNA interference technology revealed 
reduced neurite outgrowth in PC12 cells which are derived from rat adrenal medulla. 
Neurite outgrowth enhanced when ATP8A2 overexpressed in these cells. [131] These 
results suggested that ATP8A2-CDC50A complex play role in vesicle formation or 
transport across membranes.  
4.3.2 Clinical phenotypes associated with P4-type ATPases 
P4-type ATPases have been implicated in several phenotypes (Table 4.1). First, 
mutations  in ATP8B1 is associated with severe human liver diseases such as benign 
recurrent intrahepatic cholestasis type 1 (BRIC) and progressive familial intrahepatic 
cholestasis type 1 (PFIC1) in humans.[132] Similar to human phenotype, mice 
deficient with Atp8b1 suffer from hearing loss due to degeneration of hair cells.[133]  
Also, ATP2B2 is reported in a family with three affected individuals as the causal gene 
associated with sensorineural hearing loss.[134] Murine ATP8B3 is implicated in 
sperm cell capacitation and acrosome formation.[135] In vitro studies with Atp8b3 
knock-out sperm cells are deficient in fertilization.[136] P4-type ATPases are also 
implicated in complex disorders. Atp10a deficiency in mice leads to increased insulin 
levels and hyperglycemia. It is implicated in related disorders such as type-2 diabetes, 
obesity, and non-alcoholic fatty liver disease.[137] Besides that Atp10d deficiency is 
implicated in lipid metabolism in mice which results in predisposition to obesity, 
hyperglycemia, hyperinsulinemia, and hypertension.[138]  
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 P4-type ATPases have also been implicated in neurological phenotypes. First 
of all, genome-wide association studies revealed a highly significant association 
between ATP8B4 gene and Alzheimer’s disease.[139] By using linkage analysis and 
candidate gene sequencing ATP13A2 is found to be associated with Kufor-Rakeb 
syndrome which is a rare autosomal recessive form of juvenile-onset atypical 
Parkinson diseases.[140] Next, imprinting mutations in maternally expressed ATP10C 
gene is associated with Angelman syndrome.[141] In addition heterozygous mutations 
leads haploinsufficiency of ATP1A2 which is responsible for familial hemiplegic 
migraine type 2.[142] Mice deficient with Atp8b2 have impaired motor coordination 
and represents cerebellar ataxia.[143] In a very recent study, a missense mutation in 
ATP2B3 was identified in a family by using X-exome sequencing as a cause of X-
linked congenital cerebellar ataxia.[144] Lastly, Atp8a1 deficiency, which is the 
closest homolog of Atp8a2, leads to increase in phosphatidylserine externalization in 
hippocampus and associated with delayed hippocampus-dependent learning.[145] 
4.3.3 Clinical phenotypes associated with ATP8A2 
ATP8A2 haploinsufficiency is reported in a patient with a de novo t(10;13) balanced 
translocation leading to disruption of ATP8A2 gene. The patient represents severe 
neurological phenotypes including severe mental retardation and major hypotonia 
which brings into attention the clinical findings of carriers in Family C.[114] The 
translocation carrier shares partially overlapped phenotype with the affected members 
of Family C whereas the carriers of ATP8A2 p.I376M mutation (05-992 and 05-995) 
did not show any detected neurological abnormalities. This suggests that ATP8A2 
mutations should represent a clinical heterogeneity in humans, and demonstrates 
fundamental features of genomic analysis of human traits such as variable expression, 
allelic heterogeneity, and genotype–phenotype correlations.  
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Table 4.1: Clinical phenotypes associated with P4-type ATPases 
 
Gene Phenotype Species Reference MIM ID 
ATP8B1  Progressive familial intrahepatic 
cholestasis type 1 
human [129] 211600 
ATP8B1  Benign recurrent intrahepatic 
cholestasis type 1 
human [130] 243300 
ATP2B2  Deafness, autosomal recessive 12 human [131] 601386 
ATP8B3  Impairment in sperm cell acrosome 
formation and capacitation 
murine  [132] - 
Atp8b3  Inability to fertilize mice [133] - 
Atp10a  Obesity, type-2 diabetes, and non-
alcoholic fatty liver disease 
mice [134] - 
Atp10d  Obesity, hyperglycemia, 
hyperinsulinemia, and hypertension  
mice [135] - 
ATP8B4  Alzheimer’s disease  human [136] 104300 
ATP13A2  Parkinson disease 9 human [137] 606693 
ATP10C  Angelman syndrome human [138] 105830 
ATP1A2 Migraine, familial hemiplegic, 2 human [139] 602481 
Atp8b2  Cerebellar ataxia  mice [140] - 
ATP2B3  X-linked congenital cerebellar ataxia  human [141] - 
Atp8a1  Delayed hippocampus-dependent 
learning 
mice [142] - 
Atp8a2  Ataxia and body tremors mice [143] - 
ATP8A2  Mental retardation and major 
hypotonia  
human [114] - 
 
 
 
 There are several examples of heterozygous and homozygous mutations in the 
same gene causing similar phenotypes. First, both CRYBB1 homozygous and 
heterozygous mutations cause congenital cataract.[147] Another example is 
Zweymuller Weissenbacher syndrome, caused by heterozygous and homozygous 
mutations in COLL11A2.[148] A deleterious homozygous mutation in MYBPC1 
causes arthrogryposis that is more severe than that caused by heterozygous missense 
MYBPC1 mutations.[149] The osteopetroses are caused by defects in ClCN7 or ATP6i 
genes. They range from a devastating autosomal recessive neurometabolic disease to 
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more benign autosomal dominant conditions affecting adults.[150, 151] Menkes 
disease is an X-linked disorder caused by mutations in ATP7A gene, but variable forms 
exist such as occipital horn syndrome, which is the mildest form.[152] Autosomal 
recessive lethal congenital contractural syndrome is a severe form of neuromuscular 
arthrogryposis. SPG7 mutational screening in spastic paraplegia patients supports a 
dominant effect for some mutations and autosomal recessive hereditary spastic 
paraplegia.[153] It is noteworthy that in all these examples, the mutations causing the 
recessive phenotypes are more severe than the dominant phenotypes. This is likely due 
to the fact that the heterozygous mutations have dominant-negative effect where 
recessive mutations are dramatically disrupt the encoded protein resulting in a normal 
wild-type phenotype of the heterozygous individuals. 
 
  The wabbler lethal mice colonies with spontaneous homozygous mutation 
were present in the Jackson Laboratory since 1952. These mice represent phenotype 
with severe neurological abnormalities including ataxia and body tremors.[154] In a 
recent study, genetic approaches revealed that these spontaneous mutations located in 
the Atp8a2 gene. Further biochemical analysis represented that the phenotype occurs 
due to axonal degeneration since loss of phosphatidylserine translocase activity of 
Atp8a2 disrupts axonal transport in the motor neurons and accumulation of 
phosphorylated neurofilaments.[146] 
 
 These findings suggest that ATP8A2 could be critical for the developmental 
processes of central nervous system and alterations of this gene may lead to severe 
neurological phenotypes. 
4.3.4 ATP8A2 p.I376M mutation  
The disease causing variant (c.1128C>G) located at chr13:26128001 in exon 12 of 
ATP8A2 gene and results in an isoleucine (I) to methionine (M) substitution at residue 
376. There is no structural model for ATP8A2 protein so the consequences of the 
amino acid change are predicted. The protein is predicted to contain 27 β-strands and 
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32 α-helices. I376 residue is located at the N terminus of the 11th α-helix. The 
substitution predicted to alter secondary protein structure by enlarging the 11th and 
12th α-helices and creating an additional α-helix at residue 401.  
 
 The mutation lies in the predicted C-terminal-transmembrane site of the E1 E2 
ATPase domain. The domain is present on the loop of ATPase which is essential for 
the metal ion binding [155] and is highly conserved across species.  
 
The wild-type residue is a methionine which is a hydrophobic and flexible 
residue of intermediate size. It is mutated into an isoleucine which is also hydrophobic 
and of an intermediate size. However, the shape of isoleucine is different, its side-
chain is beta-branched and less flexible. The mutation might cause sterical hindrance 
with other side-chains that are surrounding the residue. In a transmembrane domain 
hydrophobic residue can be located on the surface of the protein, making interactions 
with hydrophobic membrane lipids. The mutation can affect these interactions. It is 
also possible that the residue is located on the inside of the helix, facing the other 
transmembrane helices. In that case the strong hydrophobic interactions are stabilizing 
the protein. Therefore, the mutation might destabilize the protein. 
4.3.5 Expression of ATP8A2 
Previous studies revealed that Atp8a2 is highly expressed at embryonic and new born 
stages. The strongest expression is at the heart, brain and testis tissues during these 
stages.[114] Our real time RT-PCR analysis revealed that ATP8A2 expression is high 
in the testis, whole brain, trachea, thyroid, and fetal liver. 
 
 Since the patients have cerebellar phenotype, we hypothesized that ATP8A2 
would possibly involve in motor functions. In order to test our hypothesis, firstly, 
expression profile of ATP8A2 was examined in different human brain regions. As a 
result human ATP8A2 is expressed in all regions of the brain with the highest level of 
expression in the cerebellum. In a very recent study, highest expression of Atp8A2 
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reported in central nervous system including cerebrum, cerebellum, spinal cord, and 
retina [146] which together with our expression data confirmed our hypothesis. 
Cerebellum is a crucial regulatory organ functioning in the coordination of the motor 
activities so that this expression pattern is consistent with CAMRQ.  
 
 Biological function of the ATP8A2 in brain development is still a mystery. The 
prediction-based bioinformatics approaches such as functional annotation clustering 
analysis would provide clues about the function.[115] Functional clustering of the 
genes correlated with ATP8A2 according to expression profiles revealed that they 
involved in neural pathways such as neuron differentiation, neuron projection 
morphogenesis and axonogenesis. Among the genes expressed with ATP8A2, 
doublecortin is responsible for X-linked lissencephaly and WDR81 associated with 
CAMRQ suggesting that these genes could represent similar developmental pathways. 
 
 As well as ATP8A2, CAMRQ associated genes WDR81, VLDLR, and CA8 
expressed highly in retina.[156] Since strabismus is observed among all the patients 
with CAMRQ reported eye abnormalities may be an additional clinical feature of the 
phenotype.  
4.3.6 Association with other CAMRQ genes 
Expression pattern and functional clustering analysis of the genes responsible for the 
CAMRQ syndrome revealed that these genes may be involved in a same or similar 
developmental pathways. ATP8A2 gene is a multi-pass transmembrane protein where 
VLDLR is a single-pass transmembrane protein. ATP8A2 is an ATP-dependent 
transporter of aminophospholipids from outer to inner leaflet whereas VLDLR is a 
ligand-dependent transporter of lipoproteins from outer to inner leaflet. CA8 encodes 
a carbonic anhydrase VIII protein which inhibits binding of IP3 receptors to ITPR1. 
ITPR1 is receptor localized in the intracellular membranes such as endoplasmic 
reticulum and plays role in the transport of cytoplasmic Ca+2. Binding of CA8 to ITPR1 
inhibits IP3 binding and causes calcium release from endoplasmic reticulum which 
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results in increased Ca+2 levels in the cytoplasm. [157] Increase in the cytoplasmic 
Ca+2 levels regulated by a transcription factor, CREB, which is activated by 
phosphorylation through calmodulin-dependent kinases such as Reelin. [158] VLDLR 
forms complex with Reelin, the cytoplasmic adaptor protein Disabled-1, 
apolipoprotein E receptor 2, and Src family kinases which regulates neural migration 
during embryonic development. In a more recent study, it is indicated that Reelin 
signaling is involved in the Ca+2 influx through NMDA receptors [158] which are 
responsible for the synaptic plasticity and memory. [159]  
 
 ATP8A2 forms complex with CDC50 and this complex functions in the neurite 
outgrowth in PC12 cells and in hippocampal neurons. Increase in the Ca+2 levels 
through NMDAR mediated calcium influx also triggers Reelin-dependent 
hippocampal neurite outgrowth and dendrite development through Apoer2/Vldlr-Dab1 
dependent pathway. [160] Therefore, these data suggest that three genes may play role 
in the similar pathways involved in neurite outgrowth and synapse formation.  
 
 Similar to ATP8A2, WDR81 also encodes a multi-pass transmembrane 
protein, which is predominantly expressed in the cerebellum with unknown in vivo 
function. Chracterization and functional annotation of the gene is necessary to draw a 
common pathway among these genes.  
4.4 Conclusion 
A novel missense homozygous variant in ATP8A2 is identified as causal mutation of 
the phenotype in three affected individuals with CAMRQ by filtering the all possible 
culprit genes using co-segregation analysis, population screening, protein conservation 
and disease gene prediction approaches. The mutation segregates with the autosomal 
recessive inheritance in the family. The mutation is in a functional transmembrane 
domain which is predicted to alter secondary structure of the protein and highly 
conserved across species. ATP8A2 is a P4-type ATPase involved in the transportation 
of the aminophospholipids across membranes. P4-type ATPases mostly implicated 
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with several neurological phenotypes in both humans and model organisms, especially 
Atp8b2 with motor coordination and cerebellar ataxia [143], ATP2B3 with X-linked 
congenital cerebellar ataxia [144], and the closest homolog Atp8a1 with delayed 
hippocampus-dependent learning.[145] ATP8A2 is mainly expressed in brain tissues, 
with highest levels in cerebellum which is a crucial regulatory organ for motor 
coordination. The Atp8a2 deficiency in mice revealed impaired axonal transport in the 
motor neurons associated with severe neurological phenotype including ataxia and 
body tremors.[146] Lastly, a patient with a de-novo-balanced translocation leading to 
ATP8A2 haploinsufficiency shares similar neurological phenotypes including severe 
mental retardation and major hypotonia with affected individual in Family C. All these 
findings are consistent with our observations and strongly suggest a possible role for 
ATP8A2 in development of the nervous system especially in motor behavior.  
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Chapter 5 
Future Perspectives 
CAMRQ is a novel form of autosomal recessive cerebellar ataxias with mental 
retardation, dysarthric speech and with or without quadrupedal locomotion. The 
condition is phenotypically and genetically heterogeneous since four gene locus 
identified so far:  VLDLR on chromosome region 9p24 [32], CA8 on chromosome 
region 8q12 [35], WDR81 on chromosome region 17p13 [29], and recently ATP8A2 
on chromosome region 13q12.[64] The expression profiles of these genes, mouse 
knock-out studies, and predictions about their biological roles revealed that these genes 
may be involved in similar neurological pathways. Since biochemical analysis is 
needed to observe functional common domains or motifs, gene-gene interactions, 
differential pathway expression profiles. These data would provide to compare gene-
phenotype correlations and would address the phenotype related differences in gene-
pathway interactions.  Such observations related with gene-pathway interactions are 
important to understand the pathology underlying the disease mechanisms and would 
provide clues for potential drug targeting. In addition, several consanguineous families 
with CAMRQ or related phenotypes including autosomal recessive ataxias were 
investigated so far. Identification of novel genes responsible for novel CAMRQ or 
phenotypically related cases would help discovering common neurological pathways 
involved in disease pathogenesis and classification of the clinical phenotypes arise 
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from phenotypic heterogeneity.  Homozygosity mapping following targeted next 
generation sequencing is the most efficient method for identifying novel genes 
associated with autosomal recessive disorders in consanguineous families. Thus, 
improvements in SNP genotyping arrays and target capturing arrays, as well as 
sequence analysis methods would lower the error rates associated with false positives, 
false negatives and coverage of the bases.  
 
 A novel missense homozygous variant in ATP8A2 is identified as causal 
mutation of CAMRQ. Segregation analysis, population stratification, protein 
conservation analysis, expression profiles, secondary structure predictions, functional 
annotation clustering, as well as phenotypes associated with the gene and its homolog 
relatives and mice studies revealed that the missense mutation is responsible for 
CAMRQ and associated with the clinical phenotypes. However, direct evidence is still 
missing. Introducing the same homozygous mutation into cell lines in vitro and 
additionally into model organisms in vivo would provide significant information about 
the role of ATP8A2 in nervous system development, especially in motor coordination 
associated with cerebellum, mental retardation, and hypotonia.  
 
 Comparison and classification of the phenotypes associated with other 
CAMRQ genes would help understanding the pathways involved in disease 
pathogenesis. Therefore, fully characterization of the CAMRQ associated genes is 
necessary. For that purpose, characterization of the gene structure and identification of 
the tissue specific novel transcript isoforms of the WDR81 gene which is associated 
with CAMRQ2 by using Zebrafish as a model organism have been got started in our 
laboratories.  
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Table A.1: Primers for candidate gene sequencing 
 
Locus D. Primer Tm Size 
CENPJ gene sequencing 
CN_1 
F 
R 
CGCCTACGTCGACCACTG 
TGAACGAAGCCACTGAACTG 
61.5 
60.0 
477 
CN_2 
F 
R 
TATGCTGGGTTGAGGTTTGG 
AAACAGAAACCTGCAATGACA 
60.9 
58.3 
648 
CN_3 
F 
R 
AGGAGGGAGATGGGAGGAAT 
GCATTATACTGAGGCCCTGTG 
61.2 
59.6 
247 
CN_4 
F 
R 
CACTGTGGAGAAGTCTTTGTGG 
GCTACCTGAGAGGCTGATGG 
59.8 
60.0 
577 
CN_5 
F 
R 
TCCTGGCCTCAAGTGATTCT 
CACCAAATGGGAGATGTCAA 
59.8 
59.3 
502 
CN_6 
F 
R 
GGGTTTCTATACCAGGCACAC 
TGGAGTTGCTGTCTATCCATTT 
58.4 
58.7 
500 
CN_7_1 
F 
R 
TTTAGGAAGCAGAAGGACCA 
AGCCAGTATCGCAAGGTTT 
57.5 
57.4 
468 
CN_7_2 
F 
R 
TCTTTCTCCGTCAGGATTGA 
GCCGGATTTGTCTTCTGTG 
58.4 
59.2 
483 
CN_7_3 
F 
R 
CCATAAGGGAGACCATGAAA 
CTCTCACTATTTGGAACACCTTC 
57.5 
57.0 
484 
156 
 
CN_7_4 
F 
R 
GAATTGAGGGAACAGCCTTG 
GGCGTCCCATAAGTGGATT 
59.7 
59.8 
470 
CN_7_5 
F 
R 
CACCAGGACCCAAGAAGATAA 
GGGAAGAAAGGAAACGTAGAAG 
59.0 
58.5 
697 
CN_8 
F 
R 
TTGCCATATTCTTGGCTCTT 
GTCTTAAAGGTATAACTGAGTCACTGC 
57.5 
58.2 
289 
CN_9 
F 
R 
GGATGAATGCTTTAGTGAGTGG 
TTTCCAACTCCAGGCTTGTT 
58.7 
59.7 
596 
CN_10 
F 
R 
TCATTGCTGGGTCTCTATTCTTC 
TTCCCATTCTACTTTCTGACTCTATG 
59.7 
59.3 
400 
CN_11 
F 
R 
AACCCACAGCATTCTTAGCAC 
GATGCACAGGAGCTTCAATTAC 
59.3 
58.9 
336 
CN_12_13 
F 
R 
AAGGACAGCAGTTCACAGGA 
TCTGAACGAGAAATGGCAAC 
58.4 
58.9 
627 
CN_14_16 
F 
R 
GTAGGCAGTTGGGAGGAGAA 
ACATATCATCAGAAACGCAAGG 
59.3 
59.1 
675 
CN_17 
F 
R 
GATAACCAAGGGATGTCTCCA 
GTGCTCTACGGCTGATGTGT 
58.8 
58.9 
679 
MTMR6 gene sequencing 
MTMR_1 
F 
R 
TCCATTCTCACGCAGTCTTCC 
CTTCGTCTCCTCCTGCCTCA 
62.7 
63.0 
498 
MTMR_2 
F 
R 
TGCATGTAAGTCCTGGGCTA 
GGCAGGAGTGATCTGGAGAC 
59.3 
59.8 
341 
MTMR_3 
F 
R 
TGCTTTCCATGTTGATGACC 
GGGGAGATAGAGTACAAAAGAACC 
59.5 
58.7 
340 
MTMR_4 
F 
R 
TCAGGTATTAGCCATCTCTTTGAAG 
CTGGGGTAAGTTTCACAAATCTG 
60.2 
59.9 
488 
MTMR_5 
F 
R 
TGAAATGTGCTGTTCTTGCA 
AAGCATCCTACCTCCTTATCTTGA 
59.0 
59.7 
236 
MTMR_6 
F 
R 
GGATCTTAAAGTTAATGCCTCCTAA 
AGAAGATGTAAGAAATCACCATGAG 
58.4 
57.9 
479 
MTMR_7 
F 
R 
TTCCTTTAAACTGCCTCCTAGC 
TGCCTGATTTCTAAGAGTTGATGA 
59.1 
60.3 
477 
MTMR_8 
F 
R 
CGTATTTGGTTAGTGGCTGCT 
ACTCCTTCCCAATCATTATAGACC 
59.3 
58.8 
584 
MTMR_9 
F 
R 
ATTGCAGGCATAGCACTTC 
TGCCAGTCTCATCATTTCCTT 
56.5 
59.7 
355 
MTMR_10 
F 
R 
TCCACCTCAGTCTACCACCT 
CATCACGCATGTGAGTTCAT 
57.1 
58.0 
541 
MTMR_11 
F 
R 
CAATACCTGAACAATGGACCTT 
AGCTTCACACTTAACGCTCTATG 
58.0 
57.9 
519 
157 
 
MTMR_12_14 
F 
R 
GAAGCCATCGCCTGATTTAT 
GGGATGACCTGATTTTGAAGA 
59.1 
59.0 
558 
MTMR_15_1 
F 
R 
TGTAACATATTGTGGCTTATGCAAT 
CTGACCACAGCAGGTTCTGA 
59.7 
60.0 
284 
MTMR_15_2 
F 
R 
CCCGGCAGATAATCGTTATAG 
ATTCCTTGCTGGAAATGCAA 
58.6 
60.6 
293 
MTMR_15_3 
F 
R 
GATGGTCTGTAAGCATAACCAAA 
GCAGTAATGAGAGCACAATTCTTT 
58.2 
59.0 
550 
MTMR_15_4 
F 
R 
TTCTTCTGGTCAGCCTTGTTT 
CCAGGAACAGCAACTCATTG 
59.0 
59.3 
431 
MTMR_15_5 
F 
R 
GTGGTTGGCTTTATTTCTTTCAC 
GCCAGTTGGGTGATATTGCT 
59.1 
60.0 
471 
MTMR_15_6 
F 
R 
GTGCATGGTTGCATGAATTT 
AAGTTTCCATTCCCAGTGCTT 
59.4 
60.0 
581 
MTMR_15_7 
F 
R 
GATTAACCAATCCTGCTTCCA 
CTCCTCAAACCTTATGCTGTTATG 
59.0 
59.2 
495 
NUPL1 gene sequencing 
NUPL1_1 
F 
R 
AACTCTGGGAGCCTACTCCTTT 
AGGCGAGAAAGTGCGGTTAC 
59.8 
61.7 
465 
NUPL1_2 
F 
R 
ACCCAGCCTGAAATCTGGTA 
TCCCAAGCCTACTCTCTGACA 
59.6 
60.0 
485 
NUPL1_3 
F 
R 
CACATTTCACAGCCACATCT 
TCTCCGATAAGTCACCATCTG 
57.1 
57.8 
565 
NUPL1_4 
F 
R 
CTCTCACAGATACACCCTTCTTCT 
ACAGCCTCTCCTGCTTCAAT 
58.1 
59.0 
438 
NUPL1_5 
F 
R 
TACTCCTCAAAGCCCTTATTTCTG 
AGAATCTCTCTTGAACCCTGGAG 
60.1 
60.2 
635 
NUPL1_6 
F 
R 
CGCATCATCCAAACTGCATA 
GCAACCTAGACATTCCCTCAAC 
60.6 
60.0 
381 
NUPL1_7 
F 
R 
GGCAAGCAAAGAAATGCTTAAC 
GAGAAATACCAAACACCTTTCCAG 
60.3 
60.3 
394 
NUPL1_8 
F 
R 
GAAATCATCCAGAGAAGCCATAC 
CTTGAACTTGTTTCTGCTCCTTC 
59.1 
59.6 
557 
NUPL1_9 
F 
R 
GGGAGCATCTCTTCCTCCTA 
TTCCTACCTTGTTGGGTCTTT 
58.4 
57.7 
691 
NUPL1_10 
F 
R 
TCTTTGAAGTTTCAGTCCAGAG 
GGCTCAGCCTTTCCACATAG 
56.3 
59.8 
296 
NUPL1_11 
F 
R 
CTTCCTTTCCTTGGATAACCTTG 
GCCCTAAGATTTCTGTCCTTGTT 
60.3 
60.0 
452 
NUPL1_12 
F 
R 
CTGCTACTCTGTGTGTTCTCTGG 
CGTTATGTCTGGGTATGTTATGGA 
59.2 
60.0 
397 
158 
 
NUPL1_13 
F 
R 
CCTACACCAAAGTGCATTATTAGC 
TCAGTGCTCACACAAATGGA 
59.2 
58.8 
449 
NUPL1_14 
F 
R 
AGACTGGAGAGACATCCTGAAA 
TTGCCAGATGGAACCTTAACT 
58.0 
58.7 
382 
NUPL1_15 
F 
R 
ACTTGTCCATATCCTTTAACCTGTG 
GCACACTTCATCCAGGGAGTA 
59.7 
60.1 
298 
NUPL1_16_1 
F 
R 
AATTTACTGCTCCTCCCTGTTT 
GGCCCTAGAGTTCACACCA 
58.3 
58.7 
627 
NUPL1_16_2 
F 
R 
TGTGTTGAGAGAATCCATAGCAG 
AGTGCAGTGGTGTGATCTCG 
59.4 
59.9 
545 
NUPL1_16_3 
F 
R 
GGTGGCTCACGCCTGTAATC 
TCACAGAAGCAATGTAAGGACACA 
62.9 
62.0 
495 
NUPL1_16_4 
F 
R 
TCAGTGCTTGTAGAATGATGAGC 
ACATGCCTATGCGTTATTACCTG 
59.5 
60.3 
598 
NUPL1_16_5 
F 
R 
GGCTTCTCAGCCTCTTAATGTC 
AAGCCAACCACTGCTATATGC 
59.5 
59.3 
533 
NUPL1_16_6 
F 
R 
AGCCATGATTTCGTTAGTAGACCT 
CTAACTTCCCATGTTCTGGATCTG 
59.6 
61.2 
424 
NUPL1_16_7 
F 
R 
GCATATAGCAGTGGTTGGCTTT 
GGAAATGGAAGGGAATTAGGG 
60.5 
60.8 
700 
SACS gene sequencing 
Sacs_1_2 
F 
R 
GGCGGATCCCCAGCTAAC 
AACGGAAAAGGCAAGTGATG 
62.9 
60.1 
696 
Sacs_3 
F 
R 
TTCTCCAGACAACTTCCTTCA 
GCCTGTAATCCGAACACTTTG 
57.5 
59.6 
600 
Sacs_4 
F 
R 
TGCTTCGTCAGGTAGATTTCTG 
GGAGCGACACTGCTGATTAC 
59.5 
58.5 
496 
Sacs_5 
F 
R 
TGCAAATAGTGGGTTTCCTT 
CAACTGGTGGAGACACCTTC 
57.2 
58.1 
407 
Sacs_6 
F 
R 
GAGATAGAACAGAACACCCTGGTA 
CATTGACATACCTCCTGCTACTG 
58.7 
58.8 
352 
Sacs_7_1 
F 
R 
CCTGGCATTTGTTATTGGAT 
TGAAGGTTGTAGGCGAAGAG 
57.4 
58.1 
443 
Sacs_7_2 
F 
R 
CAGTTTGCACCATTTGTTGG 
TGCTTCATCATCTCTGCTTGA 
60.0 
59.7 
564 
Sacs_7_3 
F 
R 
GGGCGAGGGATCAGTAGTAA 
AGCTCTGGAGGTAGTTGAGCA 
59.1 
59.2 
592 
Sacs_7_4 
F 
R 
GTCAGGTTGGAGCAGGTGTA 
GCTCACTGTAGGCTTGGTCA 
58.7 
59.0 
280 
Sacs_7_5 
F 
R 
GCACAACACCTGTGAGGAAG 
CTGGCCTTGTTATTATTTGCAC 
59.3 
58.7 
532 
159 
 
Sacs_8 
F 
R 
TGTGAGAGTCCTTTGTTGTGAA 
CCATGCAGGTATAAGATGTTGA 
58.4 
57.7 
932 
Sacs_9_1 
F 
R 
CCTTCCAGTACTGTGTTATTTGTGAG 
CAAGAACTTCCTCAGGGCATC 
60.4 
61.1 
623 
Sacs_9_2 
F 
R 
GATGCATCTATCCAACATCCGCT 
GGGGTGGGAAATAGGTTCCTTC 
64.5 
64.0 
602 
Sacs_9_3 
F 
R 
AAAAATGAGAATCCAAATGTGCT 
GCACTAAGGCTAGGTTTTGTGAAG 
59.1 
60.7 
599 
Sacs_9_4 
F 
R 
GCTCCTCACTTCCTCTTGTTG 
CGTGAATTTGGCTTCATGATAA 
59.1 
60.0 
601 
Sacs_9_5 
F 
R 
AGCAATCAGATTCCAGCAAGC 
GATGGGAATGTCAGTGATATGG 
61.8 
59.1 
612 
Sacs_9_6 
F 
R 
GGGAGAAGTTGACAAAGTTGGA 
CTTTGGTTCATCACTGGGAAG 
60.5 
59.6 
625 
Sacs_9_7 
F 
R 
TCCAAAGCATTGAACACACCT 
CAGGTCCCGTAAGACACTCAG 
60.5 
59.8 
633 
Sacs_9_8 
F 
R 
CAATGGGTGCTTTGCTGTTAC 
CGAAGAACTCCCGAGAACTCA 
60.5 
61.8 
621 
Sacs_9_9 
F 
R 
GCTGGCTGCAAACAGATACTAC 
GCAAACATGGTTTCAGGCTTA 
59.1 
60.1 
605 
Sacs_9_9_2 
F 
R 
AACTTCCTTCTTCGGTAAAAT 
CAATGACACTGAACCACAA 
54.0 
53.5 
746 
Sacs_9_10 
F 
R 
CAAACAATCCGCTTCCTTCCAT 
ATTATTCGTCGGCAAAGCTGA 
64.5 
62.0 
653 
Sacs_9_11 
F 
R 
TTCCGCGAACTTTTTTGAAACC 
ACACAAAGTGCTGGCCCTTGC 
64.4 
66.9 
601 
Sacs_9_12 
F 
R 
GATGCAAAGGCGACAGAAATC 
ATACAGCACATTTAGAGCTCCAGT 
62.0 
58.6 
627 
Sacs_9_13 
F 
R 
GCATCAGACAGAATGGTCCAG 
GCAATTCAACATATGCAGGAG 
60.7 
58.3 
625 
Sacs_9_14 
F 
R 
GTGAATGGCCACTTTGCACT 
TGATATCAGCAGGGGTCACAT 
61.1 
60.4 
649 
Sacs_9_15 
F 
R 
ACCACACGCAAAACAGTAGCA 
GCCATGCATTCTTAAGCCAAG 
61.7 
62.0 
610 
Sacs_9_16 
F 
R 
TGACATTTCCAGCTTTGCTGA 
AGCGGCCACTGATGGATTTAT 
61.9 
62.9 
632 
Sacs_9_17 
F 
R 
AAATGATTTTGAGGCAACTTTTG 
TTCCACCCAGGATGTCATAAA 
59.5 
60.2 
594 
Sacs_9_17_2 
F 
R 
AATATAGAGAGCCCCACAAGC 
GTTTTCTGTATTAGCCCTCACAC 
57.5 
57.0 
786 
160 
 
Sacs_9_18 
F 
R 
ACAGTAGACTAAAGCAAGCAAAGC 
ATCAAGAGGAGGATCCAGGTT 
58.6 
59.0 
647 
Sacs_9_19 
F 
R 
CATCCTGCCCTATTCTTCCAG 
TAAAGCGCAAGGTCTCGTACA 
61.0 
60.9 
619 
Sacs_9_20 
F 
R 
TGAGGGCAAACAATTAGATCC 
TCTGCTGTGGGGAATAGGATT 
59.0 
60.8 
616 
Sacs_9_21 
F 
R 
GCAAAGCCCTAAGAGAAGGAT 
TGCTTTGAGTAGCTTTCCTCAG 
59.0 
58.9 
634 
Sacs_9_22 
F 
R 
TGAAAGAGAAGATGCTGACAATTC 
GTAAGTCTGTCCGGCTGAAGG 
59.9 
61.2 
655 
Sacs_9_23 
F 
R 
CATCCCGATTTCAGTCAGACA 
TTCGTGCTACAACACATTCAAGA 
61.1 
60.7 
639 
 
 
 
 
 
 
Table A.2: Sanger sequencing primers for segregation analysis of protein altering 
variants 
 
Locus D. Primer Tm Size 
ATP8A2 
F 
R 
TCCACAGACACCACCTCAGA 
AAATGCCAAAGGCTCTGAAA 
60.3 
59.8 
197 
APBA3 
F 
R 
TTCAGGACCAGTCTGGGAAG 
AGTCAAGCCTTCAGGAGCTG 
60.2 
59.7 
227 
MUC16_A6352V 
F 
R 
GTGCCTTGGATGGATGTTCT 
ACCTCGGGGGACTCAATAGT 
59.9 
59.8 
233 
MUC16_T6290I 
F 
R 
TCGCAGAGGATCTAGGCATT 
CCTGTGACTCGTTCACCTCA 
59.9 
59.9 
247 
ZNF823 
F 
R 
GCTGAAGGCTTTCCCACATT 
TTTGCACGAAAGAACACACA 
61.5 
58.9 
235 
SERINC3 
F 
R 
TGCATCTGAGCCACTCATTT 
TTGTGATGTGCTGGTTGGTT 
59.4 
60.0 
250 
PCP2 
F 
R 
TACAGCCACAACTGGGTCAG 
GAGGCCAGCAGAAAAGTGAC 
59.7 
60.0 
214 
 
 
161 
 
Table A.3: AS-PCR primers for population screening 
 
Locus D. Primer Tm Size 
ATP8A2_AS1_WT 
F  
R 
CATGCAGGAGGTGCTCAATA 
CTCAAGAGTCACCAACAGACTG 
59.8 
57.6 
193 
ATP8A2_AS1_Mut 
F  
R 
CATGCAGGAGGTGCTCAATA 
CTCAAGAGTCACCAACAGACTC 
59.8 
56.6 
193 
APBA3_as2_wt 
F  
R 
GGAGCCCGTGGGCATCAGC 
CCTCAGTCGGATGGAACTTG 
70.8 
60.6 
170 
APBA3_as2_mut 
F  
R 
GGAGCCCGTGGGCATCAGT 
CCTCAGTCGGATGGAACTTG 
68.1 
60.6 
170 
 
 
Table A.4: Real time RT-PCR primers expression analysis 
 
Locus D. Primer Tm Size 
ATP8A2_RT 
F  
R 
GCACACTTCTGGTTGGGATT 
CGAGACTTGGTTTCCAGCTC 
60.0 
60.0 
131 
GAPDH 
F  
R 
GGCTGAGAACGGGAAGCTTGTCAT 
CAGCCTTCTCCATGGTGGTGAAGA 
68.8 
68.8 
143 
 
 
Table A.5: STR markers for haplotype construction of chromosome 13q12 
 
Marker D. Primer Expected 
Size 
D13S787 F 
R 
ATCAGGATTCCAGGAGGAAA 
ACCTGGGAGTCGGAGCTC 
252  
D13S1243 F 
R 
TGCTGACAGGCTACAGAACTTT 
CTCTTGTGCAGGTATAGGGG 
0 
D13S742 F 
R 
TCCAGCCTGGTCAACACAG 
TCCAGACTTCCCAATTCAGG 
364 
D13S283 F 
R 
TCTCATATTCAATATTCTTACTGCA 
GCCATTCCAAGCGTGT 
108 
D13S1294 F 
R 
GACCCCAATTCTATGTGTTCAG 
CAGGAGTTTTTATCTACTTTGTGCC 
251 
D13S221  F 
R 
TAGCCATGATAGGAAATCAACC 
GAGATCGTGCAGCACTTGT 
243 
  
162 
 
 
Appendix B 
Candidate genes at the homozygous regions 
 
 
Table B.1: Full list of the candidate genes located at the shared homozygous regions 
 
Chr:Start-End (bp) Gene Name Gene Biotype Status 
1:1152288-1167411 SDF4 protein_coding KNOWN 
1:1167629-1170421 B3GALT6 protein_coding KNOWN 
1:1177826-1182102 FAM132A protein_coding KNOWN 
1:1189289-1209265 UBE2J2 protein_coding KNOWN 
1:1214447-1227409 SCNN1D protein_coding KNOWN 
1:1227756-1244989 ACAP3 protein_coding KNOWN 
1:1243947-1247057 PUSL1 protein_coding KNOWN 
1:1246965-1260071 CPSF3L protein_coding KNOWN 
1:1260136-1264277 GLTPD1 protein_coding KNOWN 
1:1266694-1270686 TAS1R3 protein_coding KNOWN 
1:1270656-1284730 DVL1 protein_coding KNOWN 
1:1288069-1297157 MXRA8 protein_coding KNOWN 
1:1309110-1310875 AURKAIP1 protein_coding KNOWN 
1:1321091-1334708 CCNL2 protein_coding KNOWN 
1:1334902-1337426 RP4-758J18 protein_coding NOVEL 
1:1337288-1342693 MRPL20 protein_coding KNOWN 
1:1353800-1357149 ANKRD65 protein_coding KNOWN 
1:1361508-1363167 TMEM88B protein_coding KNOWN 
1:1370241-1378262 VWA1 protein_coding KNOWN 
1:1385069-1405538 ATAD3C protein_coding KNOWN 
163 
 
1:1407143-1433228 ATAD3B protein_coding KNOWN 
1:1447531-1470067 ATAD3A protein_coding KNOWN 
1:1470554-1475833 TMEM240 protein_coding KNOWN 
1:1477053-1510249 SSU72 protein_coding KNOWN 
1:1510355-1511373 AL645728.1 protein_coding KNOWN 
1:1533392-1535476 C1orf233 protein_coding KNOWN 
1:1550795-1565990 MIB2 protein_coding KNOWN 
1:1567474-1570639 MMP23B protein_coding KNOWN 
1:1570603-1590473 CDK11B protein_coding PUTATIVE 
1:1592939-1624167 SLC35E2B protein_coding KNOWN 
1:1634169-1655777 CDK11A protein_coding KNOWN 
1:1656277-1677431 SLC35E2 protein_coding KNOWN 
1:1682671-1711896 NADK protein_coding KNOWN 
1:1716725-1822502 GNB1 protein_coding KNOWN 
1:1846266-1848735 CALML6 protein_coding KNOWN 
1:1849029-1850712 TMEM52 protein_coding KNOWN 
1:1853396-1935276 C1orf222 protein_coding KNOWN 
1:1950780-1962192 GABRD protein_coding KNOWN 
1:1981909-2116834 PRKCZ protein_coding KNOWN 
1:2115903-2144159 C1orf86 protein_coding KNOWN 
1:2143360-2145620 AL590822.1 protein_coding KNOWN 
1:2160134-2241558 SKI protein_coding KNOWN 
1:2252692-2323146 MORN1 protein_coding KNOWN 
3:48509197-48542259 SHISA5 protein_coding KNOWN 
3:48555117-48599448 PFKFB4 protein_coding KNOWN 
3:48599160-48601206 UCN2 protein_coding KNOWN 
3:48601506-48632700 COL7A1 protein_coding KNOWN 
3:48636435-48648409 UQCRC1 protein_coding KNOWN 
3:48658192-48659288 TMEM89 protein_coding KNOWN 
3:48663156-48672926 SLC26A6 protein_coding KNOWN 
3:48673902-48700348 CELSR3 protein_coding KNOWN 
3:48701364-48723797 NCKIPSD protein_coding KNOWN 
3:48725436-48777786 IP6K2 protein_coding KNOWN 
3:48782030-48885279 PRKAR2A protein_coding KNOWN 
3:48894369-48936426 SLC25A20 protein_coding KNOWN 
3:48955221-48956818 C3orf71 protein_coding KNOWN 
3:48956254-49023815 ARIH2 protein_coding KNOWN 
3:49027319-49044587 P4HTM protein_coding KNOWN 
3:49044495-49053386 WDR6 protein_coding KNOWN 
3:49052921-49059726 DALRD3 protein_coding KNOWN 
3:49057892-49060905 NDUFAF3 protein_coding KNOWN 
164 
 
3:49061758-49066841 IMPDH2 protein_coding KNOWN 
3:49067140-49131796 QRICH1 protein_coding KNOWN 
3:49133365-49142553 QARS protein_coding KNOWN 
3:49145479-49158371 USP19 protein_coding KNOWN 
3:49158547-49170551 LAMB2 protein_coding KNOWN 
3:49199968-49203754 CCDC71 protein_coding KNOWN 
3:49209044-49213917 KLHDC8B protein_coding KNOWN 
3:49215065-49236502 RP11-694I15 protein_coding KNOWN 
3:49235861-49295537 CCDC36 protein_coding KNOWN 
3:49297518-49298749 RP11-3B7.1 protein_coding PUTATIVE 
3:49306035-49315342 C3orf62 protein_coding KNOWN 
3:49315264-49378145 USP4 protein_coding KNOWN 
3:49394609-49396033 GPX1 protein_coding KNOWN 
3:49396578-49450431 RHOA protein_coding KNOWN 
3:49449639-49453908 TCTA protein_coding KNOWN 
3:49454211-49460186 AMT protein_coding KNOWN 
3:49460379-49466759 NICN1 protein_coding KNOWN 
3:49506146-49573048 DAG1 protein_coding KNOWN 
3:49591922-49708978 BSN protein_coding KNOWN 
3:50400233-50541675 CACNA2D2 protein_coding KNOWN 
3:50595462-50608458 C3orf18 protein_coding KNOWN 
3:50606583-50622366 HEMK1 protein_coding KNOWN 
3:50643921-50649262 CISH protein_coding KNOWN 
3:50648951-50686720 MAPKAPK3 protein_coding KNOWN 
3:50712672-51421329 DOCK3 protein_coding KNOWN 
3:51422478-51426828 MANF protein_coding KNOWN 
3:51428731-51435330 RBM15B protein_coding KNOWN 
3:51433298-51534010 VPRBP protein_coding KNOWN 
3:51575596-51697610 RAD54L2 protein_coding KNOWN 
3:51696709-51738339 TEX264 protein_coding KNOWN 
3:51741086-51752629 GRM2 protein_coding KNOWN 
3:51812580-51813009 IQCF6 protein_coding KNOWN 
3:51851620-51864876 IQCF3 protein_coding KNOWN 
3:51895645-51897440 IQCF2 protein_coding KNOWN 
3:51907737-51909600 IQCF5 protein_coding KNOWN 
3:51928892-51937351 IQCF1 protein_coding KNOWN 
3:51967446-51975957 RRP9 protein_coding KNOWN 
3:51976361-51982883 PARP3 protein_coding KNOWN 
3:51989330-51991509 GPR62 protein_coding KNOWN 
3:51991470-52008032 PCBP4 protein_coding KNOWN 
3:52002526-52017425 ABHD14B protein_coding KNOWN 
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3:52005442-52015212 ABHD14A protein_coding KNOWN 
3:52009066-52023213 ACY1 protein_coding KNOWN 
3:52009066-52023199 ACY1 protein_coding NOVEL 
3:52027644-52029958 RPL29 protein_coding KNOWN 
3:52082935-52090566 DUSP7 protein_coding KNOWN 
3:52097076-52097567 C3orf74 protein_coding KNOWN 
3:52109269-52188706 POC1A protein_coding KNOWN 
3:52232102-52248343 ALAS1 protein_coding KNOWN 
3:52255096-52260179 TLR9 protein_coding KNOWN 
3:52255097-52265206 RP11-330H6.5 protein_coding NOVEL 
3:52262626-52273177 TWF2 protein_coding KNOWN 
3:52279841-52284613 PPM1M protein_coding KNOWN 
3:52288437-52322036 WDR82 protein_coding KNOWN 
3:52321105-52329272 GLYCTK protein_coding KNOWN 
3:52350335-52434507 DNAH1 protein_coding KNOWN 
3:52435029-52444366 BAP1 protein_coding KNOWN 
3:52443510-52457657 PHF7 protein_coding KNOWN 
3:155093369-155462856 PLCH1 protein_coding KNOWN 
3:155459933-155461515 AC104472.1 protein_coding KNOWN 
3:155480401-155524140 C3orf33 protein_coding KNOWN 
3:155544305-155572218 SLC33A1 protein_coding KNOWN 
3:155588325-155658457 GMPS protein_coding KNOWN 
3:155755490-156256545 KCNAB1 protein_coding KNOWN 
5:68646811-68665840 TAF9 protein_coding KNOWN 
5:68665120-68710628 RAD17 protein_coding KNOWN 
5:68710939-68740157 MARVELD2 protein_coding KNOWN 
5:68788119-68853931 OCLN protein_coding KNOWN 
5:68856035-68890550 GTF2H2C protein_coding KNOWN 
5:69321074-69338940 SERF1B protein_coding KNOWN 
5:69345350-69374349 SMN2 protein_coding KNOWN 
5:70196492-70214357 SERF1A protein_coding KNOWN 
5:70220768-70249769 SMN1 protein_coding KNOWN 
5:70264310-70320941 NAIP protein_coding KNOWN 
5:70330784-70363516 GTF2H2 protein_coding KNOWN 
9:39072764-39288456 CNTNAP3 protein_coding KNOWN 
9:39355699-39361956 FAM75A1 protein_coding KNOWN 
9:39884975-39891210 FAM75A2 protein_coding KNOWN 
9:39900338-39907240 FAM74A1 protein_coding KNOWN 
9:40028620-40032417 AL353791.1 protein_coding PUTATIVE 
9:40700291-40706537 FAM75A3 protein_coding KNOWN 
9:40760700-40836415 ZNF658 protein_coding KNOWN 
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9:43624507-43630730 FAM75A6 protein_coding KNOWN 
9:43684902-43924049 CNTNAP3B protein_coding KNOWN 
12:123104824-123215390 HCAR1 protein_coding KNOWN 
12:123185840-123187890 HCAR2 protein_coding KNOWN 
12:123199303-123201439 HCAR3 protein_coding KNOWN 
12:123237321-123255611 DENR protein_coding KNOWN 
12:123258874-123312075 CCDC62 protein_coding KNOWN 
12:123319000-123347507 HIP1R protein_coding KNOWN 
12:123349882-123380991 VPS37B protein_coding KNOWN 
12:123405498-123466196 ABCB9 protein_coding KNOWN 
12:123459127-123464590 OGFOD2 protein_coding KNOWN 
12:123464333-123467456 ARL6IP4 protein_coding KNOWN 
12:123468027-123634562 PITPNM2 protein_coding KNOWN 
12:123636867-123728561 MPHOSPH9 protein_coding KNOWN 
12:123717463-123742506 C12orf65 protein_coding KNOWN 
12:123745528-123756881 CDK2AP1 protein_coding KNOWN 
12:123773656-123834988 SBNO1 protein_coding KNOWN 
12:123868320-123893905 SETD8 protein_coding KNOWN 
12:123899936-123921264 RILPL2 protein_coding KNOWN 
12:123942188-123957701 SNRNP35 protein_coding KNOWN 
12:123955925-124018265 RILPL1 protein_coding KNOWN 
12:124069078-124083116 TMED2 protein_coding KNOWN 
12:124086624-124105482 DDX55 protein_coding KNOWN 
12:124104953-124118313 EIF2B1 protein_coding KNOWN 
12:124118375-124146479 GTF2H3 protein_coding KNOWN 
12:124155660-124192948 TCTN2 protein_coding KNOWN 
13:24995064-25086948 PARP4 protein_coding KNOWN 
13:25254549-25285921 ATP12A protein_coding KNOWN 
13:25338290-25454059 RNF17 protein_coding KNOWN 
13:25457171-25497018 CENPJ protein_coding KNOWN 
13:25670006-25673392 PABPC3 protein_coding KNOWN 
13:25735822-25746426 FAM123A protein_coding KNOWN 
13:25802307-25862147 MTMR6 protein_coding KNOWN 
13:25875662-25923938 NUPL1 protein_coding KNOWN 
13:25946209-26599989 ATP8A2 protein_coding KNOWN 
13:26442061-26455095 AL138815.1 protein_coding KNOWN 
19:40267234-40276775 LEUTX protein_coding KNOWN 
19:40315993-40324841 DYRK1B protein_coding KNOWN 
19:40325094-40337054 FBL protein_coding KNOWN 
19:40353964-40440533 FCGBP protein_coding KNOWN 
19:40477073-40487351 PSMC4 protein_coding KNOWN 
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19:40502943-40523514 ZNF546 protein_coding KNOWN 
19:40534167-40562116 ZNF780B protein_coding KNOWN 
19:40575059-40596845 ZNF780A protein_coding KNOWN 
19:40697651-40721481 MAP3K10 protein_coding KNOWN 
19:40721965-40724306 TTC9B protein_coding KNOWN 
19:40728115-40732597 CNTD2 protein_coding KNOWN 
19:40736224-40791443 AKT2 protein_coding KNOWN 
19:40825443-40854434 C19orf47 protein_coding KNOWN 
19:40854491-40886346 PLD3 protein_coding KNOWN 
19:40885179-40896094 HIPK4 protein_coding KNOWN 
19:40899672-40919271 PRX protein_coding KNOWN 
19:40927499-40931932 SERTAD1 protein_coding KNOWN 
19:40946749-40950282 SERTAD3 protein_coding KNOWN 
19:40953693-40971725 BLVRB protein_coding KNOWN 
19:40973126-41082364 SPTBN4 protein_coding KNOWN 
19:41082757-41097301 SHKBP1 protein_coding KNOWN 
19:41099072-41135725 LTBP4 protein_coding KNOWN 
19:41171810-41196556 NUMBL protein_coding KNOWN 
19:41197434-41222790 ADCK4 protein_coding KNOWN 
19:41223008-41246763 ITPKC protein_coding KNOWN 
19:41246761-41256408 C19orf54 protein_coding KNOWN 
19:41256759-41271296 SNRPA protein_coding KNOWN 
19:41281300-41283392 MIA protein_coding KNOWN 
19:41284171-41302847 RAB4B protein_coding KNOWN 
19:41305048-41314336 EGLN2 protein_coding KNOWN 
19:41349444-41356352 CYP2A6 protein_coding KNOWN 
19:41381344-41388657 CYP2A7 protein_coding KNOWN 
19:41396731-41406413 CYP2G1P protein_coding KNOWN 
19:41414377-41416754 AC008537.1 protein_coding KNOWN 
19:41497204-41524301 CYP2B6 protein_coding KNOWN 
19:41530172-41533615 CYP2A7P1 protein_coding KNOWN 
19:41594368-41602099 CYP2A13 protein_coding KNOWN 
19:41620337-41634271 CYP2F1 protein_coding KNOWN 
19:41699115-41713443 CYP2S1 protein_coding KNOWN 
19:41725108-41767670 AXL protein_coding KNOWN 
19:41768391-41813811 HNRNPUL1 protein_coding KNOWN 
19:41816094-41830785 CCDC97 protein_coding KNOWN 
19:41836813-41859831 TGFB1 protein_coding KNOWN 
19:41856816-41889988 TMEM91 protein_coding KNOWN 
19:41860322-41870078 B9D2 protein_coding KNOWN 
19:41882662-41930906 CTC-435M10.3 protein_coding NOVEL 
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19:41892281-41903256 EXOSC5 protein_coding KNOWN 
19:41903365-41930910 BCKDHA protein_coding KNOWN 
19:41931265-41934635 B3GNT8 protein_coding KNOWN 
19:41937224-41945843 ATP5SL protein_coding KNOWN 
19:41949063-41950670 C19orf69 protein_coding KNOWN 
19:42041702-42093197 CEACAM21 protein_coding KNOWN 
19:42125344-42133442 CEACAM4 protein_coding KNOWN 
19:42177235-42192296 CEACAM7 protein_coding KNOWN 
19:42212504-42233718 CEACAM5 protein_coding KNOWN 
19:42259329-42276113 CEACAM6 protein_coding KNOWN 
19:42300369-42315591 CEACAM3 protein_coding KNOWN 
19:42341148-42348736 LYPD4 protein_coding KNOWN 
19:42349086-42356398 DMRTC2 protein_coding KNOWN 
19:42363988-42375482 RPS19 protein_coding KNOWN 
19:42381190-42385439 CD79A protein_coding KNOWN 
19:42387267-42411597 ARHGEF1 protein_coding KNOWN 
19:42460838-42463528 RABAC1 protein_coding KNOWN 
19:42470734-42498384 ATP1A3 protein_coding KNOWN 
19:42502477-42569957 GRIK5 protein_coding KNOWN 
19:42572864-42585717 ZNF574 protein_coding KNOWN 
19:42592650-42700737 POU2F2 protein_coding KNOWN 
19:42702752-42721813 DEDD2 protein_coding KNOWN 
19:42724492-42732353 ZNF526 protein_coding KNOWN 
19:42734338-42746777 GSK3A protein_coding KNOWN 
19:42746927-42749125 AC006486.1 protein_coding KNOWN 
19:42751717-42759309 ERF protein_coding KNOWN 
19:42772689-42799948 CIC protein_coding KNOWN 
19:42801185-42806929 PAFAH1B3 protein_coding KNOWN 
19:42806284-42814973 PRR19 protein_coding KNOWN 
19:42817477-42829214 TMEM145 protein_coding KNOWN 
19:42829761-42882921 MEGF8 protein_coding KNOWN 
19:42891173-42894444 CNFN protein_coding KNOWN 
19:42905666-42931578 LIPE protein_coding KNOWN 
19:42928421-43030020 AC011497.1 protein_coding KNOWN 
19:42932696-42947136 CXCL17 protein_coding KNOWN 
19:43011458-43032661 CEACAM1 protein_coding KNOWN 
20:44451853-44462384 TNNC2 protein_coding KNOWN 
20:44462449-44471914 SNX21 protein_coding KNOWN 
20:44470360-44486045 ACOT8 protein_coding KNOWN 
20:44486256-44507761 ZSWIM3 protein_coding KNOWN 
20:44509866-44513905 ZSWIM1 protein_coding KNOWN 
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20:44515128-44516274 SPATA25 protein_coding KNOWN 
20:44517264-44519926 NEURL2 protein_coding KNOWN 
20:44519591-44527459 CTSA protein_coding KNOWN 
20:44527399-44540794 PLTP protein_coding KNOWN 
20:44563267-44576662 PCIF1 protein_coding KNOWN 
20:44577292-44600833 ZNF335 protein_coding KNOWN 
20:44637547-44645200 MMP9 protein_coding KNOWN 
20:44650329-44688789 SLC12A5 protein_coding KNOWN 
20:44689624-44718591 NCOA5 protein_coding KNOWN 
20:44746911-44758502 CD40 protein_coding KNOWN 
20:44802372-44937137 CDH22 protein_coding KNOWN 
20:44978167-44993043 SLC35C2 protein_coding KNOWN 
20:44994688-45061704 ELMO2 protein_coding KNOWN 
20:45129709-45142198 ZNF334 protein_coding KNOWN 
20:45169585-45179213 OCSTAMP protein_coding KNOWN 
20:45186463-45304714 SLC13A3 protein_coding KNOWN 
20:45313004-45318418 TP53RK protein_coding KNOWN 
20:45338126-45364965 SLC2A10 protein_coding KNOWN 
20:45523263-45817492 EYA2 protein_coding KNOWN 
20:45837859-45985567 ZMYND8 protein_coding KNOWN 
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Appendix C 
Novel homozygous variants  
 
 
Table C.1: Full list of novel homozygous variants at the homozygous regions 
 
Chr:Start-End Func. Gene aa Change ExonicFunc 
13:23363737-23363737 exonic C1QTNF9B p.F231F syn 
13:24642937-24642937 exonic FAM123A p.D274A nonsyn 
13:24643067-24643067 exonic FAM123A p.T231P nonsyn 
13:24643068-24643068 exonic FAM123A p.L230delinsLP nonfr ins 
13:24643070-24643070 exonic FAM123A p.L230fs fr ins 
13:24643073-24643073 exonic FAM123A p.S229P nonsyn 
13:25026001-25026001 exonic ATP8A2 p.I376M nonsyn 
19:3551210-3551210 exonic TBXA2R p.P141P syn 
19:3577742-3577742 exonic CACTIN p.S7A nonsyn 
19:3703551-3703551 exonic APBA3 p.T450fs fr del 
19:3710974-3710974 exonic APBA3 p.A97T nonsyn 
19:4005416-4005416 exonic ZBTB7A p.Y272F nonsyn 
19:4125809-4125809 exonic SIRT6 p.R264R syn 
19:4125810-4125810 exonic SIRT6 p.R264H nonsyn 
19:4188027-4188027 exonic EBI3 p.Y211C nonsyn 
19:4462725-4462725 exonic PLIN4 p.Q735fs fr ins 
19:4494834-4494834 exonic SEMA6B p.G816R nonsyn 
19:4767464-4767464 exonic TICAM1 p.P642P syn 
19:4905679-4905679 exonic UHRF1 p.A672fs fr ins 
19:4905702-4905702 exonic UHRF1 p.P679P syn 
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19:4905706-4905706 exonic UHRF1 p.K681Q nonsyn 
19:5180539-5180539 exonic PTPRS p.P758L nonsyn 
19:5182618-5182618 exonic PTPRS p.A607T nonsyn 
19:6326342-6326342 exonic PSPN p.P145H nonsyn 
19:6326343-6326343 exonic PSPN p.P145A nonsyn 
19:6375676-6375676 exonic KHSRP p.P13A nonsyn 
19:6375677-6375677 exonic KHSRP p.G12G syn 
19:6418744-6418744 exonic DENND1C p.F726S nonsyn 
19:7007501-7007501 exonic MBD3L3 p.P153P syn 
19:7007502-7007502 exonic MBD3L3 p.P153R nonsyn 
19:6969691-6973065 exonic MBD3L3 p.V2502I nonsyn 
19:7244837-7244837 exonic INSR p.L22L syn 
19:7244859-7244859 exonic INSR p.L15R nonsyn 
19:7604326-7604328 exonic PCP2 p.6_6del nonfr del 
19:7840631-7840631 exonic FLJ22184 p.P1166P syn 
19:7840639-7840639 exonic FLJ22184 p.E1164Q nonsyn 
19:7840649-7840649 exonic FLJ22184 p.L1160L syn 
19:8306001-8306001 exonic KANK3 p.A237G nonsyn 
19:8470398-8470398 exonic PRAM1 p.P98P syn 
19:8470404-8470404 exonic PRAM1 p.P96P syn 
19:8470422-8470422 exonic PRAM1 p.D90E nonsyn 
19:8470433-8470433 exonic PRAM1 p.E87K nonsyn 
19:8929391-8929391 exonic MUC16 p.A6352V nonsyn 
19:8929577-8929577 exonic MUC16 p.T6290I nonsyn 
19:9223311-9223311 exonic OR7E24 p.D198fs fr del 
19:9942658-9942658 exonic COL5A3 p.G1292V nonsyn 
19:10063156-10063156 exonic C19orf66 p.W165G nonsyn 
19:10268245-10268245 exonic ICAM5 p.S910P nonsyn 
19:10268267-10268267 exonic ICAM5 p.F917C nonsyn 
19:10268279-10268279 exonic ICAM5 p.L921P nonsyn 
19:10292454-10292454 exonic RAVER1 p.P566P syn 
19:10843437-10843437 exonic CARM1 p.P20R nonsyn 
19:11477594-11477594 exonic ZNF653 p.E3G nonsyn 
19:11694601-11694601 exonic ZNF823 p.C250R nonsyn 
19:12357800-12376367 exonic ZNF443 p.V44G nonsyn 
19:12618497-12618497 exonic MAN2B1 p.T991T syn 
19:12661806-12661806 exonic FBXW9 p.R334R syn 
19:12706132-12706132 exonic C19orf43 p.S114C nonsyn 
19:12797543-12797543 exonic RTBDN p.S255G nonsyn 
19:13270590-13270590 exonic CACNA1A p.G957R nonsyn 
19:13270602-13270602 exonic CACNA1A p.T953P nonsyn 
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19:13934528-13934528 exonic RFX1 p.V973V syn 
19:13934530-13934530 exonic RFX1 p.V973L nonsyn 
19:14061755-14061755 exonic SAMD1 p.G160S nonsyn 
19:14133169-14133169 exonic LPHN1 p.Q489K nonsyn 
19:44490126-44490126 exonic LRFN1 p.E768G nonsyn 
19:44490202-44490202 exonic LRFN1 p.A743T nonsyn 
19:44689902-44689902 exonic DLL3 p.L493V nonsyn 
19:44722476-44722476 exonic EID2 p.G28G syn 
19:45084190-45084190 exonic FCGBP p.G2718G syn 
19:45103599-45103599 exonic FCGBP p.R1290P nonsyn 
19:45411495-45411495 exonic MAP3K10 p.D690G nonsyn 
19:45411570-45411570 exonic MAP3K10 p.G715D nonsyn 
19:45411859-45411859 exonic MAP3K10 p.T811T syn 
19:45412809-45412809 exonic MAP3K10 p.T879P nonsyn 
19:45415716-45415716 exonic TTC9B p.Y138C nonsyn 
19:45415790-45415790 exonic TTC9B p.P113P syn 
19:45415792-45415792 exonic TTC9B p.P113S nonsyn 
19:45415793-45415793 exonic TTC9B p.G112G syn 
19:45567764-45567764 exonic PLD3 p.L180R nonsyn 
19:45592376-45592376 exonic PRX p.G1241G syn 
19:45814933-45814933 exonic LTBP4 p.Q1011fs fr ins 
19:45957320-45957320 exonic SNRPA p.T131P nonsyn 
19:45960753-45960753 exonic SNRPA p.G178G syn 
19:45960761-45960761 exonic SNRPA p.P181Q nonsyn 
19:45960767-45960767 exonic SNRPA p.G183E nonsyn 
19:45960770-45960770 exonic SNRPA p.A184D nonsyn 
19:45960775-45960775 exonic SNRPA p.P186T nonsyn 
19:46059261-46085147 exonic CYP2A6 p.V80M nonsyn 
19:46419682-46419682 exonic AXL p.F156S nonsyn 
19:47065071-47065071 exonic RPS19 p.R101R syn 
19:47092377-47092377 exonic ARHGEF1 p.E335A nonsyn 
19:47195040-47195040 exonic GRIK5 p.A922A syn 
19:47195041-47195041 exonic GRIK5 p.A922fs fr ins 
19:47195045-47195045 exonic GRIK5 p.P921S nonsyn 
19:47444878-47444878 exonic ERF p.L409P nonsyn 
19:47571934-47571934 exonic MEGF8 p.V2502I nonsyn 
19:47572454-47572454 exonic MEGF8 p.G2675E nonsyn 
19:47572456-47572456 exonic MEGF8 p.P2676T nonsyn 
19:47572457-47572457 exonic MEGF8 p.P2676L nonsyn 
19:47597847-47597847 exonic LIPE p.T1063R nonsyn 
19:47597853-47597853 exonic LIPE p.G1061V nonsyn 
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19:47597854-47597854 exonic LIPE p.G1061R nonsyn 
19:47597858-47597858 exonic LIPE p.P1059fs fr del 
19:48064301-48064301 exonic PSG1 p.R345R syn 
19:48064305-48064305 exonic PSG1 p.Y344F nonsyn 
19:48551709-48551709 exonic CD177 p.T146A nonsyn 
19:48803930-48803930 exonic ZNF428 p.A82A syn 
19:48803931-48803931 exonic ZNF428 p.A82D nonsyn 
19:49353814-49353814 exonic ZNF234 p.G602E nonsyn 
19:49867907-49867907 exonic CEACAM19 p.Q85Q syn 
19:49944090-49944090 exonic BCL3 p.A68G nonsyn 
19:50104029-50104029 exonic APOE p.T212T syn 
20:41976994-41976994 exonic TOX2 p.G17R nonsyn 
20:41977001-41977001 exonic TOX2 p.E19A nonsyn 
20:41977005-41977005 exonic TOX2 p.P20P syn 
20:42574904-42574904 exonic SERINC3 p.M116T nonsyn 
20:43953645-43953645 exonic CTSA p.L29M nonsyn 
20:43953646-43953646 exonic CTSA p.L29Q nonsyn 
20:43953647-43953647 exonic CTSA p.L29L syn 
20:44097037-44097037 exonic SLC12A5 p.T55T syn 
19:5182626-5182626 exonic; 
splicing 
PTPRS p.K604I nonsyn 
19:7844306-7844306 exonic; 
splicing 
FLJ22184 p.L90fs fr ins 
19:49708831-49708831 exonic; 
splicing 
CEACAM20 p.E390G nonsyn 
19:8858187-8858187 splicing MUC16 - - 
19:12741693-12741693 splicing HOOK2 - - 
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Appendix D 
Exons of ATP8A2 isoform 1 
 
 
Table D.1: Exons of longest transcript (ENST00000381655) of ATP8A2 isoform 1 
(ENSP00000371070) 
 
Exon 
Rank 
Ensembl Exon ID Exon Start/End (bp) CDS 
Start/End 
Length 
(bp) 
- 5' UTR 25946209-25946350 - 141 
1 ENSE00001423490 25946209-25946426 1-76 217 
2 ENSE00001719877 26043115-26043259 77-221 144 
3 ENSE00001161731 26104137-26104236 222-321 99 
4 ENSE00001002176 26104700-26104798 322-420 98 
5 ENSE00001295032 26106410-26106455 421-466 45 
6 ENSE00001335438 26107411-26107451 467-507 40 
7 ENSE00001002184 26112126-26112199 508-581 73 
8 ENSE00001002177 26114457-26114526 582-651 69 
9 ENSE00001002183 26116057-26116184 652-779 127 
10 ENSE00001002179 26117429-26117540 780-891 111 
11 ENSE00001002181 26125476-26125641 892-1057 165 
12 ENSE00001002182 26127931-26128058 1058-1185 127 
13 ENSE00001002185 26129129-26129206 1186-1263 77 
14 ENSE00001764388 26133111-26133199 1264-1352 88 
15 ENSE00001144543 26133859-26133903 1353-1397 44 
16 ENSE00001161708 26138094-26138169 1398-1473 75 
17 ENSE00001144526 26144905-26145010 1474-1579 105 
175 
 
18 ENSE00001326309 26145748-26145830 1580-1662 82 
19 ENSE00001144512 26148946-26148995 1663-1712 49 
20 ENSE00001144505 26151207-26151276 1713-1782 69 
21 ENSE00001144500 26152953-26153037 1783-1867 84 
22 ENSE00001144494 26153946-26154085 1868-2007 139 
23 ENSE00001144484 26155957-26156095 2008-2146 138 
24 ENSE00001292904 26163773-26163837 2147-2211 64 
25 ENSE00001144464 26273311-26273483 2212-2384 172 
26 ENSE00001312575 26343184-26343367 2385-2568 183 
27 ENSE00001002197 26348987-26349097 2569-2679 110 
28 ENSE00001313811 26402256-26402330 2680-2754 74 
29 ENSE00001714062 26411301-26411423 2755-2877 122 
30 ENSE00001002198 26413684-26413762 2878-2956 78 
31 ENSE00001002195 26434333-26434394 2957-3018 61 
32 ENSE00001687596 26434942-26434998 3019-3075 56 
33 ENSE00001771180 26436439-26436546 3076-3183 107 
34 ENSE00001002200 26535713-26535801 3184-3272 88 
35 ENSE00001161721 26542713-26542817 3273-3377 104 
36 ENSE00001002199 26586669-26586760 3378-3469 91 
37 ENSE00001489373 26594026-26599989 3470-3567 5963 
- 3' UTR 26594124-26599989 - 5865 
 
  
176 
 
 
Appendix E 
Functional Annotation Clusters 
 
 
Table E.1: DAVID analysis to determine enrichment for genes whose expression 
profiles correlated with ATP8A2  
Annotation Cluster 1 (Enrichment Score: 3.73) 
Catagory Term Count P_Value Benjamini 
GOterm BP FAT neuron differentiation 18 1.8E-6 2.1E-3 
GOterm BP FAT cell projection 
morphogenesis 
13 2.2E-6 1.4E-3 
GOterm BP FAT neuron projection 
morphogenesis 
12 3.7E-6 1.5E-3 
GOterm BP FAT cell morphogenesis 
involved in differentiation 
13 3.7E-6 1.1E-3 
GOterm BP FAT cell part morphogenesis 13 3.7E-6 1.1E-3 
GOterm BP FAT neuron projection 
development 
13 4.9E-6 1.2E-3 
GOterm BP FAT cell morphogenesis 
involved in neuron 
differentiation 
12 5.1E-6 1.0E-3 
GOterm BP FAT cell projection 
organization 
15 1.1E-5 1.9E-3 
GOterm BP FAT axonogenesis 11 1.2E-5 1.9E-3 
GOterm BP FAT neuron development 14 2.0E-5 2.7E-3 
GOterm BP FAT cell morphogenesis 14 3.5E-5 4.3E-3 
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GOterm BP FAT cellular component 
morphogenesis 
14 1.3E-4 1.0E-2 
GOterm BP FAT developmental cell growth 4 2.6E-4 2.0E-2 
GOterm BP FAT developmental growth 7 8.0E-4 4.4E-2 
GOterm BP FAT growth 9 1.3E-3 5.5E-2 
GOterm BP FAT axon extension 3 4.1E-3 1.1E-1 
GOterm BP FAT cell growth 4 7.6E-3 1.5E-1 
GOterm BP FAT regulation of cellular 
component size 
5 1.0E-1 6.5E-1 
GOterm BP FAT regulation of cell size 4 1.2E-1 6.8E-1 
GOterm BP FAT regulation of growth 6 1.5E-1 7.6E-1 
GOterm BP FAT cell motion 5 5.8E-1 9.9E-1 
Annotation Cluster 2 (Enrichment Score: 3.61) 
Catagory Term Count P_Value Benjamini 
SP PIR Keywords developmental protein 24 3.7E-5 4.0E-3 
SP PIR Keywords neurogenesis 9 2.1E-4 1.5E-2 
SP PIR Keywords differentiation 14 1.9E-3 6.7E-2 
Annotation Cluster 3 (Enrichment Score: 3.01) 
Catagory Term Count P_Value Benjamini 
GOterm BP FAT neuron differentiation 18 1.8E-6 2.1E-3 
GOterm BP FAT regulation of nervous 
system development 
10 3.6E-5 4.0E-3 
GOterm BP FAT regulation of neurogenesis 9 1.0E-4 8.8E-3 
GOterm BP FAT regulation of cell 
development 
9 3.6E-4 2.4E-2 
GOterm BP FAT regulation of neuron 
differentiation 
7 8.9E-4 4.3E-2 
GOterm BP FAT regulation of neuron 
projection development 
5 1.7E-3 6.5E-2 
GOterm BP FAT forebrain development 8 2.4E-3 7.7E-2 
GOterm BP FAT regulation of cell 
projection organization 
5 3.5E-3 9.4E-2 
GOterm BP FAT regulation of cell 
morphogenesis involved in 
differentiation 
4 1.7E-2 2.8E-1 
GOterm BP FAT regulation of cell 
morphogenesis 
5 2.2E-2 3.2E-1 
GOterm BP FAT regulation of axonogenesis 3 6.8E-2 5.5E-1 
Annotation Cluster 4 (Enrichment Score: 2.8) 
Category Term Count P_Value Benjamini 
GOterm BP FAT regulation of transcription 45 4.1E-5 4.2E-3 
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GOterm MF FAT transcription regulator 
activity 
29 1.1E-4 2.9E-2 
GOterm BP FAT regulation of RNA 
metabolic process 
32 3.1E-4 2.2E-2 
GOterm BP FAT regulation of transcription, 
DNA-dependent 
31 5.3E-4 3.2E-2 
SP PIR Keywords DNA-binding 30 8.4E-4 4.4E-2 
SP PIR Keywords transcription regulation 32 8.9E-4 3.8E-2 
GOterm MF FAT DNA binding 34 1.6E-3 1.9E-1 
GOterm BP FAT transcription 32 5.2E-3 1.2E-1 
SP PIR Keywords Transcription 32 7.0E-3 1.9E-1 
GOterm MF FAT transcription factor activity 17 1.1E-2 6.4E-1 
GOterm MF FAT sequence-specific DNA 
binding 
13 2.0E-2 6.6E-1 
SP PIR Keywords nucleus 54 3.9E-2 4.6E-1 
Annotation Cluster 5 (Enrichment Score: 2.78) 
Catagory Term Count P_Value Benjamini 
GOterm MF FAT transcription regulator 
activity 
29 1.1E-4 2.9E-2 
GOterm BP FAT regulation of RNA 
metabolic process 
32 3.1E-4 2.2E-2 
GOterm BP FAT regulation of transcription, 
DNA-dependent 
31 5.3E-4 3.2E-2 
GOterm BP FAT positive regulation of 
transcription 
15 7.3E-4 4.2E-2 
GOterm BP FAT positive regulation of gene 
expression 
15 9.5E-4 4.4E-2 
GOterm BP FAT regulation of transcription 
from RNA polymerase II 
promoter 
17 1.2E-3 5.2E-2 
GOterm BP FAT positive regulation of 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolic process 
15 1.4E-3 5.9E-2 
GOterm BP FAT positive regulation of 
macromolecule metabolic 
process 
17 1.6E-3 6.2E-2 
GOterm BP FAT positive regulation of 
nitrogen compound 
metabolic process 
15 1.9E-3 7.1E-2 
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GOterm BP FAT positive regulation of 
macromolecule 
biosynthetic process 
15 2.1E-3 7.4E-2 
GOterm BP FAT positive regulation of 
transcription, DNA-
dependent 
13 2.1E-3 7.3E-2 
GOterm BP FAT positive regulation of 
RNA metabolic process 
13 2.2E-3 7.3E-2 
GOterm BP FAT positive regulation of 
cellular biosynthetic 
process 
15 3.0E-3 8.5E-2 
GOterm BP FAT positive regulation of 
biosynthetic process 
15 3.2E-3 9.0E-2 
GOterm BP FAT positive regulation of 
transcription from RNA 
polymerase II promoter 
11 6.1E-3 1.3E-1 
SP PIR Keywords activator 10 9.1E-2 6.4E-1 
Annotation Cluster 6 (Enrichment Score: 2.3) 
Catagory Term Count P_Value Benjamini 
GOterm BP FAT regulation of transcription 
from RNA polymerase II 
promoter 
17 1.2E-3 5.2E-2 
GOterm BP FAT negative regulation of 
macromolecule 
biosynthetic process 
13 2.2E-3 7.3E-2 
GOterm BP FAT negative regulation of 
transcription 
12 2.7E-3 8.2E-2 
GOterm BP FAT negative regulation of 
cellular biosynthetic 
process 
13 2.8E-3 8.3E-2 
GOterm BP FAT negative regulation of 
biosynthetic process 
13 3.0E-3 8.7E-2 
GOterm BP FAT negative regulation of 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolic process 
12 4.3E-3 1.1E-1 
GOterm BP FAT negative regulation of 
nitrogen compound 
metabolic process 
12 4.7E-3 1.1E-1 
GOterm BP FAT negative regulation of 
gene expression 
12 5.5E-3 1.2E-1 
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GOterm BP FAT negative regulation of 
transcription, DNA-
dependent 
10 6.9E-3 1.4E-1 
GOterm BP FAT negative regulation of 
RNA metabolic process 
10 7.2E-3 1.4E-1 
GOterm BP FAT negative regulation of 
macromolecule metabolic 
process 
13 9.8E-3 1.8E-1 
GOterm BP FAT negative regulation of 
transcription from RNA 
polymerase II promoter 
8 1.4E-2 2.3E-1 
GOterm MF FAT transcription repressor 
activity 
7 2.9E-2 6.3E-1 
Annotation Cluster 7 (Enrichment Score: 1.97) 
Category Term Count P_Value Benjamini 
INTERPRO Basic helix-loop-helix 
dimerisation region bHLH 
7 1.3E-3 4.5E-1 
SMART HLH 7 3.1E-3 2.9E-1 
UP SEQ Feature domain:Helix-loop-helix 
motif 
6 1.2E-2 8.3E-1 
UP SEQ Feature DNA-binding region:Basic 
motif 
7 1.3E-2 8.0E-1 
INTERPRO Helix-loop-helix DNA-
binding 
3 2.3E-1 1.0E0 
Annotation Cluster 8 (Enrichment Score: 1.69) 
Category Term Count P_Value Benjamini 
GOterm BP FAT negative regulation of 
transcription from RNA 
polymerase II promoter 
8 1.4E-2 2.3E-1 
GOterm BP FAT positive regulation of 
mesenchymal cell 
proliferation 
3 2.4E-2 3.4E-1 
GOterm BP FAT regulation of mesenchymal 
cell proliferation 
3 2.6E-2 3.6E-1 
     
     
     
     
     
     
181 
 
Chapter 8 
Publications 
 
Abstract. Recently, a functional T to G polymorphism at
nucleotide 309 in the promoter region of the MDM2 gene (rs:
2279744, SNP 309) has been identified. This polymorphism
has an impact on the expression of the MDM2 gene, which is
a key negative regulator of the tumor suppressor molecule p53.
The effect of T309G polymorphism of the MDM2 gene on
bladder cancer susceptibility was investigated in a case-control
study of 75 bladder cancer patients and 103 controls from
Turkey. The G/G genotype exhibited an increased risk of 2.68
(95% CI, 1.34-5.40) for bladder cancer compared with the
combination of low-risk genotypes T/T and T/G at this locus.
These results show an association between MDM2 T309G
polymorphism and bladder cancer in our study group. To the
best of our knowledge, this is the first study reporting that
MDM2 T309G polymorphism may be a potential genetic
susceptibility factor for bladder cancer.
Bladder cancer is a major cause of morbidity and mortality.
In the Turkish population, it is the third most common
cancer in men and the eighth in women (1). Although
multiple environmental and host genetic factors are known
to be important in bladder cancer development, the exact
molecular mechanisms of genetic susceptibility and
molecular changes during malignant transformation are still
under investigation.
Recently, a functional T to G polymorphism at nucleotide
309 in the promoter region of the MDM2 gene (rs: 2279744)
has been identified (2). We hypothesized that this gene
polymorphism might be a critical predisposition factor for
bladder cancer, as the MDM2 molecule is an important
player in bladder cancer pathogenesis, evidenced by its over-
expression in 30% of urothelial carcinoma (3). This
oncoprotein attenuates p53 activity by promoting ubiquitin-
mediated degradation (4). In addition to functional
inactivation by MDM2, structural TP53 mutations have been
observed in 50% of urothelial cancer and these mutations
were associated with poor prognosis, advanced stage and
higher grade of the bladder cancer (3).
MDM2 T309G polymorphism is a functional polymorphism
having an impact on the p53 protein level in the cell. The G
allele confers an increased binding affinity to the Sp1
transcriptional activator, hence increased transcription of the
MDM2 gene. Eventually, the relative increase in the level of
MDM2 protein causes a relative decrease in the level of the
p53 protein (2).
It is recognized that host genetic factors modifying the
genotoxicity of carcinogens are important for the genetic
susceptibility to bladder cancer. For example, gene
polymorphisms decreasing the carcinogen detoxification
activity of glutathione S-tranferases and N-acetyl
transferases are established predisposition factors for this
cancer (5). The p53 molecule is considered to be the
guardian of the genome, since it plays a vital part in various
antineoplastic mechanisms such as cell cycle arrest,
senescence and apoptosis, preventing the carcinogenic effect
of mutagens (6). Therefore, it is conceivable that MDM2
SNP 309, which has an effect on the level of p53, may also
be a genetic predisposition factor for bladder cancer. 
In order to investigate the role of MDM2 T309G
polymorphism in bladder cancer, a case-control study was
performed with 75 patients and 103 controls. Our results
indicated an association between bladder cancer risk and
MDM2 SNP309 polymorphism in the group indicated.
Patients and Methods
Peripheral blood samples were collected from 75 bladder cancer
patients and 103 age-matched controls (non-cancer) diagnosed at
Hacettepe University Medical School, and Ankara Numune
Hospital, Turkey. The mean age of the bladder cancer patients was
59.87 years, with a standard deviation of 12.54, range 25-87; the
mean age of the control group was 59.33 years, with a standard
deviation of 13.58, range 23-79. Genomic DNA was isolated from
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200 Ìl blood by standard phenol-chloroform extraction. MDM2
T309G polymorphism was determined by polymerase chain reaction
(PCR) and restriction digestion. The PCR amplification was carried
out using primers: MDM2F (5’-GCTTTGCGGAGGTTTTGTT-3’)
and MDM2R (5’-TCAAGTTCAGACACGTTCCG-3’). After
confirming the presence of the 304-bp amplicon on 2% agarose test
gel, the PCR products were digested with MspA1I and
electrophoresed in 3% agarose gel for SNP 309 genotyping. The T
allele had a constitutional restriction site, which also served as an
internal control for restriction digestion. The G allele had an
additional restriction site to the constitutional restriction site. After
digestion, T allele yielded two fragments (193 bp and 111 bp), where
as the G allele yielded three fragments (147 bp, 111 bp and 46 bp)
(Figure 1).
The G/G genotype was defined as the risk group for statistical
analysis. Odds ratio (OD) tests with 95% confidence interval (CI)
and ¯2 analysis were performed with the GraphPad Prism4
statistical software.
Results and Discussion 
The genotype frequencies of MDM2 T309G polymorphism
in the bladder cancer patients and control groups are
summarized in Table I. The genotype frequency values for
the control group closely resembled the results from other
Caucasian populations (7-9) and were in Hardy Weinberg
equilibrium. The comparison of the high-risk genotype
(G/G) with the combination of the two low-risk alleles (G/T
and T/T) revealed that the G/G genotype conferred a risk of
2.68 (95% CI 1.34-5.40) relative to the low-risk genotypes
(Table I). The G allele frequency in the patient group was
0.58 (T allele: 0.42), the control group it was 0.44 (T allele:
0.56). There was a significant difference between the allelic
frequencies of the control (n=150 alleles) and patient groups
(n=206 alleles) (¯2: 6.76, df: 1, p=0.0093). Odds ratio
analysis revealed that the G allele resulted in a 1.72-fold risk
increase (95% CI 1.14-2.60) compared to the T allele.
After the initial discovery of MDM2 T309G polymorphism,
several reports were published with discordant results
regarding the impact of this polymorphism on cancer risk. In
two separate studies, it was shown that G/G genotype caused a
reduction in the age of onset of cancer in Li-Fraumeni
syndrome patients (2, 10). However, no age of onset reduction
was observed for Lynch syndrome (7). The case-control studies
on colorectal cancer (9), squamous cell carcinoma of the head
and neck (9), uterine leiomyosarcoma (9), breast (8, 11) and
ovarian cancer (8) did not show an association. Interestingly,
two lung cancer studies in the Chinese population reported
discordant results: in one study an association was observed
(12), while in the other it was not (13). 
Issues with sampling and population stratification have
always been cited for the lack of reproducibility between
different case-control studies (14), but p53-related factors
might also have contributed to such problems. It is intriguing
that MDM2 T309G polymorphism had an impact on a
hereditary cancer syndrome (2, 10) characterized by germ
line p53 mutations (i.e., Li-Fraumeni syndrome), but had no
effect on another hereditary cancer such as lynch syndrome
(7) with relatively rare somatic p53 mutations (15). 
In conclusion, this study showed an association between
MDM2 T309G polymorphism and bladder cancer in the
Turkish population. The small sample size was a limitation
of the study and the results should definitely be validated
on larger bladder cancer cohorts in different populations.
That said, to our knowledge, the study is the first study to
indicate that MDM2 T309G polymorphism could be a
potential genetic susceptibility factor for bladder cancer.
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Quadrupedal gait in humans, also known as Unertan syndrome, is
a rare phenotype associated with dysarthric speech, mental retar-
dation, and varying degrees of cerebrocerebellar hypoplasia. Four
large consanguineous kindreds from Turkey manifest this pheno-
type. In two families (A and D), shared homozygosity among
affected relatives mapped the trait to a 1.3-Mb region of chromo-
some 9p24. This genomic region includes the VLDLR gene, which
encodes the very low-density lipoprotein receptor, a component of
the reelin signaling pathway involved in neuroblast migration in
the cerebral cortex and cerebellum. Sequence analysis of VLDLR
revealed nonsense mutation R257X in family A and single-
nucleotide deletion c2339delT in family D. Both these mutations
are predicted to lead to truncated proteins lacking transmembrane
and signaling domains. In two other families (B and C), the
phenotype is not linked to chromosome 9p. Our data indicate that
mutations in VLDLR impair cerebrocerebellar function, conferring
in these families a dramatic influence on gait, and that hereditary
disorders associated with quadrupedal gait in humans are genet-
ically heterogeneous.
genetics  Unertan syndrome
Obligatory bipedal locomotion and upright posture of mod-ern humans are unique among living primates. Studies of
fossil hominids have contributed significantly to modern under-
standing of the evolution of posture and locomotion (1–5), but
little is known about the underlying molecular pathways for
development of these traits. Evaluation of changes in brain
activity during voluntary walking in normal subjects suggests that
the cerebral cortices controlling motor functions, visual cortex,
basal ganglia, and the cerebellum might be involved in bipedal
locomotor activities (6). The cerebellum is particularly impor-
tant for movement control and plays a critical role in balance and
locomotion (7).
Neurodevelopmental disorders associated with cerebellar hy-
poplasias are rare and often accompanied by additional neuro-
pathology. These clinical phenotypes vary from predominantly
cerebellar syndromes to sensorimotor neuropathology, ophthal-
mological disturbances, involuntary movements, seizures, cog-
nitive dysfunction, skeletal abnormalities, and cutaneous disor-
ders, among others (8). Quadrupedal locomotion was first
reported when Tan (9, 10) described a large consanguineous
family exhibiting Unertan syndrome, an autosomal recessive
neurodevelopmental condition with cerebellar and cortical hy-
poplasia accompanied by mental retardation, primitive and
dysarthric speech, and, most notably, quadrupedal locomotion.
Subsequent homozygosity mapping indicated that the phenotype
of this family was linked to chromosome 17p (11). Thereafter,
three additional families from Turkey (12–14) and another from
Brazil (15) with similar phenotypes have been described, and
video recordings illustrating the quadrupedal gait have been
made (10–12). Here, we report that VLDLR is the gene respon-
sible for the syndrome in two of these four Turkish families and
report additional genemapping studies that indicate the disorder
to be highly genetically heterogeneous.
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Fig. 1. Phenotypic (A) and cranial radiologic (B) presentation of quadrupe-
dal gait in families A and D. (A) Affected brothers VI:20 and VI:18 and cousin
VI:25 in family A (Upper) and the proband II:2 in family D (Lower) display
palmigrate walking. This is different from quadrupedal knuckle-walking of
the great apes (2). The hands make contact with the ground at the ulnar palm,
and consequently this area is heavily callused as exemplified by VI:20. Stra-
bismus was observed in all affected individuals. (B) Coronal and midsagittal
MRI sections of VI:20, demonstrating vermial hypoplasia, with the inferior
vermial portion being completely absent. Inferior cerebellar hypoplasia and a
moderate simplification of the cerebral cortical gyri are noted. The brainstem
and the pons are particularly small (Left and Center). Similar findings are
observed for II:2 (Right).
4232–4236  PNAS  March 18, 2008  vol. 105  no. 11 www.pnas.orgcgidoi10.1073pnas.0710010105
Results
The proband of Family A (12) is a 37-year-old male with habitual
quadrupedal gait (Fig. 1A Upper Left and Fig. 2A, VI:20). He did
not make the transition to bipedality during his childhood
despite the efforts of his healthy parents. He has dysarthric
speech with a limited vocabulary, truncal ataxia, and profound
mental retardation. He was not aware of place or of the year,
month, or day. His MRI brain scan revealed inferior cerebellar
and vermial hypoplasia, with the inferior vermial portion being
completely absent. Whereas corpus callosum appeared normal,
a moderate simplification of the cerebral cortical gyri accom-
panied by a particularly small brainstem and the pons was
observed (Fig. 1 B Left andCenter). Subsequently, we studied the
proband’s affected brother and cousin (Fig. 1AUpper Center and
Fig. 2. Homozygosity mapping of cerebellar hypoplasia and quadrupedal locomotion to chromosome 9p24 (A) and identification of the VLDLR c769C 3 T
mutation in family A (B) and of theVLDLR c2339delT mutation in family D (C). (A) Pedigree of family A; filled symbols represent the affected individuals. Squares
indicate males, and circles indicate females. Black bars represent the haplotype coinherited with the quadrupedal phenotype in the family. Recombination events
in individuals VI:16 (obligate carrier) and VII:4 (normal sibling) positioned the disease gene between markers rs7847373 and rs10968723. Physical positions and
pairwise lod scores for each marker are shown on the upper left. Zmax represents the maximum lod score obtained at  0.00 cM. (B and C) Sequences of critical
regions of VLDLR for wild-type and homozygous mutant genotypes.
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Upper Right and Fig. 2A, VI:18 and VI:25) and other branches
of the family living in nearby villages in southeastern Turkey. All
affected individuals were offspring of consanguineous marriages
(Fig. 2A). With the exception of one female (VII:1), who was an
occasional biped with ataxic gait, all affected persons in family
A had quadrupedal locomotion.
The proband of family D (14) is a 38-year-old male (Fig. 1A
Lower Left and Center). Like all other quadrupedal individuals
in these families, he did not make the transition to bipedality
during his early childhood. He is profoundly retarded and
exhibits dysarthric speech along with truncal ataxia. His MRI
brain scan images are consistent with moderate cerebral cortical
simplification and inferior cerebellar and vermial hypoplasia
(Fig. 1BRight). The 65-year-old aunt and 63-year-old uncle of the
proband are both mentally retarded and continue to walk on
their wrists and feet despite their advanced ages. The family is
consanguineous; all relatives were raised in neighboring villages
on the western tip of the Anatolian peninsula.
All patients in these four families had significant developmen-
tal delay noted in infancy (Table 1). They sat unsupported
between 9 and 18months, and began to crawl on hands and knees
or feet. Whereas normal infants make the transition to bipedal
walking in a short period, the affected individuals continued to
move on their palms and feet and never walked upright. All
patients had severe truncal ataxia affecting their walking pat-
terns. They can stand from a sitting position and maintain the
upright position with flexed hips and knees. However, they
virtually never initiate bipedal walking on their own and instead
ambulate efficiently in a quadrupedal fashion. All patients had
hyperactive lower leg and vivid upper extremity reflexes. Normal
tone and power were observed in motor examination. All
affected persons were mentally retarded to the degree that
consciousness of place, time, or other experience appeared to be
absent. However, no autistic features were expressed. The
affected individuals all had good interpersonal skills, were
friendly and curious to visitors, and followed very simple ques-
tions and commands. Additional clinical information on families
A and D is provided in supporting information (SI) Table 2.
To identify the chromosomal locale of the gene or genes
responsible for this phenotype, we carried out genome-wide
linkage analysis and homozygosity mapping in families A–C (see
Materials and Methods below). Although the families lived in
isolated villages 200–300 km apart and reported no ancestral
relationship, the rarity of the quadrupedal gait in humans led us
to expect a single locus shared by affected individuals in all
families. Instead, the trait mapped to three different chromo-
somal locales. In family A, linkage analysis and homozygosity
mapping positioned the critical gene on chromosome 9p24
between rs7847373 and rs10968723 in a 1.032-Mb region (Fig.
2A and SI Fig. 4). In family B, the trait mapped to chromosome
17p13, confirming a previous study (11). In family C, highly
negative logarithm of odds (lod) scores were obtained for both
chromosomes 9p24 and 17p13 (SI Figs. 5 and 6); gene mapping
in this family is ongoing. In family D, polymorphic markers from
the critical intervals of chromosomes 9p24 and 17p13 were
genotyped, and homozygosity was detected with markers on
9p24. Together, these results indicate that the syndrome includ-
ing quadrupedal gait, dysarthric speech, mental retardation, and
cerebrocerebellar hypoplasia is genetically heterogeneous.
The chromosome 9p24 region linked to the trait in families A
and D includes VLDLR, the very low-density lipoprotein recep-
tor. We hypothesized that a gene involved in neural develop-
ment, cell positioning in brain, and cerebellar maturation could
be involved in the pathogenesis of quadrupedal gait. In addition,
cerebellar hypoplasia with cerebral gyral simplification was
shown to be associated with a genomic deletion that includes
VLDLR (16). We therefore considered VLDLR (17) to be a
prime positional candidate for our phenotype and sequenced the
gene in genomic DNA from probands of the four families (SI
Table 3). The VLDLR sequence of affected members of family
A was homozygous for a nonsense mutation in exon 5 (c769C3
T; R257X) (Fig. 2B). The VLDLR sequence of the proband of
family D was homozygous for a single-nucleotide deletion in
exon 17 resulting in a stop codon (c2339delT; I780TfsX3) (Fig.
2C). VLDLR sequences excluded the possibility of compound
heterozygosity in families B and C (SI Fig. 7). In families A and
D, homozygosity for the VLDLR mutations was perfectly coin-
herited with quadrupedal gait (SI Figs. 8 and 9). Both mutations
were absent from 100 unaffected individuals who live in the same
local areas of southeastern and western Turkey as families A and
D (SI Fig. 10).
Table 1. Physical, radiological, and genetic characteristics of the Turkish families in this study and of Hutterite family DES-H (27)
Characteristic Family A Family B Family C Family D DES-H
Chromosomal location 9p24 17p Not 9p or 17p 9p24 9p24
Gene and mutation VLDLR
(c769C3 T)
Unknown Unknown VLDLR
(c2339delT)
Deletion including VLDLR
and LOC401491
Gait Quadrupedal Quadrupedal Quadrupedal Quadrupedal Bipedal
Speech Dysarthric Dysarthric Dysarthric Dysarthric Dysarthric
Hypotonia Absent Absent Absent Absent Present
Barany caloric nystagmus Normal Cvs defect Pvs defect Not done Not done
Mental retardation Profound Severe to profound Profound Profound Moderate to profound
Ambulation Delayed Delayed Delayed Delayed Delayed
Truncal ataxia Severe Severe Severe Severe Severe
Lower leg reflexes Hyperactive Hyperactive Hyperactive Hyperactive Hyperactive
Upper extremity reflexes Vivid Vivid Vivid Vivid Vivid
Tremor Very rare Mild Present Absent Present
Pes-planus Present Present Present Present Present
Seizures Very rare Rare Rare Absent Observed in 40% of cases
Strabismus Present Present Present Present Present
Inferior cerebellum Hypoplasia Hypoplasia Mild hypoplasia Hypoplasia Hypoplasia
Inferior vermis Absent Absent Normal Absent Absent
Cortical gyri Mild simplification Mild simplification Mild simplification Mild simplification Mild simplification
Corpus callosum Normal Reduced Normal Normal Normal
Cvs, central vestibular system; Pvs, peripheral vestibular system.
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VLDLRR257X is in the ligand-binding domain, and
VLDLRI780TfsX3 is in the O-linked sugar domain of the
VLDLR protein (Fig. 3 A and B). Mutant VLDLR transcripts
were expressed in endothelial cells from blood of affected
individuals (Fig. 3C), and in these cells, levels of mutant and
wild-type transcript expression appeared approximately equal
(Fig. 3D; please also see SI Text). Because the stop codons of
both mutations are located in the extracellular domain of
VLDLR (Fig. 3B), the encoded mutant proteins could not be
inserted into the membrane and could not function as receptors
for reelin.
We propose VLDLR-associated Quadrupedal Locomotion
(VLDLR-QL) or Unertan Syndrome Type 1 to describe the
phenotype of families A and D.
Discussion
The identification of these VLDLR mutations provides molec-
ular insight into the pathogenesis of neurodevelopmental move-
ment disorders and expands the scope of diseases caused by
mutations in components of the reelin pathway (18). Reelin is a
secreted glycoprotein that regulates neuronal positioning in
cortical brain structures and the migration of neurons along the
radial glial fiber network by binding to lipoprotein receptors
VLDLR and APOER2 and the adapter protein DAB1 (19). In
the cerebellum, reelin regulates Purkinje cell alignment (20),
which is necessary for the formation of a well defined cortical
plate through which postmitotic granual cells migrate to form the
internal granular layer (21). Homozygous mutations in the reelin
gene (RELN) cause the Norman–Roberts type lissencephaly
syndrome, associated with severe abnormalities of the cerebel-
lum, hippocampus, and brainstem (OMIM 257320) (22). Muta-
tion of Reln in the mouse results in the reeler phenotype and
disrupts neuronal migration in several brain regions and gives
rise to functional deficits such as ataxic gait and trembling (23).
In contrast, mice deficient forVldlr appear neurologically normal
(24), but the cerebellae of these mice are small, with reduced
foliation and heterotopic Purkinje cells (17).
In humans, homozygosity for either of two VLDLR truncating
mutations leads to cerebrocerebellar hypoplasia, specifically
vermial hypoplasia, accompanied by mental retardation, dysar-
thric speech, and quadrupedal gait. In the Hutterite population
of North America, homozygosity for a 199-kb deletion encom-
passing the VLDLR gene leads to a form of Disequilibrium
Syndrome (DES-H, OMIM 224050), characterized by nonpro-
gressive cerebellar hypoplasia with moderate-to-profound men-
tal retardation, cerebral gyral simplification, truncal ataxia, and
delayed ambulation (16). The designation Disequilibrium Syn-
drome was originally given to cerebral palsy characterized by a
variety of congenital abnormalities, including mental retarda-
tion, disturbed equilibrium, severely retarded motor develop-
ment, muscular hypotonia, and perceptual abnormalities (25,
26). Neither DES-H nor other disequilibrium syndromes have
been reported to include quadrupedal gait. The movement of
most DES-H patients was so severely affected that independent
walking was not possible. Those who could walk had a wide-
based, nontandem gait (27).
The neurological phenotypes in the Turkish families and in the
Hutterite families appear similar, with the most striking differ-
ence being the consistent adoption of efficient quadrupedal
locomotion by the affected Turkish individuals (Table 1). In our
view, the movement disorder described for the Hutterite patients
may be a more profound deficit, with the patients perhaps
lacking the motor skills for quadrupedal locomotion. The 199-kb
deletion in DES-H encompasses the entire VLDLR gene and
part of a hypothetical gene. LOC401491, the hypothetical gene,
is an apparently noncoding RNA that shares a CpG island and
likely promoter with VLDLR, and is represented by multiple
alternative transcripts expressed in brain. It has been suggested
that the DES-H phenotype could be the result of deletion of
VLDLR or both VLDLR and the neighboring gene (16).
Fig. 3. Functional domains of VLDLR with positions of the mutations relative to the exons (A), domains (B), and the analysis of VLDLR transcript (C and D).
(A) The gene consists of 19 exons. Arrows indicate the locations of the mutations. (B) VLDLR consists of ligand-binding type repeat (LBTR), epidermal growth
factor repeat (EGFR) I–III, YWTD -propeller (YWTD), O-linked sugar domain (OLSD), transmembrane domain (TD), and cytoplasmic domain (CD) (34)
(www.expasy.org/uniprot/P98155). (C) Restriction-based analysis with HphI revealed the presence of only the mutant (347 bp) and both the mutant and wild type
(396 and 347 bp; please note that the 49-bp fragment is not visible) VLDLR transcripts in patient VI:20 and carrier V:18 (both from family A), respectively. M is
a DNA size marker. (D) Quantitative RT-PCR analysis of VLDLR transcript from peripheral blood samples of all probands in families A and D and controls was
performed. Relative expression ratios were normalized according to the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and the
endothelial marker KDR (kinase insert domain receptor). Ct values were calculated from duplicate samples and were converted to linear scale (35). Control
denotes ‘‘VLDLR expression in controls,’’ VLDLR-GAPDH denotes ‘‘VLDLR expression in patients normalized to GAPDH,’’ and finally VLDLR-KDR denotes ‘‘VLDLR
expression in patients normalized to KDR.’’
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It has been suggested that in the Turkish families, lack of
access to proper medical care exacerbated the effects of cere-
bellar hypoplasia, leading to quadrupedality. Although it may be
true that family B lacked proper medical care, families A and D
had consistent access to medical attention, and both families
actively sought a correction of quadrupedal locomotion in their
affected children. An unaffected individual in family A is a
physician who was actively involved in the medical interventions.
In family D, the proband’s mother sought a definitive diagnosis
and correction of the proband’s quadrupedal locomotion from
private medical practices and from two major academic medical
centers. The parents in family A discouraged quadrupedal
walking of their affected children, but without success. We
conclude that social factors were highly unlikely to contribute to
the quadrupedal locomotion of the affected individuals.
In conclusion, we suggest that VLDLR-deficiency in the brain
at a key stage of development leads to abnormal formation of the
neural structures that are critical for gait. Given the heteroge-
neity of causes of quadrupedal gait, identification of the genes in
families B and C promises to offer insights into neurodevelop-
mental mechanisms mediating gait in humans.
Materials and Methods
Study Subjects. Parents of patients and other unaffected individuals gave
consent to the study by signing the informed consent forms prepared accord-
ing to the guidelines of the Ministry of Health in Turkey. The Ethics Commit-
tees of Baskent and Cukurova Universities approved the study (decision
KA07/47, 02.04.2007 and 21/3, 08.11.2005, respectively).
Genome-Wide Linkage Analysis. Linkage analysis was performed by SNP geno-
typing with the commercial release of the GeneChip 250K (NspI digest) or 10K
Affymetrix arrays as described (28). In addition, genotype data were analyzed
by hand to identify regions of homozygosity. The parametric component of
the Merlin package v1.01 was used for the multipoint linkage analysis assum-
ing autosomal recessive mode of inheritance with full penetrance (29, 30). The
analysis was carried out along a grid of locations equally spaced at 1 cM.
Haplotype analysis was performed on chromosomal regions with positive lod
scores (Fig. 2A and SI Figs. 4–6). Pairwise linkage was analyzed by using the
MLINK component of the LINKAGE program (FASTLINK, version 3) (31–33).
Markers D17S1298 (3.51 Mb) and D9S1779 (0.4 Mb), D9S1871 (3.7 Mb) were
used to test for homozygosity to chromosomes 17p13 and 9p24, respectively.
Mutation Search. Sequencing primers were designed for each VLDLR exon by
using Primer3, BLAST, and the sequence of NC000009. DNA from all of the
probands was sequenced in both directions by using standard methods. The
mutations in exons 5 (c769C 3 T) and 17 (c2339delT) were detected in all
affected (homozygous) and carrier (heterozygous) individuals of families A
and D, respectively. The c769C3 T mutation creates a restriction site for the
enzyme HphI (5-GGTGA(N)82 3), and the c2339delT mutation abolishes a
restriction site for the enzyme MboI (5-G2 ATC-3). Assays using these
restriction enzymes were developed to test for the mutations in all four
families and in 200 healthy controls from the Turkish population. Restriction
based mutation and quantitative RT-PCR analyses of VLDLR transcript in
patients and controls was also performed (please see SI Text relating to Fig. 3
C and D).
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LETTER
Reply to Herz et al. and Humphrey
et al.: Genetic heterogeneity of
cerebellar hypoplasia with
quadrupedal locomotion
Mutations in the very low-density lipoprotein receptor
VLDLR are responsible for cerebellar hypoplasia with qua-
drupedal gait (1). The most likely mechanism leading to this
phenotype is that VLDLR deficiency in the brain at a key
stage of development precludes the normal formation of neu-
ral structures critical for gait. Quadrupedal gait is an integral
part of VLDLR-associated cerebellar hypoplasia syndrome in
these families (1, 2). It is not necessary to invoke an ‘‘epiphe-
nomenon’’ or ‘‘unfavorable environmental conditions’’ to ex-
plain the phenotype (3), but rather simply considering clinical
heterogeneity in the context of genomic understanding of
complex traits is sufficient.
Disequilibrium syndrome was first described by the Swedish
neuropediatrician Bengt Hagberg and colleagues (4) as a
form of cerebral palsy characterized by a variety of congenital
abnormalities. Subsequently, Schurig et al. (5) described, in
the North American Hutterite population, inherited cerebellar
disorder with mental retardation, the genetic basis of which
proved to be homozygous deletion of the VLDLR gene and
the adjacent noncoding LOC401491 sequence (6). Based on
the phenotypic similarities of the Swedish and Hutterite pa-
tients, the acronym DES-H [disequilibrium syndrome-
Hutterites, Online Mendelian Inheritance in Man (OMIM)
accession no. 224050] was adopted for this syndrome (6).
Our results (1) and those of others (7) extend these find-
ings to different VLDLR mutations leading to cerebellar hyp-
oplasia and related disequilibrium features, including in some
families bipedal gait (5, 6), in other families quadrupedal gait
(1, 8), and in another family ‘‘gait ataxia’’ (7). Additional kin-
dreds with disequilibrium syndrome and quadrupedal gait
have been described in Brazil (9) and Iraq (10). It will be in-
teresting to know whether mutations responsible for the phe-
notype in these families lie in the VLDLR gene or in one
of the other loci linked to this genetically heterogeneous
phenotype (1).
The comments of Humphrey et al. (11) address three fun-
damental features of genomic analysis of human traits: allelic
heterogeneity, genotype–phenotype correlations, and variable
expression.
Allelic heterogeneity—the expression of the same pheno-
type due to different mutations in a gene—is characteristic of
virtually all human genetic disease. For example, homozygos-
ity for any of 300 different mutations in the LDL receptor
leads to hypercholesterolemia. It was to be expected, there-
fore, that in different families different mutations in VLDLR
would lead to a phenotype comprising cerebellar hypoplasia
with quadrupedal gait. It would not be expected that quadru-
pedalism would be present only in the presence of one ‘‘spe-
cific mutation.’’
The converse observation, of a correlation between geno-
type and phenotype, is also characteristic of inherited human
disease. Different mutations in the same gene frequently lead
to different clinical phenotypes. Contrary to the statement of
Humphrey et al. (11), the Hutterite families in North America
and families A and D in Turkey do not carry ‘‘the same ho-
mozygous mutation.’’ The Hutterite mutation is a complete
genomic deletion of VLDLR; the mutations in Turkish fami-
lies A and D are, respectively, a nonsense mutation and a
single-base-pair deletion leading to a frame shift in VLDLR.
It is not surprising, therefore, that features of the cerebellar
hypoplasia syndrome, including presence or absence of qua-
drupedal walking, differ among families with different muta-
tions in the gene.
Third, variable expression of a phenotype is frequently ob-
served even among persons with the same mutation in a criti-
cal gene. Variable expression may be due to differences in
genetic background of the individual, to differences in envi-
ronmental exposures, or to chance. Among affected individu-
als in families A and D, none displays exclusively bipedal
locomotion; two affected individuals can walk bipedally for
short distances but prefer quadrupedal locomotion (1, 8).
Finally, the use of a walking frame to assist bipedalism in
affected individuals (12) does not demonstrate that the cause
of quadrupedalism was ‘‘local cultural environment.’’ Wear-
ing eyeglasses assists persons with myopia. Should we then
conclude that near-sightedness is caused by ‘‘local cultural
environment’’?
Some descriptions by the press of Turkish families with cer-
ebellar hypoplasia and quadrupedal gait have portrayed the
affected individuals as doomed to quadrupedal gait by the
religious beliefs of their parents (13). We hope that future
descriptions of these families will conform to standards re-
f lected in recent genomic analyses of their disorder.
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Homozygosity mapping and targeted genomic
sequencing reveal the gene responsible for cerebellar
hypoplasia and quadrupedal locomotion
in a consanguineous kindred
Suleyman Gulsuner,1 Ayse Begum Tekinay,2 Katja Doerschner,3,4 Huseyin Boyaci,3,4
Kaya Bilguvar,5,6,7 Hilal Unal,2 Aslihan Ors,4 O. Emre Onat,1 Ergin Atalar,4,8
A. Nazli Basak,9 Haluk Topaloglu,10 Tulay Kansu,11 Meliha Tan,12 Uner Tan,13
Murat Gunel,5,6,7 and Tayfun Ozcelik1,2,14
1Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara 06800, Turkey; 2Institute of Materials
Science and Nanotechnology, Bilkent University, Ankara 06800, Turkey; 3Department of Psychology, Faculty of Economics,
Administrative and Social Sciences, Bilkent University, Ankara 06800, Turkey; 4National Research Center for Magnetic Resonance,
Bilkent University, Ankara 06800 Turkey; 5Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
06510, USA; 6Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA; 7Department of
Genetics, Center for Human Genetics and Genomics and Program on Neurogenetics, Yale University School of Medicine, New Haven,
Connecticut 06510, USA; 8Department of Electrical and Electronics Engineering, Faculty of Engineering, Bilkent University, Ankara
06800, Turkey; 9NDAL Laboratory, School of Arts and Sciences, Bogazici University, Istanbul 34342, Turkey; 10Department of Pediatric
Neurology, Ihsan Dogramaci Children’s Hospital, Ankara 06100, Turkey; 11Department of Neurology, Hacettepe University Faculty of
Medicine, Ankara 06100, Turkey; 12Department of Neurology, Baskent University Faculty of Medicine, Ankara 06490, Turkey;
13Department of Physiology, Cukurova University Faculty of Medicine, Adana 01330, Turkey
The biological basis for the development of the cerebro-cerebellar structures required for posture and gait in humans is
poorly understood. We investigated a large consanguineous family from Turkey exhibiting an extremely rare phenotype
associated with quadrupedal locomotion, mental retardation, and cerebro-cerebellar hypoplasia, linked to a 7.1-Mb region
of homozygosity on chromosome 17p13.1–13.3. Diffusion weighted imaging and fiber tractography of the patients’ brains
revealed morphological abnormalities in the cerebellum and corpus callosum, in particular atrophy of superior, middle,
and inferior peduncles of the cerebellum. Structural magnetic resonance imaging showed additional morphometric ab-
normalities in several cortical areas, including the corpus callosum, precentral gyrus, and Brodmann areas BA6, BA44,
and BA45. Targeted sequencing of the entire homozygous region in three affected individuals and two obligate carriers
uncovered a private missense mutation, WDR81 p.P856L, which cosegregated with the condition in the extended family.
The mutation lies in a highly conserved region of WDR81, flanked by an N-terminal BEACH domain and C-terminal
WD40 beta-propeller domains. WDR81 is predicted to be a transmembrane protein. It is highly expressed in the cere-
bellum and corpus callosum, in particular in the Purkinje cell layer of the cerebellum. WDR81 represents the third gene,
after VLDLR and CA8, implicated in quadrupedal locomotion in humans.
[Supplemental material is available for this article.]
Developmental abnormalities of the cerebellum are a rare and ge-
netically heterogeneous group of disorders characterized by loss of
balance and coordination. Identification of the genes responsible
for these disorders providesmechanistic insights into the regulation
of neuronal development, differentiation, morphogenesis, migra-
tion, and organization (Fogel and Perlman 2007). These genes can
be identified by exploiting targeted genomic sequencing in com-
bination with linkage analysis and homozygosity mapping (Ropers
2007; Bilguvar et al. 2010).We applied this approach to the analysis
of cerebellar hypoplasia and quadrupedal locomotion in an ex-
tended consanguineous family from southern Turkey.
Multiple families have been reported with cerebellar ataxia,
mental retardation, and disequilibrium syndrome (CAMRQ) (Tan
2006; Turkmen et al. 2006, 2009; Moheb et al. 2008; Ozcelik et al.
2008; Kolb et al. 2010). All the reported CAMRQ families are con-
sanguineous with recessive inheritance of their condition. Clinical
characteristics vary slightly among the families. In four families
from Turkey and Iran, the condition is due to homozygosity for
mutations in the VLDLR gene encoding the very low density lipo-
protein receptor (CAMRQ1 [MIM 224050]). Each of these four
families harbors a different VLDLRmutation. In a fifth family, from
Iraq, the condition is due to homozygosity for a missense mutation
in theCA8 gene encoding carbonic anhydrase VIII (CAMRQ3 [MIM
613227]). In Family B, the first family described in the literature
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and also referred to as Uner Tan syndrome (Tan 2006), homozy-
gosity mapping revealed a 7.1-Mb interval on chromosome 17p13,
containing 192 genes and at least 20 pseudogenes, that segre-
gates with the disease (CAMRQ2 [MIM 610185]) (Turkmen et al.
2006; Ozcelik et al. 2008). In order to identify the mutation re-
sponsible for CAMRQ2 in Family B, we targeted and fully se-
quenced the 7.1-Mb genomic interval and evaluated all variation
in the region.
Results
Description of the affected family
Family B came to medical attention because of the unusual form of
locomotion in five of the 19 siblings. A detailed clinical description,
including video recordings and genetic mapping, was published
elsewhere (Tan 2006; Turkmen et al. 2006; Ozcelik et al. 2008).
Pedigree analysis suggested autosomal recessive inheritance. Link-
age analysis and homozygosity mapping revealed a single locus on
chromosome 17p between D17S1866 and D17S960. Illumina 300
Duo v2 BeadChip SNP genotype data of two of the affected in-
dividuals (05-984 and 05-987) revealed a single 6.8-Mb homozy-
gous stretch between markers rs4617924–rs7338 (chr17: 114,669–
6,917,703) and confirmed that chromosome 17p is the only region
of interest (Supplemental Fig. 1).
The phenotype was further characterized by magnetic reso-
nance imaging (MRI) and morphometric analyses (Fig. 1). The
most dramatic morphological differences were significant re-
ductions in volume in the cerebellum and corpus callosum of the
patient’s brain (Fig. 1A). Both the cortex and the white matter of
the cerebellum were significantly smaller in the patients. In con-
trast, the volume occupied by the caudate nucleus was signifi-
cantly larger. Significant structural differences were also detected
in the motor areas precentral gyrus and BA6 (increased mean
curvature and gray matter volume) and motor speech areas pars
opercularis and pars triangularis (increased cortical thickness and
mean curvature) (Fig. 1B). A detailed account of themorphometric
analyses is presented in Supplemental Figure 2 and Supplemental
Table 1. Diffusion tensor imaging (DTI) and fiber tractography
revealed moderate to high atrophy in superior, middle, and in-
ferior cerebellar peduncles (Supplemental Fig. 3).
Targeted next-generation sequencing of the critical region
The critical region at chr17: 82,514–7,257,922 (hg19)was captured
by NimbleGen 385K microarrays and sequenced with 454 Life
Sciences (Roche) GS FLX in DNA of two of the affected individuals
(05-985, 05-987) and two of the unaffected obligate carrier parents
(05-981 father, 05-982 mother). An average of ;400 Mb, yielding
46.33 haploid coverage, was sequenced from the captured DNA of
each individual. An average of 79% of all reads from each sample
mapped to the target region, representing 1275-fold to 2247-fold
enrichment (Supplemental Table 2).Onaverage, 99.4%of all targeted
bases were covered by at least four reads (Supplemental Table 3).
In a parallel experiment, the same region from the DNA of
another affected sibling (05-984) was captured with NimbleGen
HD2 2.1M sequence capture microarrays and sequenced on an
Illumina Genome Analyzer IIx. The captured region was enriched
123-fold, with 2.98 billion bases and 40.3 million reads obtained
and 28% of reads mapped to the targeted region; 99.6% of targeted
bases were covered by at least four reads. Combined sequence data
for the three affected siblings yielded at least a fourfold coverage of
99.78% of all coding base pairs, 95.32% of intronic and UTR base
pairs, and 91.36%of intergenic base pairs. The remaining 0.22% of
coding regions with less than fourfold coverage was analyzed by
Sanger sequencing (Supplemental Table 4).
With the 454 GS FLX platform, a total of 18,410 different
variants were detected at high confidence (defined as in Hedges
et al. 2009) in at least one sample (Supplemental Table 2). No ad-
ditional functional variants were detected with the Illumina se-
quencing platform. Comparison of the sequence data from both
platforms with Illumina 300 Duo v2 SNP genotype data indicated
that the alleles were detectedwith sensitivity and specificity >99%.
Heterozygous SNPs detected at the borders of the homozygous
blocks of the affected individuals narrowed the region of homo-
zygosity to 6.74 Mb (Supplemental Table 5). The Mendelian error
rate, an indicator of call errors (Hedges et al. 2009), was calculated
as 0.3%.
Of the 18,410 high-confidence variants, 17,281 were reported
by dbSNP. For each nonsynonymous SNP compatible with the
Mendelian transmission of the disease allele, the frequencies of
homozygotes for each allele were accessed from public databases.
With one exception, homozygosity at both alleles had been reported
in control populations. The one exception, rs55916885, was at a
nonconserved site and was predicted as tolerated by SIFT (Ng and
Henikoff 2001) and Polyphen-2 (Sunyaev et al. 2001). Based on
these observations, all previously reported nonsynonymous vari-
ants were excluded (Supplemental Table 6).
Of the 18,410 high-confidence variants, 1119 variants were
both novel vis-a´-vis dbSNP132 and present in both the affected
siblings and their obligate carrier parents. These 1119 novel shared
variants were classified by genomic context: coding sequence or
flanking splice junctions (n = 20), 59 UTR or 39 UTR (n = 15),
intronic (n = 689), or intergenic (n = 395). The 20 variants in the
Figure 1. MRI-based morphological analysis of brain from affected and
unaffected individuals. (A) Midsagittal MRI scans of a healthy control in-
dividual (left) and affected relative from Family B (right). The highlighted
regions show areas where volumetric differences are readily visible: corpus
callosum (1), third ventricle (2), fourth ventricle (3), and cerebellum (4).
(B) Cortical regions with significant differences in morphometric param-
eters are displayed on a reference cortex, from lateral and medial view:
BA45 (5), BA44 (6), BA6 (7), precentral (8), superior temporal (9), superior
parietal (10), lateral occipital (11), fusiform (12), isthmus cingulated (13),
posterior cingulated (14), frontal pole (15), medial orbitofrontal (16), and
temporal pole (17). Additional details are provided in Supplemental
Figure 2 and Supplemental Table 1.
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coding sequence or flanking splice junctions were genotyped in the
family to evaluate cosegregationwith the phenotype (Supplemental
Table 7). Genotypes of three missense variants were consistent with
the recessive inheritance of the disease allele in Family B: WDR81
p.P856L,MYBBP1A p.R671W, and ZNF594 p.L639F (Table 1). Of the
15 59/39UTR variants, five cosegregatedwith the disease phenotype.
Therefore, they were carried to a more detailed analysis, including
evaluation of the protein interactions. None was found to interact
with previously identified genes with cerebellar phenotypes, in-
cludingCAMRQ-associatedVLDLR andCA8 (Supplemental Table 8).
Identification of disease causing variant
MYBBP1Ap.R671Wcould be excludedas the causalmutation for the
disorder of Family B based on the genotypes of controls (Supple-
mental Table 9). In 214 unrelated healthy controls (428 chromo-
somes), 50 of whomwere sampled from the same region of Turkey as
Family B, 13 individuals were heterozygous for MYBBP1A p.R671W.
This carrier frequency yields an allele frequency of 0.016 and an
expected frequency of homozygotes of about one in 4000, far higher
than the frequency of CAMRQ2, which occurs in only one extended
family. In a second, independent series of 400 individuals of various
European and Middle Eastern ancestries, MYBBP1A was fully se-
quenced in the context of whole-exome sequencing. Of these 400
individuals, two were homozygous for MYBBP1A p.R671W. Neither
of these two homozygotes had any signs consistent with CAMRQ2.
MYBBP1A p.R671Wwas therefore excluded as the allele responsible
for the disorder of Family B.
ZNF594 p.L639F could be excluded as the causal mutation for
the disorder based on conservation considerations. Residue 639 of
ZNF594 is not well conserved: Two of 16 species sequenced have
phenylalanine (F) at the orthologous site, strongly suggesting that
phenylalanine at this site would also not be damaging in humans. A
negative GERP score (0.665) for the mutated nucleotide indicates
that this site is probably evolving neutrally (Davydov et al. 2010).
The variant is predicted as ‘‘benign’’ (PSIC score difference, 0.301) by
PolyPhen (Sunyaev et al. 2001) and ‘‘damaging low confidence’’
(SIFT score, 0.04) by SIFT (Supplemental Table 10; Ng and Henikoff
2001). In addition, the human ZNF594 gene harbors polymorphic
nonsense mutations at sites near the missense at L639F. ZNF594
p.E684X appeared in four of 118 Yoruban controls (rs114754534;
allele frequency, 0.034), and ZNF594 p.Q681X appeared in one of
120 CEU controls (rs116878311; allele frequency, 0.0083) in the
HapMap series.
In contrast, WDR81 p.P856L (Fig. 2A,B; Supplemental Fig. 4) is
both rare and alters a highly conserved site. This missense did not
appear in any of the 549 individuals of the control series. WDR81 is
a highly conserved protein throughout vertebrates, with no poly-
morphic stops in any sequenced species. In particular, proline at
residue 856 is completely conserved in all known sequences of the
WDR81 protein (Fig. 2C).
The extended genealogy of Family B revealed consanguinity
in several branches of the kindred (Fig. 2D), whose ancestors have
migrated from a village on the Syrian side of the border withHatay,
Turkey, in the early 1950s. Approximately 240 individuals span-
ning seven generation could be ascertained. WDR81 p.P856L was
genotyped in 177 members of the kindred spanning five genera-
tions. A single union of heterozygous carriers, 05-981 3 05-982,
was observed whose children include the affected individuals of
this study. None of the 172 unaffected individuals in the kindred is
homozygous for WDR81 p.P856L. Genetic counseling is in prog-
ress for the 27members of the familywho are heterozygous carriers
of the mutation. The status of WDR81 was evaluated in two dif-
ferent cohorts of the patients with neurodevelopmental/cerebellar
phenotypes for whom the underlying genetic cause is still un-
known. The first cohort consisted of 750 patients with structural
cortical malformations or degenerative neurological disorders. By
using the whole-genome genotyping data based on Illumina Hu-
man 370 Duo or 610K Quad BeadChips, we did not identify any
patient with a cerebellar phenotype or ataxia phenotype to harbor
a homozygous interval ($2.5 cM) surrounding the WDR81 locus.
Exome sequencing of the same group did not reveal any muta-
tions, including compound heterozygous substitutions. In the
second cohort of 58 probands, 12 had cerebellar hypoplasiawith or
without quadrupedal gait. No additional mutations in WDR81
were identified by Sanger sequencing of the entire coding regions.
Characterization of WDR81
WDR81 p.P856L at chr17: 1,630,820 (hg19) lies in exon 1 of
WDR81 isoform 1 (ENST00000409644, NM_001163809.1, NP_
001157281.1), the longest isoform of WDR81, containing 10
exons and encoding 1941 amino acids (Fig. 2A). Proline at this site
was present in all species analyzed (Fig. 2C), including the most
distantly related sequenced ortholog, the Tetraodon nigroviridis
WDR81 protein, which is 47.8% identical and 57.2% similar and
has a distance score of 0.76 compared with the human protein.
WDR81 p.P856L was predicted to be ‘‘damaging’’ (SIFT score, 0) by
SIFT (Ng and Henikoff 2001), ‘‘probably damaging’’ (PSIC score
difference, 2.724) by PolyPhen (Sunyaev et al. 2001), and ‘‘under
evolutionary constraint’’ (GERP score, 5.68) by GERP (Davydov
et al. 2010).
The function ofWDR81 is unknown, but clues can be derived
from its structure. The conserved region of WDR81 that includes
P856 is flanked on the N-terminal side by a BEACH (Beige and
Chediak-Higashi) domain at amino acids 352–607. BEACH proteins
Table 1. Missense variants co-inherited with cerebellar hypoplasia and quadrupedal locomotion in Family Ba
No. and percentage of variant reads
Gene Position (hg19) Ref Var Effect 05-981b 05-982b 05-985c 05-987c
WDR81 chr17: 1,630,820 C T P856L 41 (51%) 33 (52%) 40 (97%) 53 (100%)
MYBBP1A chr17: 4,448,967 G A R671W 29 (52%) 21 (48%) 32 (97%) 29 (100%)
ZNF594 chr17: 5,085,637 G A L639F 39 (54%) 50 (56%) 38 (97%) 37 (100%)
Ref indicates reference nucleotide; Var, variant nucleotide.
aCoding regions, consensus splices-sites, and RNA genes.
bCarrier.
cAffected individual.
WDR81 is associated with CAMRQ2
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have been implicated in membrane trafficking (Wang et al. 2000),
synapse morphogenesis (Khodosh et al. 2006), and lysosomal axon
transport (Lim and Kraut 2009). A BEACH domain is the major
structural feature of neurobeachin, a scaffoldingprotein disrupted in
a patient with autism (Volders et al. 2011). WDR81 p.P856L lies in
amajor facilitator superfamily (MFS) domain, a region characteristic
of solute carrier transport proteins (Saier et al. 1999). The C terminus
ofWDR81 is composedof sixWD-repeats that are likely constituents
of a beta-propeller. Based on analysis by TMpred (www.ch.embnet.
org/software/TMPRED_form.html), WDR81 is a transmembrane
proteinwith sixmembrane-spanningdomains, themostN-terminal
at amino acids 45–66 and the other five at the C terminus of the
protein, between amino acids 980 and 1815 (Fig. 2A). Supporting
the likelihood that WDR81 is a transmembrane protein is the
observation that WDR81 transcript expression is increased in
membrane-associated RNA in contrast to cytoplasmic RNA (4.14
folds, P = 0.03, and 1.78 folds, P = 0.0002 in Gene Expression Om-
nibus [GEO] [http://www.ncbi.nlm.nih.gov/geo/] data setGSE4175)
(Diehn et al. 2006).
In order to assess a possible role for WDR81 in regulating
motor behavior, we evaluated the expression profiles of human
andmouseWDR81/Wdr81 isoform 1 in the brain. HumanWDR81
isoform 1 transcript was expressed in all the tissues evaluated
(Supplemental Fig. 5). In particular, all the brain tissues were pos-
itive for the transcript, with highest levels of expression in the
cerebellum and corpus callosum (Fig. 3A). In the mouse brain at
post-partum day P7, Wdr81 expression was observed in Purkinje
cell layer in the cerebellum (Fig. 3B,C). The cerebellum is a crucial
regulatory center for motor function.
We examined the expression of WDR81 in the context of ex-
pression profiles of the early embryonic mouse brain (GSE8091)
(Hartl et al. 2008). Differentially expressed genes within the day
groups were filtered (one-way ANOVA test Bonferroni-corrected P <
0.001, n = 3611). From these profiles, we identified the subset of
genes whose expression was highly correlated with that ofWDR81
(R > 0.95, n = 670) and then usedDAVID tools (Huang et al. 2009) to
evaluate the predicted functions of this subset of genes. The subset
of genes coexpressed withWDR81 was enriched for those involved
in neuronal differentiation and neuronal projection, axonogenesis,
and cell morphogenesis (Bonferroni-corrected P-values 2.3 3
1011, 1.33 109, and 3.73 109, respectively). Among the genes
coexpressed with WDR81 were those encoding prion protein,
doublecortin (responsible for lissencephaly), and L1CAM (re-
sponsible for MASA syndrome) (Supplemental Table 11).WDR81
is not coexpressed with VLDLR and CA8, raising the possibility
that WDR81 represents a different developmental regulatory
pathway.
Discussion
The identification of genes responsible for human disease has been
greatly facilitated with new technologies, particularly the targeted
enrichment of the genome by solution capture, followed by geno-
mic sequencing (Bilguvar et al. 2010). Despite these advances,
demonstrating the causality for a mutation in the absence of two or
more independent cases remains a challenge. This is particularly
true when multiple variants, none of them with obvious effect on
protein function, cosegregate with the phenotype in the family; the
candidate gene encodes a previously uncharacterized protein with
multiple isoforms, ofwhich the criticalmutation is ononlyone; and
the candidatemutation is amissense. However, unique families and
uncharacterized proteins exist, and precisely because of this reason,
it becomes imperative to fully exploit genetics and genomics ap-
proaches to distinguish the causative mutation.
We describe here the discovery of a mutation associated with
an extremely rare and genetically heterogeneous autosomal re-
cessive phenotype in a unique consanguineous family (Tan 2006).
The putative causative mutation could be distinguished from pre-
viously unknown rare polymorphisms in the same genomic region
by analysis of conservation at all candidate variant sites, by the
presence of polymorphic stops in the critical region of another
candidate gene, and by genotyping ethnically matched unaffected
individuals who would not be expected to carry homozygous mu-
tations at the mutant site. We conclude that the WDR81 p.P856L
mutation is the cause of cerebellar hypoplasia associated with qua-
drupedal locomotion in Family B.
WDR81 is an uncharacterized gene. It shows similarity with
a host of genes, including NSMAF (neutral sphyngomyelinase ac-
tivation associated factor), NBEA (neurobeachin), and LYST (lyso-
somal trafficking regulator). The LYST gene contains HEAT/ARM
repeats, a BEACH domain, and seven WD40 repeats (Ward et al.
2000). Nearly all reported LYST mutations result in protein trun-
cation and lead to Chediak-Higashi syndrome (CHS), which is
characterized by accumulation of giant intracellular vesicles lead-
ing to defects in the immune and blood systems (Rudelius et al.
2006). Two patients with missense LYST mutations have been
reported (Karim et al. 2002). Interestingly, these patients presented
with neurological symptoms without immunological involvement.
The LystIng3618/LystIng3618 mutant mouse harbors a missense mu-
tation in the WD40 domain. Purkinje cell degeneration accom-
paniedby age-dependent impairmentofmotor coordinationwithout
Figure 3. Expression pattern of WDR81 in brain. (A) Expression in hu-
man brain with highest levels in cerebellum and corpus callosum. (B) In
situ hybridization of mouse embryonic brain revealing increased expres-
sion of Wdr81 in purkinje cells and molecular layer of cerebellum. (C ) No
hybridization was observed with the sense probe. (ML) Molecular layer,
(GL) granular layer.
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signs of lysosomal deficiency in immunological organs were charac-
teristics of these animals (Rudelius et al. 2006).
Expression ofWDR81 at high levels in the human cerebellum
and corpus callosum and in the Purkinje cell layer of the mouse
cerebellum is consistent with our observations of major structural
abnormalities in these regions of the brain of affected individuals.
Together, these observations suggest a possible role for WDR81 in
motor behavior. Further work will be required to understand the
normal biological function ofWDR81 and the role of themutation
in causing cerebellar hypoplasia and quadrupedal locomotion.
Genomic analysis of Family B demonstrates that WDR81 is highly
likely to be critical to these developmental processes.
Methods
Human subjects
The institutional review boards of Bilkent, Hacettepe, Baskent,
and Cukurova Universities approved the study (decisions: BEK02,
28.08.2008; TBK08/4, 22.04.2008; KA07/47, 02.04.2007; and21/3,
08.11.2005, respectively). Written informed consent, prepared
according to the guidelines of theMinistry ofHealth in Turkey, was
obtained from all familymembers and control group subjects prior
to the study. A total of 18 subjects participated in MRI scans. Six of
themwere from Family B, including four affected siblings (05-984,
05-986, 05-987, 05-988), one normal female sibling homozygous
for the wild-type allele of the WDR81 p.P856L variant (10-033),
and their carrier father (05-981). The remaining 14 participants
were age- and sex-matched healthy controls. The two male pa-
tients (age,mean6 SD = 37.006 4.24) werematched to sevenmale
controls (age, mean 6 SD = 35.14 6 5.76), and the two female
patients (age, mean 6 SD=27.00 6 4.24) were matched to seven
female controls (age, mean 6 SD = 28.57 6 3.64). Family B mem-
bers were scanned under sedation. For the healthy controls, no
sedation was performed. Sedation was achieved by initial admin-
istration of midazolam (2 mg per subject), which was followed by
propofol (120 mg) and fentanyl (50 mcg) administration in-
travenously. Hypnosis level was adjusted by 20 mg injections
of propofol approximately every 10 min to eliminate somatic re-
sponses such as slight movements. Blood oxygen level and heart
rate were monitored during the entire procedure. Eyelash reflexes
were absent at all times. Neuromuscular blockade was not used.
Next-generation sequencing
NimbleGen 385K microarrays were produced to capture the criti-
cal region at chr17: 82,514–7,257,922 (hg19) using 7464 unique
probes with a total probe length of 4,853,455 bp. Sequence Search
and Alignment by Hashing Algorithm (SSAHA) (Ning et al. 2001)
was used to determine probe uniqueness by NimbleGen (Roche
NimbleGen). Sequence capture was conducted by the NimbleGen
facility using 25 mg of input DNA. Captured DNA samples were
subjected to standard sample preparation procedures for 454 GS
FLX sequencing with Titanium series reagents. Four full 454 GS
FLX runs were conducted for two affected individuals (05-985, 05-
987) and their unaffected obligate carrier parents (05-981 father,
05-982 mother). Sequence data were initially mapped to human
genome reference sequence and annotated using the GSMapper
software package (Roche). Fold enrichment of the target regionwas
calculated with the formula +REMTrm/STrm: +RMG/SG as de-
scribed previously (REMTrm, number of reads mapped to target
region; STrm, size of target region; RMG, number of reads mapped
outside of the target region; SG, size of human genome) (Rehman
et al. 2010). Variants were identified with ALLDiff and more strin-
gentHCDiff approaches (Hedges et al. 2009). Annotation of variants
was made by GSMapper software using the refGene table of the
University of California, Santa Cruz (UCSC) Genome Browser
(Fujita et al. 2010). Ensembl 62 genome annotation data for hg19
human genome assemblywere extracted using the BIOMARTdata-
mining tool for further analysis of intronic and intergenic variants
in terms of hypothetical genes and splicing variants (Flicek et al.
2011). Novel variants were reported based on the SNPs included
in the reference SNP database. For Illumina sequencing, a total of
6,184,539-bp-long unique probes were designed to target a 9-Mb
genomic region spanning the disease locus (chr17:0–9,059,276;
hg19) using a custom NimbleGen HD2 2.1M sequence capture
microarray. Another affected individual was sequenced with the
Illumina Genome Analyzer IIx. Illumina sequence data were map-
ped to the reference genome using MAQ tools (Li et al. 2008), and
single nucleotide variants were determined with Samtools (Li et al.
2009). To determine indels, data were mapped with BWA (Li and
Durbin 2010) and analyzed with Samtools. Sequence data were
visually analyzed using the Integrative Genomics Viewer (IGV)
(Robinson et al. 2011).
Array based genotyping
We conducted Illumina 300 Duo v2 BeadChip for two affected
individuals (05-984, 05-987) according to the manufacturer’s rec-
ommendations (Illumina). The image data were normalized, and
the genotypes were called using data analysis software (Bead Stu-
dio, Illumina). Sex, inbreeding, and sibship were confirmed.
The Mendelian compatibility of sequence variants was analyzed
with PLINK (Purcell et al. 2007).
DNA sequencing
Confirmation of novel variants identified by next-generation se-
quencing was done with conventional capillary sequencing. The
Primer3 software (Rozen and Skaletsky 2000) was used to design
PCR primers for the amplification of candidate variants (Supple-
mental Table 12). Products were analyzed via gel electrophoresis
and were sequenced using forward and reverse primers on an ABI
3130 XL capillary sequencing instrument (Applied Biosystems).
Sanger sequence trace files were analyzed with the CLCBio Main
Workbench software package (CLCBio Inc.).
Population screening
To distinguish the disease-causing variant from novel polymor-
phisms, a population screening approach was conducted for each
candidate variant. Allele-specific PCR (AS-PCR) and restriction frag-
ment length polymorphism (RFLP) analyses were performed (Sup-
plemental Table 12) on 1098 chromosomes from a healthy control
population. In addition, the first-, second-, and third-degree rela-
tives of the affected family, amounting to 177 individuals, were
sampled for genotype analysis. Sanger sequencingwas performed to
confirm all of the variants detected in the normal population using
the above-mentioned methods. Racial distribution of the control
groupwas100%Caucasian, including22%fromsoutheasternTurkey.
Quantitative real-time RT-PCR analysis of WDR81 expression
First-strand cDNA was prepared from multi-tissue RNA panels
(Clontech: 636567, 636643; Agilent: 540007, 540117, 540137,
540157, 540053, 540005, 540143, 540135) with RevertAid kit and
random hexamer primers (Fermentas; K1622) after DNase I (Fer-
mentas; EN0521) digestion. The PCR primers located in exon 1
and flanking the mutation site were designed using Primer3 soft-
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ware (Supplemental Table 13; Rozen and Skaletsky 2000). SYBR
Green real-time PCR were realized according to standard protocols
(BioRad; 170-8882) with 100% PCR efficiency. Each assay included
minus RT and nontemplate controls. Ct values were normalized to
GAPDH as an internal control. The data were analyzed using the
Pfaffl method (Pfaffl 2001).
In situ hybridization
In order to examine the specific expression pattern ofWdr81 gene
in the mouse brain, probes that contain the mutated region in
human patients were prepared by PCR amplification of the region
frommouse genomic DNA and subsequent cloning into plasmids.
The riboprobes were synthesized by using Dig-labeled NTPs, and
in situ hybridization experiments were performed as described
(Tekinay et al. 2009). The Animal Ethics Committee of Bilkent
University approved procedures for the tissue extraction and for in
situ hybridization tests. Animals were group housed in a 12-h dark,
12-h light cycle. Embryo and P7 brain sections were prepared as
described (Gong et al. 2003). Twenty-micrometer sagittal sections
were takenwith a cryostat (Leica). The antisense probewas prepared
by PCR amplification from the mouse genomic DNA and sub-
sequent cloning into pCR4-TOPO vector (Invitrogen). A modified
version of pSK vector was used for cloning the sense probe of the
same region. Digoxigenin (Dig)-labeled riboprobe was transcribed
using Dig-NTP in the transcription reaction. Riboprobes were pu-
rified with Mini Quick Spin DNA columns (Roche) prior to hy-
bridization. Sections were incubated at 60°C overnight in hybrid-
ization buffer containing 50% formamide, 53 SSC, 53Denhardt’s
reagent, 50 mg/mL heparin, 500 mg/mL herring sperm DNA, and
250mg/mLyeast tRNA.Hybridized sectionswerewashed for 90min
with 50% formamide and 23 SSC at 60°C. Probes were detected
with anti-Dig Fab fragments conjugated to alkaline phosphatase
and NBT/BCIP substrate mixture (Tekinay et al. 2009).
Bioinformatics analyses
Homozygosity mapping analysis was performed using Homo-
zygosityMapper software (Seelow et al. 2009). SIFT (Ng andHenikoff
2001) and PolyPhen (Sunyaev et al. 2001) tools were used to pre-
dict the functional impact of the variants. Genomic Evolutionary
Rate Profiling (GERP) scores for each variant were obtained from
the UCSC Genome Browser allHg19RS_BW track (Davydov et al.
2010). The PFAM protein domain search module of CLCMain
Workbench V5.0 (CLCBio, Inc.) and ScanProsite (Gattiker et al.
2002) toolswere used to predict domains and possible effects of the
variant on protein product. Membrane spanning domains were
predicted using TMpred software (www.ch.embnet.org/software/
TMPRED_form.html). Homology searches were performed with
CLCMain Workbench using appropriate modules (reference se-
quence accession codes for WDR81 orthologs are Ailuropoda
melanoleuca, XP_002918082; Callithrix jacchus, XP_002747874;Danio
rerio, XP_001921778; Equus caballus, XP_001502383; Gallus gallus,
XP_415806;Monodelphis domestica, XP_001371487;Mus musculus,
NP_620400; Oryctolagus cuniculus, XP_002718930; Pan troglodytes,
XP_523527; Pongo abelii, XP_002826860; Rattus norvegicus, NP_
001127832; Sus scrofa, XP_003131868; Taeniopygia guttata, XP_
002194363; Tetraodon nigroviridis, CAG08933; Xenopus [Silurana]
tropicalis, XP_002937192). Published microarray data sets of E9.5,
E11.5, and E13.5 mouse brain tissue (GSE8091) were downloaded
from the GEO database (http://www.ncbi.nlm.nih.gov/projects/
geo/query/acc.cgi) (Hartl et al. 2008) and processed with GeneSpring
GX V11.1 software (Agilent Technologies). Data sets were grouped
within day groups, and standard quality control and filtering
analysis were performed (http://www.chem.agilent.com/cag/bsp/
products/gsgx/manuals/GeneSpring-manual.pdf). Differentially ex-
pressed genes within the day groups were filtered using a one-way
ANOVA test (Bonferroni-corrected P < 0.001). Genes that corre-
lated with Wdr81 (R = 0.95  1.0) were obtained using the ‘‘Find
Similar Entity Lists’’ module of the software. Functional annota-
tion clustering was performed using the obtained gene list by
DAVID tools (Huang et al. 2009).WDR81differential expression in the
GEO data sets was further investigated using the NextBio System,
a web-based data-mining engine (Kupershmidt et al. 2010), and the
GSE4175 (Diehn et al. 2006) data set was selected as a significant dif-
ference in membrane-associated RNA versus cytoplasmic RNA com-
parisons. Ensembl identifiers of the candidate genes and transcripts
are as follows: WDR81 [ENSG00000167716; ENST00000409644],
MYBBP1A [ENSG00000132382; ENST00000254718], and ZNF594
[ENSG00000180626; ENST00000399604].
MRI data acquisition and structural analysis procedures
MRI data were acquired using a three Tesla scanner (Magnetom
Trio, Siemens AG)with a 12-channel phase-array head coil. A high-
resolution T1-weighted three-dimensional (3D) anatomical-vol-
ume scan was acquired for each participant (single-shot turbo
flash; voxel size = 13 13 1mm3; repetition time [TR] = 2600msec;
echo time[TE]= 3.02msec; flip angle = 8°; field of view [FOV] = 2563
224 mm2; slice orientation = sagittal; phase encode direction =
anterior-posterior; number of slices = 176; acceleration factor
[GRAPPA] = 2). DTI datawere acquired using a single-shot spin-echo
EPI with a parallel imaging technique GRAPPA (acceleration factor
2). The sequencewasperformedwith30 gradient directions, and the
diffusion weighting b-factor was set to 800 sec/mm2 (TR, 6400
msec; TE, 88 msec; in-plane resolution, 1 mm 3 1 mm; slice thick-
ness, 3.0 mm; 50 transverse slices; base resolution, 128 3 128).
Structural analyses were performed with the Freesurfer image anal-
ysis package (http://surfer.nmr.mgh.harvard.edu/). The analyses
involved intensity normalization, removal of nonbrain tissue, sub-
cortical segmentation (Fischl et al. 2002), and identification of the
white matter/gray matter boundary upon which cortical re-
construction and volumetric parcellation were performed. The
cortexwas then registered to a spherical atlas andparceled into units
according to the gyral and sulcal structure based on the Desikan-
Kilinay Atlas (Desikan et al. 2006) and theDestrieuxAtlas (Destrieux
et al. 2010). Next, using the same software, we performed mor-
phometric analyses of cortical thickness, mean curvature, surface
area, and volume for each unit of parcellation and computed the
group differences. Significant differences between the groups are
determined using two-tailed unpaired t-tests at an alpha level of
0.05. Fiber tracking was performed in MedINRIA (Toussaint et al.
2007). Fibers with FA < 0.3 were excluded from the analysis. Region
of interests (ROIs) were drawn manually over cross-sections of su-
perior, middle, and inferior cerebellar peduncles, using the MRI
Atlas of HumanWhiteMatter as a reference (Oishi et al. 2010). ROIs
were drawn at approximately corresponding locations for the pa-
tients and healthy controls. Fiber tracts were first limited to pass
through these ROIs and were then subsequently refined using a re-
cursive tracking technique (Toussaint et al. 2007). T1-weighted
images were coregistered with DWI data using FSL (Smith et al.
2004;Woolrich et al. 2009). Final tractsweremanuallyoverlaidonto
high-resolution T1-weighted images for illustration purposes.
Data access
Sequence data of the homozygous region has been deposited at the
DNAData Bank of Japan (DDBJ; http://www.ddbj.nig.ac.jp/) under
accession no. DRA000432. SNP genotype data have been deposited
at the European Genome-Phenome Archive (EGA; http://www.
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ebi.ac.uk/ega/), which is hosted at the EBI, under accession no.
EGAS00000000099.
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ARTICLE
Missense mutation in the ATPase, aminophospholipid
transporter protein ATP8A2 is associated with
cerebellar atrophy and quadrupedal locomotion
Onur Emre Onat1,10, Suleyman Gulsuner1,10, Kaya Bilguvar2,3,4, Ayse Nazli Basak5, Haluk Topaloglu6,
Meliha Tan7, Uner Tan8, Murat Gunel2,3,4 and Tayfun Ozcelik*,1,9
Cerebellar ataxia, mental retardation and dysequilibrium syndrome is a rare and heterogeneous condition. We investigated a
consanguineous family from Turkey with four affected individuals exhibiting the condition. Homozygosity mapping revealed that
several shared homozygous regions, including chromosome 13q12. Targeted next-generation sequencing of an affected
individual followed by segregation analysis, population screening and prediction approaches revealed a novel missense variant,
p.I376M, in ATP8A2. The mutation lies in a highly conserved C-terminal transmembrane region of E1 E2 ATPase domain. The
ATP8A2 gene is mainly expressed in brain and development, in particular cerebellum. Interestingly, an unrelated individual has
been identified, in whom mental retardation and severe hypotonia is associated with a de novo t(10;13) balanced translocation
resulting with the disruption of ATP8A2. These findings suggest that ATP8A2 is involved in the development of the cerebro-
cerebellar structures required for posture and gait in humans.
European Journal of Human Genetics advance online publication, 15 August 2012; doi:10.1038/ejhg.2012.170
Keywords: ATP8A2; cerebellar hypoplasia; targeted next-generation sequencing; quadrupedal locomotion; CAMRQ
INTRODUCTION
Cerebellar ataxia, mental retardation and dysequilibrium syndrome
(CAMRQ) is a rare and genetically heterogeneous autosomal recessive
disorder characterized by mental retardation, cerebellar ataxia and
dysarthric speech with or without quadrupedal gait.1–8 Multiple
consanguineous families have been reported with autosomal
recessive inheritance of the condition. The first locus was mapped
to a 7.1-Mb region on chromosome 17p13 and a missense mutation
was reported on WDR81 (WD repeat domain 81; CAMRQ2; MIM:
610185; also referred to as Uner Tan syndrome).1,2,7 Linkage mapping
followed by candidate gene sequencing also led to the identification of
mutations in very low-density lipoprotein receptor (CAMRQ1; MIM:
224050)3–5 and carbonic anhydrase VIII (CAMRQ3; MIM: 613227).6
In another consanguineous family (Family C)3,9 from Turkey, the
involvement of VLDLR, WDR81 and CA8 genes were excluded, and
four shared-homozygous regions on chromosomes 13, 19 and 20 were
uncovered by homozygosity mapping. To identify the culprit gene, we
utilized targeted next-generation sequencing of all homozygous
regions and evaluated all co-segregated variants using functional
and structural predictions and population screening. We report herein
that a recessive missense mutation in ATP8A2, encoding ATPase,
aminophospholipid transporter, class I, type 8A, member 2, is
associated with the phenotype in Family C. In an independent
study, a de novo t(10;13) balanced translocation disrupting the
coding sequence of ATP8A2 on 13q12 was observed in a patient
with severe mental retardation and major hypotonia, raising the
possibility that haploinsufficiency of this gene could be implicated in
neurodevelopmental phenotypes.10 On the basis of these observations,
we suggest that ATP8A2 could be critically important in the
development of the nervous system.
SUBJECTS AND METHODS
Patients
The consanguineous family analyzed in this study has four members affected
by mental retardation, mild cerebellar and cerebral atrophy and truncal ataxia
(Figure 1). The index case was a 27-year-old man exhibiting total inability to
walk (05-993). Briefly, patients share the following clinical features: truncal
ataxia with/without quadrupedal gait, mental retardation and dysarthric
speech. MRI results revealed mild atrophy of cerebral cortex, corpus callosum
and inferior cerebellum. Clinical description of Family C was published
elsewhere.3,9 The only affected female in the family could not be included in
the study, as her parents did not give consent for DNA analysis. Case 05-993
recently died secondary to a respiratory infection. The study was approved by
the institutional review boards at the Baskent and Cukurova Universities
(decision KA07/47, 02.04.2007 and 21/3, 08.11.2005, respectively). Written
informed consent was obtained from all participants or their parents before
the study.
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Homozygosity mapping analysis
Participants’ DNA from peripheral blood samples were genotyped using 10 K
Affymetrix SNP chips. Experiments were performed according to the
manufacturer’s instructions (Affymetrix, Santa Clara, CA, USA). DNA of
two affected individuals (05-994 and 05-996) was genotyped using Illumina
Human610-Quad BeadChip according to manufacturer’s recommendations
(Illumina, Inc., San Diego, CA, USA). The image data were normalized and the
genotypes were called using data analysis software (Bead Studio, Illumina).
Homozygosity mapping analysis was performed using HomozygosityMapper
software.11 Homozygosity was ruled out for the previously reported loci.
Markers D13S787, D13S1243, D13S742, D13S283, D13S1294 and D13S221
were used to test homozygosity for the most likely candidate locus,
chromosome 13q12. Haplotype analysis was carried out by hand.
Mutation analysis
A total of 16 711 445 base long unique probes were designed to target
homozygous regions (Supplementary Table 1) using a custom-designed
Nimblegen Human Sequence Capture HD2 microarray (Roche NimbleGen,
Madison, WI, USA). DNA sample from an affected individual (05-996) was
captured using 3mg input DNA. Captured DNA sample was sequenced with
Illumina Genome Analyzer IIx. Illumina sequence data were mapped to
reference genome (hg18) using Maq12 and single-nucleotide variants were
determined with Samtools.13 To determine indels, data were mapped with
BWA14 and analyzed with Samtools. Variant coordinates were converted to
hg19 before publication by liftOver tool (http://genome.ucsc.edu/cgi-bin/
hgLiftOver). Coverage calculations of coding regions were done with
mpileup module of Samtools13 and intersectBED command of BEDTools.15
Novel variants were determined based on SNPs reported in dbSNP database
and further analyzed in 1000 genome data sets (http://www.1000genomes.org),
NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/, data
release ESP5400) and exome sequencing data of 2400 individuals with non-
neurological disorders generated at Yale University. Common variants were
excluded if minor allele frequency was lower than 0.1%. Novel variants were
confirmed by Sanger sequencing. Segregation analysis of the variants in the
pedigree and its presence in healthy population were carried out using allele-
specific PCR analysis (Supplementary Table 2). Racial distribution of control
group was 100% Caucasian, including 22% from southeastern Turkey.
Bioinformatics analysis
DNA and protein sequences were obtained from ENSEMBL database.16 SIFT,17
PolyPhen218 and MutationTaster19 tools were used to predict causative
variants. Genomic evolutionary rate profiling (GERP) and phylogenetic
P-value (phyloP) conservation scores for each variant were extracted
seperately from the UCSC Genome Browser allHg19RS_BW track20 and
phyloP46wayall track,21 respectively. Functional and transmembrane domains
of the ATP8A2 protein were predicted using Pfam database22 and TmPred
prediction tool (www.ch.embnet.org/software/TMPRED_form.html),
respectively. Homology searches were performed with CLCMain Workbench
(CLC Bio, Aarhus, Denmark) using appropriate modules. CLCMain
Workbench also generates phylogenetic tree using UPGMA algorithm that is
evaluated by bootstrap analysis. Possible effects of the variant on protein
secondary structure were predicted using PSIPRED server.23 Published
microarray data sets of E9.5, E11.5 and E13.5 mouse brain tissue
(GSE8091)24 were obtained from the GEO database (http://
www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi) and analyzed with
GeneSpring GX V11.1 software (Agilent Technologies, Santa Clara, CA,
USA). Differentially expressed genes within day groups were filtered (one-
way ANOVA test Bonferroni-corrected Po0.001) and genes that correlated
with Atp8a2 (R¼ 0.95–1.0) were functionally annotated using DAVID tools.25
Primers used in this study were designed with Primer326 software and are listed
in Supplementary Table 2.
Quantitative real-time RT-PCR
First-strand cDNAs were prepared from human RNA samples (Clontech,
Mountain View, CA, USA: 636567 (corpus callosum); Agilent: 540007
(cerebellum), 540117 (frontal cortex), 540137 (occipital cortex), 540157 (fetal
brain), 540053 (brain stem), 540005 (total brain), 540143 (parietal cortex),
540135 (striatum)) using RevertAid First Strand cDNA Synthesis kit with
random hexamer primers (Fermentas, now Thermo Fisher Scientific, Waltham,
MA, USA; K1622) after DNaseI (Fermentas EN0521) digestion. Real-time RT-
PCR was performed using IQ SYBR Green Supermix according to standard
protocols (BioRad, Hercules, CA, USA; 170-8882). Ct values were normalized
to GAPDH as an internal control. The data were analyzed using the Pfaffl
method.27
RESULTS
We identified four common homozygous regions in two affected
individuals (05-994 and 05-996) using Ilumina Human610-Quad
BeadChip. Targeted next-generation sequencing of all homozygous
regions (Supplementary Figure 1 and Supplementary Table 1) was
carried out using DNA of one affected individual (05-996). This
region was enriched 629-fold in the capture experiment. In total,
48.62 million single-end 75 bp reads were obtained and 29.2% of the
reads mapped to the targeted regions. This in turn provided a mean
coverage depth of 62.96-fold across the targeted homozygosity
intervals with 97.41% of the targeted bases being covered by at least
four reads (Supplementary Table 3). Next, the constitutive exons in
the homozygous intervals were analyzed and 99.51% of the protein
coding regions was found to be covered by at least four reads. When
the genes encoding for the constitutive exons in the low- or zero-
coverage regions were analyzed, they either do not have cerebellar
expression or do not display a phenotype compatible with cerebellar
involvement in mouse knockouts (Supplementary Table 4). On the
basis of these results, we find it highly unlikely that a causative
mutation is missed.
Figure 1 Pedigree of Family C with haplotype structure of the disease
interval on chromosome 13q12. Haplotype segregating with the disease is
boxed. ATP8A2 c.1128 C4G mutation is bold. Please note that the DNA of
one affected individual is not available for the study.
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A total of 14 103 homozygous variants (13 394 single-nucleotide
variants and 709 indels) were detected by next-generation sequencing.
Of these, 13 528 variants were reported by dbSNP132. Remaining 575
novel variants were classified by genomic context: protein altering or
flanking splice junctions (n¼ 11), coding synonymous (n¼ 4),
50-UTR (n¼ 44), 30-UTR (n¼ 30), intronic (n¼ 224) and intergenic
(n¼ 262). Of the 11 protein-altering variants, four were excluded
based on the comparison for novelty with 1000 genomes data, NHLBI
Exome Sequencing Project and the exome sequence data of 2400
individuals with non-neurological diseases. The remaining seven
variants in the coding regions of homozygous blocks were verified
by Sanger sequencing and four of them were excluded by segregation
analysis (Supplementary Figures 2–3). Two missense variants (ATP8A2
p.I376M and APBA3 p.A97T) and a 3-bp in-frame deletion (PCP2
p.E6del) were consistent with the recessive inheritance of the disease
allele in Family C (Table 1, Figure 1 and Supplementary Figure 2).
APBA3 p.A97T variant was excluded based on the conservation
considerations and prediction analyses. Four of 20 species sequenced
have threonine (T) at the orthologous site (Supplementary Figure 4),
suggesting that this variant would be a polymorphism and not
damaging to humans. A negative GERP score (4.11) for the
mutated nucleotide suggests that this site is probably evolving
neutrally.20 PhyloP score of the variant (0.308) suggests a faster
evolution than expected for this site.21 Furthermore, the variant was
predicted as ‘tolerated’ by SIFT17 (SIFT score, 0.16), ‘benign’ by
PolyPhen218 (PSIC score difference, 0.0) and ‘polymorphism’ by
MutationTaster19 (P-value, 0.999) (Table 1).
PCP2 p.E6del was excluded based on population screening. In 360
healthy chromosomes, four heterozygous individuals were identified
(Supplementary Figure 5), yielding an expected homozygote fre-
quency of approximately 1 in 8000. The region containing the
mutation is not conserved among species, and the deletion was
predicted as ‘polymorphism’ by MutationTaster19 (P-value, 0.717;
Table 1 and Supplementary Figure 6).
The remaining variant at chr13:26128001 (hg19; c.1128 C4G)
is located in exon 12 of ATP8A2 (ENSG00000132932,
ENST00000381655) and results in an isoleucine (I) to methionine
(M) substitution at residue 376. The mutation co-segregated with the
disease in Family C (Figure 1) lies in the C-terminal-predicted
transmembrane site of the E1 E2 ATPase domain (Figure 2a) and is
highly conserved across species (Figure 2b and Supplementary
Figure 7). Screening of 1210 control chromosomes, including 300
individuals from the same geographic region as Family C, excluded
presence of the variant in this control population. SIFT,17 PolyPhen218
and MutationTaster19 tools predicted the ATP8A2 p.I376M as a
causative mutation (scores: 0.0, 1.0 and 0.955, respectively).
Consequences of the amino acid change in protein structure were
evaluated by comparing the predicted secondary structures of wild-
type and mutant protein sequences. The wild-type protein is
predicted to contain 27 b-strands and 32 a-helices. I376 residue is
located at the N terminus of the 11th a-helix. The mutation enlarges
the 11th and 12th a-helices and creates an additional a-helix at
residue 401 (Figure 2c).
The status of ATP8A2 was evaluated in a cohort of 750 patients
with structural cortical malformations or degenerative neurological
disorders, and the underlying genetic cause is still unknown. Whole-
genome genotyping data generated by Illumina Human 370 Duo or
610K Quad BeadChips is available for this cohort. None of the
patients were found to harbor a homozygous interval (Z2.5 cM)
surrounding the ATP8A2 locus. Exome sequencing of the same group
did not reveal any mutations, including compound heterozygous
substitutions, in ATP8A2.
The transmembrane protein, ATP8A2, consists of four protein-
coding isoforms. The longest isoform (ENST00000381655) contains
37 exons and encodes a 112 kDa protein. The protein is highly
expressed in newborn and embryonic tissues, with strongest expres-
sion in mouse heart, brain and testis.10,28 RT-PCR analysis revealed
similar expression in different regions of the human brain.10 To
evaluate the possible involvement of ATP8A2 in motor functions, we
examined its expression profile in different human brain regions by
quantitative real-time RT-PCR. Human ATP8A2 is expressed in all
brain regions with the highest level of expression in cerebellum
(Figure 3). ATP8A2 expression in the patients cannot be evaluated, as
the gene is not expressed in lymphocytes.
To further investigate the role of ATP8A2 in brain development, we
examined the expression profiles of early embryonic mouse brain
(GSE8091)24 and identified genes with significantly correlated
expression profiles (R40.95, n¼ 218) with that of ATP8A2.
Functional clustering analysis suggested that positively correlated
genes were enriched for those involved in neuron differentiation,
cell, and neuron projection morphogenesis and axonogenesis
(Bonferroni-corrected P-values: 2.1E-3, 2.7E-3, 4.5E-3 and 1.5E-2
respectively). ATP8A2 is co-expressed with doublecortin responsible
for lissencephaly and WDR81 associated with CAMRQ2,7 suggesting
that these genes could represent similar developmental pathways.
DISCUSSION
CAMRQ is a rare genetically heterogeneous cerebellar ataxia with
mental retardation and dysarthric speech, with or without quad-
rupedal gait. Since the first mapping of the gene locus on chromo-
some 17p13, two additional loci on chromosomes 9p24 and 8q12
have been reported, and causative mutations have been identified in
VLDLR, CA8 and WDR81.2,3,6,7 Here we present the identification of
a fourth gene locus in a consanguineous family of two affected
Table 1 Novel coding variants identified by targeted next-generation sequencing of 05-996
Gene Position (hg19) Ref Var Effect GERP (score) PhyloP (score) SIFT (score) Polyphen2 (score) M. Taster (P-value) Segregation
ATP8A2 chr13:26,128,001 C G I376M 2.18 1.091 D. (0.02) P.D. (1.00) D.C. (0.995) Yes
APBA3 chr19:3,759,974 C T A97T 4.11 0.308 T. (0.16) B. (0.14) P. (0.999) Yes
MUC16 chr19:9,068,391 G A A6352V 1.45 0.803 n.a. n.a. P. (0.999) No
MUC16 chr19:9,068,577 G A T6290I 2.35 2.273 n.a. n.a. P. (0.999) No
ZNF823 chr19:11,833,601 A G C250R 0.632 1.532 D. (0.00) P.D. (1.00) P. (0.994) No
SERINC3 chr20:43,141,490 A G M116T 3.98 2.524 T. (0.34) B. (0.13) D.C. (0.999) No
PCP2 chr19:7,698,326 CTC — E6del n.a. 0.168 n.a. n.a. P. (0.717) Yes
Abbreviations: Ref, reference allele; Var, variant allele; M.Taster, Mutation Taster, D., damaging; T., tolerated; P.D., probably damaging; B., benign; n.a., not available; D.C., disease causing;
P., polymorphism.
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siblings and an affected nephew. Using whole-genome homozygosity
mapping followed by targeted next-generation sequencing, several
missense variants were observed. Filtering the variants by
co-segregation analysis, population screening, protein conservation
and disease gene prediction approaches revealed a novel missense
variant in ATP8A2 (c.1128 C4G; p.I376M) that segregates with the
phenotype. The mutation is located inside a transmembrane domain
and is predicted to change secondary structure of the protein.
ATP8A2 belongs to the P4-ATPases subfamily of P-type ATPases,
which are involved in the transport of aminophospholipids.
Biochemical studies have shown that P4-ATPases determine the
curvature of the phospholipid bilayer by flipping aminophospholipids
from the exoplasmic to the cytoplasmic leaflet.29,30 ATPases have been
implicated in human diseases such as ATP10C in Angelman
syndrome,31 ATP8B1 in hearing loss32 and hereditary cholestasis,33
and ATP8A2 in a severe neurological phenotype.10
ATP8A2 is involved in the transport of aminophospholipids toward
the cytoplasmic leaflet in brain cells, retinal photoreceptors and
testis.34 In humans, ATP8A2 is mainly expressed in brain tissues, with
highest levels in cerebellum, as well as in retina and testis.10
Cerebellum is a crucial regulatory organ for motor coordination
and this expression pattern is consistent with CAMRQ. The fact that
CAMRQ-associated genes have retinal expression34,35 raises the
possibility that eye abnormalities may be an additional clinical
feature of the phenotype. Strabismus has been observed in almost
all affected individuals in all the families reported thus far.1–8 In
addition, homozygous WDR81 mutation carriers display downbeat
nystagmus, temporal disk pallor and macular atrophy.36 However,
retinopathy is not a feature of WDR81-, VLDLR- and CA8-associated
CAMRQ.6,36 With respect to ATP8A2, further information is not
available, as Family C declined neuro-ophthalmological investigations.
Documentation of a de-novo-balanced translocation leading to
ATP8A2 haploinsufficiency10 brings into attention the clinical findings
of carriers in Family C. Whereas 05-992 and 05-995 did not
show neurological abnormalities, the t(10;13) de-novo-balanced
translocation carrier presented with a severe neurological phenotype
Figure 2 Graphical representation of the predicted functional and structural elements of ATP8A2 protein. (a) ATP8A2 is composed of an E1 E2 ATPase
domain and a haloacid dehalogenase-like hydrolase (HAD) domain. Ten transmembrane domains were predicted by TMPRED. The mutation lies in the
transmembrane region of C-terminal end of E1 E2 ATPase domain (dot). (b) Multiple amino acid sequence alignments show the sequence homology of
ATP8A2 protein in vertebrates. I376 residue is indicated with a box. (c) Graphical representation of secondary structural elements as predicted by
PSIPRED. The predicted elements (Pred) are indicated above the amino acid (AA) sequences (straight lines: coils; cylinders: helices; arrows: strands). The
mutation is predicted to alter the secondary structure of the protein. Transmembrane region is represented within the Pred graphs of wild-type (WT) and
mutant (Mut) proteins. EC, extracellular; IC, intracellular.
Figure 3 Expression pattern of ATP8A2 in nine different regions of human
brain. Real-time RT-PCR analysis showed that ATP8A2 is expressed in all
regions of the brain with the highest levels in the cerebellum.
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that partially overlaps with the phenotype of the affected members of
Family C. The possibility of a chimeric protein was ruled out, leaving
haploinsufficiency of ATP8A2 as the most likely explanation for the
phenotype. This suggests that ATP8A2 mutations represent yet
another example of clinical heterogeneity in the context of genomic
understanding of complex traits in humans and demonstrates
fundamental features of genomic analysis of human traits such as
variable expression, allelic heterogeneity and genotype–phenotype
correlations. Other examples include CRYBB1 in congenital cataract,37
COLL11A2 in Zweymuller Weissenbacher syndrome38 and MYBPC1
in arthrogryposis.39
These findings suggest that ATP8A2 could be critical for the
developmental processes of central nervous system, and alterations
of this gene may lead to severe neurological phenotypes.
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